Module 5 — Inter-GLP-1 Transition Protocol

What this protocol is. Stack Protocol #4 in the Module 5 series — the operational reference for switching a patient from one Module 5 GLP-1-axis compound to another. The unit of analysis is the transition, not the compound. Where a per-canonical protocol answers “how do I use semaglutide / tirzepatide / retatrutide / liraglutide / survodutide / orforglipron / cagrilintide / CagriSema / IcoSema correctly?”, this protocol answers “how do I move a patient from compound X to compound Y, what is the washout arithmetic, what is the AE-tolerability re-priming, what does the patient counseling sound like, and when does class-switch take precedence over dose-up or adjunct-addition?”

Scope. Ten transition scenarios:

1. Sema → Tirz (most common transition; SURMOUNT-5 anchored)
2. Tirz → Sema (less common; ESSENCE/FLOW/MASH-CKD-indication-driven)
3. Sema → Reta (anticipated post-TRIUMPH-3 approval; magnitude-after-sema-plateau)
4. Tirz → Reta (anticipated; magnitude-after-tirz-plateau)
5. Sema/Tirz → Lira (pre-conception pivot; short half-life advantage)
6. Sema/Tirz → Survodutide (MASH-driven pivot; Tesa-adjunct-insufficient context)
7. Injectable → Orforglipron (oral platform transition; injection-burden patients)
8. Sema → CagriSema (post-FDA-approval; combo-product magnitude extension via amylin axis)
9. Sema → IcoSema (T2D + basal insulin patients; combo platform; EMA Kyinsu approved 2025)
10. Non-response algorithmic transitions (per M5.8 + per-canonical §7 logic — when class-switch beats dose-up, lifestyle reinforcement, or adjunct addition)

Transition-as-unit-of-analysis. The 12-section Protocol Template applies, with section-by-section adaptation:

• §1 Indication scope = “transition scenarios” (not “primary indication”). Each transition is its own clinical scenario with its own indication-driver and its own decision criteria.
• §4 Initiation = transition-execution protocol (the actual switching mechanics: hold prior compound, washout window, AE-tolerability re-priming, new-compound starting dose).
• §5 Maintenance = post-transition monitoring (4–6 week observation, tolerability, response trajectory on the new compound).
• §6 AE management = transition-period-specific AEs (loss of GI-tolerability buildup, weight-rebound pulse, hypoglycemia in concurrent-agent transitions).
• §7 Plateau / non-response = transition-anchored non-response algorithm; when a transition itself is the non-response answer; when a second transition is warranted.
• §10 Counseling = patient-counseling beats per transition scenario.
• §12 Decision tree = matrix of “when to use which transition path.”

Pattern AA.marketing-claims discipline — load-bearing. This protocol traverses regulatory states. Semaglutide, tirzepatide, and liraglutide are FDA-approved-for-marketing-claims for specific indications (per their respective protocols’ §1). Retatrutide, survodutide, cagrilintide, CagriSema, IcoSema (US), and orforglipron are investigational as of 2026-05-14 — Phase 3 readouts reported in some cases, FDA submissions filed in others, EMA Kyinsu IcoSema approval already in hand for T2D in some jurisdictions. The protocol uses the convention “FDA-approved for marketing claims for [indication X]; investigational pending [trial/readout]; EMA-approved for [Y]” at every transition-target reference, so the regulatory state of the destination of each transition is explicit at the point of recommendation. Transition logic to an investigational compound is framed as anticipated / pending-approval framework, not as current operational option, unless the trial-enrollment pathway is itself the access mechanism (Survodutide LIVERAGE; Retatrutide TRIUMPH; CagriSema REDEFINE).

Pattern Z calibration — all five anchors apply across the transition matrix:

• Anchor 1 + 2 (compounded counseling). Multiple transitions cross compounded supply (compounded sema → FDA-approved Wegovy; compounded tirz → branded Zepbound; brand → compounded for cost/access). The transition mechanics frame compounded options as real-world clinical options used by substantial patient populations; the counseling beat does not steer between compounded and FDA-approved on the basis of regulatory framing alone.
• Anchor 3 (pregnancy-planning research-state-leading). Pre-conception pivot (sema/tirz → lira) is Scenario 5 — one of the most clinically meaningful transitions in the matrix. The half-life-driven pre-conception window arithmetic (sema ~35-day clearance / 8-week label; tirz ~25-day clearance / ~4-week PK plus margin; lira ~2-day clearance) is the substantive PK basis; Parker 2025 PMID 40329607 human pregnancy-exposure pooled data LEADS the counseling beat per canonical Anchor 3.
• Anchor 4 (multi-dimensional comparator framing). Every transition scenario is a comparator decision: the patient is asking “should I move from X to Y?” The counseling beats present multi-dimensional facts (magnitude, CV evidence, MASH evidence, kidney evidence, NAION class-differentiation, GI tolerability, route, cost, regulatory state) per transition pair; opens with affirmation of both compounds; closes with shared decision-making.
• Anchor 5 (off-label / extrapolation transparency). Transitions to investigational compounds (reta, surv, cagri, CagriSema, IcoSema US, orfo) are framed as research-state-incomplete with explicit trial-population scope; transitions for off-label indications (CWM intent on a T2D-only formulation; longevity/microdosing intent) are framed transparently per canonical Anchor 5.

Pattern Z.injection-framing and Pattern Z.research-precision discipline throughout. Self-injection during transition is a routine clinical skill, not a daunting barrier (Anchor 1 IS-framing for the new compound). Research-state vocabulary for investigational transition targets is precise — “Phase 3 readout reported,” “FDA submission filed,” “EMA-approved for [indication]” — never “fringe,” “highly experimental,” “speculative,” or “unproven.”

Pattern V trial-anchored framing. Where head-to-head data exists, the protocol cites it explicitly: SURMOUNT-5 (PMID 40353578) for sema vs tirz; SURPASS-2 (PMID 34170647) for tirz vs sema in T2D; STEP 8 (PMID 35015037) for sema vs lira CWM. Where head-to-head data does not exist (sema vs reta; tirz vs reta; sema vs orfo; sema vs surv; sema vs CagriSema head-to-head), the protocol uses cross-trial comparison framing with explicit Pattern V cross-trial qualification — the trials are not the same enrollment, the placebo response differs across trial programs, and the differentially-effective compound on cross-trial may not be the differentially-effective compound in a head-to-head that has not been done.

Pattern W cross-section consistency. §7 non-response transitions in this Stack Protocol align with the per-canonical §7 logic across all nine protocols — the non-response algorithm reads the same whether the clinician enters from [[Semaglutide Protocol]] §7, [[Tirzepatide Protocol]] §7, [[Liraglutide Protocol]] §7, or any of the other six per-canonical §7s. Drift between per-canonical §7 and this Stack Protocol §7 is a Pattern W violation and the per-canonical canon is authority.

§4 IS the protocol. The transition-execution protocol (§4) is the load-bearing operational section. Sections 1–3 set up the indication scope (transition scenarios), selection criteria (when each transition is indicated and contraindicated), and pre-transition workup (what to confirm before transitioning); §4 specifies the actual switching mechanics; §5–§8 handle post-transition monitoring, AE management, second-line transitions if the first transition does not succeed, and discontinuation of the new compound; §9 covers transition-as-combination-decision (when to layer rather than transition); §10 counsels the patient through the transition; §11 anchors every transition fact to primary sources; §12 collects the matrix as a one-page operational reference.

Table of Contents

1. Indication scope and transition scenarios
2. Selection criteria — when to transition, when not to transition
3. Pre-transition workup
4. Transition-execution protocol (the actual switching mechanics)
5. Post-transition monitoring and maintenance
6. Transition-period-specific adverse event management
7. Transition-anchored non-response algorithm
8. Discontinuation of the new compound
9. Transition vs combination — layering decisions
10. Patient counseling beats per transition scenario (Pattern Z calibration-anchor-compliant)
11. Source citations
12. Transition decision matrix (one-page operational reference)

Appendices

• A. Half-life and pre-conception washout arithmetic — class summary
• B. Pattern discipline summary — transition-specific applications
• C. Self-audit findings and cross-protocol wikilink index

Cross-references

• Per-canonical protocols (load-bearing for transition source and destination):
  • [[Semaglutide Protocol]] — six FDA-approved-for-marketing-claims indications; longest pharmacovigilance record in the class
  • [[Tirzepatide Protocol]] — four FDA-approved-for-marketing-claims indications; SURMOUNT-5 head-to-head superior on CWM weight-magnitude
  • [[Retatrutide Protocol]] — investigational; TRIUMPH Phase 3 program; magnitude-extension transition target
  • [[Liraglutide Protocol]] — FDA-approved T2D + CWM + adolescent; daily-SC; short half-life pre-conception advantage
  • [[Survodutide Protocol]] — investigational; LIVE-1 MASH Phase 2; SYNCHRONIZE CWM Phase 3 ongoing; LIVERAGE MASH F2/F3 recruiting
  • [[Orforglipron Protocol]] — investigational; ATTAIN-1 / ACHIEVE Phase 3 read; FDA filing pending decision; oral non-peptide
  • [[Cagrilintide Protocol]] — investigational as monotherapy; amylin axis; principal use is as CagriSema component
  • [[CagriSema Protocol]] — investigational; REDEFINE Phase 3 readout reported; fixed-ratio cagrilintide + semaglutide combination
  • [[IcoSema Protocol]] — EMA Kyinsu approved 2025 for T2D + basal insulin; FDA investigational; fixed-ratio insulin icodec + semaglutide combination
• Meta-protocol bridge: [[Module 5 – Phenotype-Guided Decision Tree Protocol]] — Axis 6 pre-conception planning; §12 cross-phenotype combination logic; §13 Pattern Z patient-counseling beat library
• Adjunct stack protocols (for transition-vs-adjunct-addition decisions): [[Tesamorelin + AOD-9604 – Visceral Fat Adjunct Protocol]]; [[CJC-1295 + Ipamorelin + MOTS-c – Lean Mass Preservation Stack Protocol]]; [[GHK-Cu – Post-Weight-Loss Skin Laxity Protocol]]
• Clinical-education anchor: M5.8 - Patient Titration Schedules, Side Effect Management & Dose Optimization — §4 cross-compound switching protocol; §4.4 non-response-algorithm-with-class-switch evidence base; §4.5 daily-to-weekly transition; Q2 + Q5 knowledge-check rationales
• Template: /obsidian-peptides/Methodology/Protocol Template.md (v1.0)
• Pattern Z anchor: /Internal/Module-5-Pipeline/pattern-z-calibration-anchor.md (all five anchors)
• Editorial framework: /obsidian-peptides/Methodology/Synergy Editorial Framework.md (v1.2; §1.2.1 FDA-approved-for-marketing-claims discipline)
• System observations: /obsidian-peptides/Methodology/AC2-26 - System Observations.md (Patterns R / R.1 / R.2; V; W; X; Y; Z; AA; AA.marketing-claims; AB / AB.4; N.1; Z.injection-framing; Z.research-precision; the five new sub-patterns for this Stack Protocol — see Appendix B)
• Voice profile: /obsidian-peptides/Methodology/Voice Profile - Dr. Jeff Gross MD.md

---

1. Indication scope and transition scenarios

1.1 Purpose

Define when a transition is the clinical question. The transition is the unit of analysis in this protocol — not the compound. A patient presents to the clinician already on a Module 5 GLP-1-axis compound, and either the patient or the clinician (or both) is asking whether to move to a different compound. Section 1 catalogues the ten transition scenarios that arise across the Module 5 portfolio and anchors each to the clinical driver that triggers the question.

Pattern R.1 enforcement at this section: §1 opens with what each transition is and for whom — the scenario, the patient phenotype, the clinical driver. It does not open with “when not to transition” (that lives in §2 relative-exclusion / contraindication framing) or with “the transition is risky” (that lives in §6 AE-management). Pattern R.2 enforcement: the ten-scenario taxonomy is locked at the section-architecture-design step; the protocol does not drift into a different transition framework mid-draft.

The ten transition scenarios are not mutually exclusive — a single patient may meet criteria for two or three scenarios simultaneously (e.g., a patient on semaglutide with plateau response AND pre-conception planning may be evaluating Scenario 1 sema → tirz AND Scenario 5 sema → lira; the clinician and patient weigh both against the patient’s reproductive-planning horizon and weight-magnitude objectives). §12 walks the cross-scenario combination logic.

1.2 The ten transition scenarios — Pattern Z Anchor 4 multi-dimensional summary

Scenario 1 — Sema → Tirz (the most common transition). Trial-anchored. SURMOUNT-5 head-to-head (Aronne 2025 NEJM, PMID 40353578; n=751 max-tolerated-dose comparison at 72 weeks; CWM in adults with obesity) demonstrated tirzepatide –20.2% vs semaglutide –13.7% — approximately 6.5 percentage-point difference favoring tirzepatide. SURPASS-2 head-to-head (Frías 2021 NEJM, PMID 34170647; T2D) demonstrated tirzepatide 15 mg HbA1c reduction ~2.3 percentage points vs semaglutide 1 mg ~1.9 percentage points at Week 40. Clinical driver: semaglutide non-response or partial response on adherent target dose; T2D HbA1c above target on 2.0 mg semaglutide; patient-preference magnitude objective. Pattern AA: both compounds FDA-approved-for-marketing-claims for the relevant indications. See §4.2 transition-execution protocol; §10.2 counseling beat.

Scenario 2 — Tirz → Sema (less common; indication-driven). No head-to-head trial in the reverse direction (SURMOUNT-5 / SURPASS-2 anchor sema → tirz as the magnitude-superior direction; tirz → sema is anchored by indication-specific evidence). Clinical driver: ESSENCE-anchored MASH F2/F3 indication (semaglutide FDA-approved 2025; tirzepatide MASH program in development); FLOW-anchored CKD-in-T2D indication (semaglutide FDA-approved 2025); SELECT-anchored ASCVD-in-BMI ≥27 indication (semaglutide FDA-approved 2024); patient-preference for oral formulation (Rybelsus 14 mg for T2D; oral Wegovy 25 mg for CWM, FDA-approved 2025); tirzepatide GI intolerance with patient electing alternative class member. Pattern AA: both compounds FDA-approved-for-marketing-claims; the indication-driver determines the direction. See §4.3.

Scenario 3 — Sema → Reta (anticipated; magnitude-extension). Investigational target. TRIUMPH Phase 2 (Jastreboff 2023 NEJM, PMID 37356046; n=338 non-diabetic obesity 48 weeks): retatrutide –24.2% at 12 mg vs –2.1% placebo. TRIUMPH-4 Phase 3 readout (Lilly investor disclosure December 2025; peer-reviewed publication pending): –28.7%. Clinical driver: semaglutide plateau or non-response on adherent target dose with patient electing magnitude objective beyond what within-class-monoagonist or even tirzepatide can provide; clinician judgment that the triple-agonist (GLP-1 + GIP + glucagon) mechanism is the magnitude-extension path. Pattern AA: retatrutide is investigational pending FDA decision; transition framework is anticipated, not current operational option except via TRIUMPH Phase 3 enrollment or post-approval. See §4.4; §10.4 counseling beat anchored to Pattern Z Anchor 5 (extrapolation transparency).

Scenario 4 — Tirz → Reta (anticipated; magnitude-extension after tirz). Investigational target. Cross-trial comparison: SURMOUNT-1 tirzepatide 15 mg –22.5% (PMID 35658024; non-diabetic obesity 72 weeks) vs TRIUMPH-4 retatrutide 12 mg –28.7%. Pattern V cross-trial qualification: not head-to-head; trial-program enrollment phenotypes differ; the head-to-head sema-vs-tirz analog (SURMOUNT-5) does not exist for tirz-vs-reta as of 2026-05-14. Clinical driver: tirzepatide plateau or partial response on adherent 15 mg target dose with patient electing magnitude objective beyond dual-agonist mechanism. Pattern AA: retatrutide investigational. See §4.5; §10.5.

Scenario 5 — Sema/Tirz → Lira (pre-conception pivot). The pharmacokinetics-driven transition. Liraglutide elimination half-life ~13 hours vs semaglutide ~7 days vs tirzepatide ~5 days; substantial-clearance washout: liraglutide **~2 days** vs semaglutide ~35 days vs tirzepatide ~25 days. Clinical driver: reproductive-age patient on sema or tirz with conception planning horizon ≤6 months electing to remain on GLP-1 RA therapy for as long as possible before pre-conception discontinuation. Pivot from long-half-life weekly to short-half-life daily allows substantially compressed pre-conception window. Pattern AA: liraglutide FDA-approved-for-marketing-claims for T2D (Victoza 2010), CWM (Saxenda 2014), and adolescent CWM (≥12y, 2020) — the destination is FDA-approved; the pivot is operationally a within-class-change. Pattern Z Anchor 3 LEADS counseling beat with Parker 2025 PMID 40329607 human pregnancy-exposure pooled data. See §4.6; §10.6 counseling beat.

Scenario 6 — Sema/Tirz → Survodutide (MASH-driven pivot; Tesa-adjunct-insufficient). Investigational target. LIVE-1 Phase 2 (Sanyal 2024 NEJM, PMID 38863223; n=293 MASH F1-F3 48 weeks): survodutide 76% histologic resolution at F2/F3 vs ~14% placebo. LIVERAGE Phase 3 (NCT06632444) recruiting as of 2026-05-14 per ClinicalTrials.gov verification. Clinical driver: MASH F2/F3 indication where semaglutide ESSENCE (FDA-approved August 2025) is the current first-line, but the patient is non-response on semaglutide MASH indication with persistent F2/F3 fibrosis on follow-up imaging or biopsy; tesamorelin visceral-adipose-tissue adjunct (per [[Tesamorelin + AOD-9604 – Visceral Fat Adjunct Protocol]]) has been trialed and is insufficient for the MASH-fibrosis trajectory. Pattern AA: survodutide investigational; transition pathway is LIVERAGE Phase 3 trial enrollment rather than commercial off-label access (Boehringer Ingelheim has not commercialized for off-label use). See §4.7; §10.7.

Scenario 7 — Injectable → Orforglipron (oral platform transition). Investigational target (FDA decision pending as of 2026-05-14 per [[Orforglipron Protocol]] §1). Clinical driver: patient on weekly-SC semaglutide or tirzepatide with patient-preference oral platform (injection burden, needle aversion, travel-pattern non-compatibility with weekly-SC schedule, peri-procedural medication-pause complexity), OR cost-access dimension shift if orforglipron commercial pricing post-approval is meaningfully different. Pattern AA: orforglipron investigational; transition framework is anticipated. Pattern N.1: orforglipron is a small-molecule non-peptide oral GLP-1 RA — the half-life (~29 hours) and platform consequences differ from peptide GLP-1 RAs. Pattern Z.injection-framing reciprocity: the protocol does NOT default-frame self-injection as “burden” to be relieved by oral transition; the transition is patient-preference-anchored, not steered by injection-framing-anxiety. See §4.8; §10.8.

Scenario 8 — Sema → CagriSema (post-FDA-approval; amylin-axis magnitude extension). Investigational as of 2026-05-14; REDEFINE Phase 3 readout reported; Novo Nordisk filed for FDA approval. REDEFINE-1 (PMID 40544433): –20.4% body weight (treatment-policy) / –22.7% adherent vs –3.0% placebo in non-diabetic obesity at 68 weeks. Clinical driver: patient on stable semaglutide 2.4 mg with plateau response or partial response electing the amylin-pathway additive mechanism; the semaglutide-component dose is unchanged (2.4 mg → 2.4 mg within CagriSema); the cagrilintide-component is added through titration. Pattern AA: CagriSema FDA-pending as of 2026-05-14; transition is anticipated post-approval. See §4.9; §10.9.

Scenario 9 — Sema → IcoSema (T2D + basal insulin patients; combo platform). EMA Kyinsu approved 2025 for T2D in adults inadequately controlled on basal insulin (per [[IcoSema Protocol]] §1); FDA submission status check current; Phase 3 COMBINE program (1, 2, 3) anchors the indication. COMBINE-2 (T2D on prior GLP-1 RA): structured switch protocol; the GLP-1R tolerance is established; the new clinical consideration is the basal-insulin-icodec component addition with hypoglycemia surveillance. Sulfonylurea or insulin-secretagogue co-medications discontinued or substantially dose-reduced at IcoSema initiation per [[IcoSema Protocol]] §6.11.1. Clinical driver: T2D patient on prior semaglutide with HbA1c above target on adherent target dose AND basal-insulin requirement emerging or already established; the regimen-simplification value (52 weekly IcoSema injections vs 730+ basal-bolus injections per year if patient was on basal-bolus) is patient-preference-anchored. Pattern AA: IcoSema EMA-approved for T2D; FDA investigational. See §4.10; §10.10.

Scenario 10 — Non-response transitions (algorithmic; per per-canonical §7 logic). This scenario integrates Scenarios 1–9 into the algorithmic decision tree that operates when a patient is on Module 5 compound X and the clinical question is “is the next decision a within-compound dose-up, an adjunct addition (lean-mass / visceral / behavioral / nutritional intensification), or a class-switch (transition to compound Y)?” The non-response algorithm is the workhorse §7 logic across all nine per-canonical protocols; this Stack Protocol §7 consolidates the algorithm with explicit cross-canonical consistency (Pattern W). See §7 in full; §10 cross-cutting counseling beats.

1.3 Indication scope of this Stack Protocol

The indication scope of this Stack Protocol is any patient on a Module 5 GLP-1-axis compound where transition is on the clinical table — whether driven by non-response, by indication shift, by pre-conception planning, by patient preference, by AE intolerance, by regulatory shift (new approval expanding the compound matrix), or by access-and-cost considerations. The scope is intentionally broad: a typical Module 5 practice will see transition questions across all ten scenarios over the course of a year; the protocol is therefore designed as a transition-matrix reference, not as a single-transition protocol.

The scope excludes:

• Transitions out of the Module 5 portfolio entirely (e.g., transition from GLP-1 RA to bariatric surgery, to phentermine, to setmelanotide for MC4R deficiency) — these are covered in their respective protocols and in the [[Module 5 – Phenotype-Guided Decision Tree Protocol]] cross-class-decision sections.
• De novo initiation (a patient not currently on any Module 5 compound starting a first compound) — this is covered in the per-canonical §4 initiation protocols.
• Adjunct addition without transition (a patient on sema adding a lean-mass adjunct or a visceral-fat adjunct without changing the GLP-1 RA backbone) — these are covered in the respective adjunct stack protocols.

The scope includes:

• Within-class transitions (sema ↔︎ tirz ↔︎ reta ↔︎ lira; within the GLP-1 RA mono- / dual- / triple-agonist family).
• Cross-platform transitions (injectable ↔︎ oral within the GLP-1 axis; orforglipron is the principal oral non-peptide; Rybelsus and oral Wegovy are oral peptide).
• Mechanism-class transitions within Module 5 (GLP-1 mono → GLP-1 + amylin combo via CagriSema; GLP-1 mono → GLP-1 + basal insulin combo via IcoSema; GLP-1 mono → GLP-1 + glucagon via survodutide; GLP-1 + GIP → GLP-1 + GIP + glucagon via retatrutide).
• Pre-conception pivot transitions (long-half-life → short-half-life within the GLP-1 RA class for compressed pre-conception window).
• Patient-preference transitions on platform / route / cost / access dimensions.

1.4 Phenotype-targeting taxonomy applied to transitions

The Module 5 phenotype taxonomy from [[Module 5 – Phenotype-Guided Decision Tree Protocol]] §2.2 (the ten axes) maps onto the ten transition scenarios. Phenotype dimensions that most heavily drive transition decisions:

• Pharmacologic history (the §1.3 phenotype-taxonomy “pharmacologic history” dimension). Prior GLP-1 RA exposure — response or non-response or intolerance — is the foundational data for transition decisions. A patient who tolerated semaglutide well but achieved sub-target weight loss is a different transition candidate than a patient who experienced severe GI intolerance on semaglutide; the former is a candidate for magnitude-extension (Scenario 1 sema → tirz; Scenario 3 sema → reta; Scenario 8 sema → CagriSema), the latter for class-switch with explicit AE-class differentiation (some transitions cross GI-tolerability-profile differences; tirzepatide trial-program GI AE incidence is similar-to-modestly-different than semaglutide per cross-trial data, and the individual-patient response is not predictable from class-level data).
• Comorbidity-load (polycondition vs monocondition). A polycondition T2D + ASCVD + CKD + MASH patient on tirzepatide may be a Scenario 2 tirz → sema candidate to access the FDA-approved-for-marketing-claims indications for MASH (ESSENCE), CKD-in-T2D (FLOW), and ASCVD-in-non-diabetic-obesity (SELECT) that semaglutide carries and tirzepatide does not yet (as of 2026-05-14). The transition is not a magnitude-decision; it is an indication-coverage decision.
• Life-stage modifier — pre-conception planning (Axis 6). The dominant transition driver for reproductive-age patients with a conception horizon ≤12 months. Scenario 5 sema/tirz → lira applies; the half-life-driven pre-conception window arithmetic determines the operational timeline. Pattern Z Anchor 3 calibration governs the counseling beat.
• Route / platform preference (Axis 8). Patient-preference oral vs injectable; weekly vs daily; peri-procedural medication-pause complexity. Scenario 7 injectable → orforglipron applies for the platform-shift; Scenario 5 sema/tirz → lira applies for the daily-vs-weekly shift (though pre-conception planning is the dominant Scenario 5 driver).
• Cost / access (Axis 9). Liraglutide off-patent in EU markets 2023 with generic competition emerging in US; compounded sema and tirz under 503A/503B pathways; insurance coverage variable by indication and formulation. Cost-access transitions cross compounded↔︎FDA-approved and brand↔︎generic dimensions; counseling beat per Pattern Z Anchor 1 + 2.
• Indication coverage (Axis 5 hepatic; Axis 4 kidney; Axis 3 cardiovascular). The MASH / CKD / ASCVD indication-coverage transition decisions (Scenario 2 tirz → sema; Scenario 6 sema/tirz → survodutide) are anchored to which compound carries the FDA-approved-for-marketing-claims indication or the active investigational pathway for the patient’s comorbidity profile.

1.5 Worked example — phenotype mapping to transition scenario

A 49-year-old female on semaglutide 2.4 mg Wegovy for CWM, Month 14 on target dose, weight loss 8.5% from baseline (sub-target relative to STEP-1 ~14.9% effect-size anchor and below the patient’s pre-stated 15% objective). Comorbidity: borderline hypertension on lisinopril; no T2D, no ASCVD, no CKD, no MASH. Reproductive-age, post-menopausal, no conception planning. Patient asks: “Should I switch to tirzepatide? My friend lost more on it.”

Phenotype-mapping walk. Pharmacologic-history dimension: patient is adherent semaglutide partial-responder on target dose at adequate observation window (Month 14, target dose since Month 4-5). Comorbidity-load: monocondition CWM with non-active comorbidity (borderline HTN). Life-stage: post-menopausal — Axis 6 pre-conception planning does not apply; Scenario 5 is not on the table. Route: weekly-SC already; injection-tolerance established. Cost / access: variable depending on insurance coverage and compounded-vs-FDA-approved supply chain.

Transition-scenario mapping. Patient phenotype maps to Scenario 1 sema → tirz primarily (magnitude-extension with within-class transition; SURMOUNT-5 head-to-head data anchored). Scenario 8 sema → CagriSema is a candidate post-FDA-approval. Scenario 3 sema → reta is a candidate post-TRIUMPH approval. The patient and clinician decide among the candidate transitions per the §10 counseling beats and the §12 transition decision matrix.

Pattern AA precision applied. Tirzepatide FDA-approved-for-marketing-claims for CWM (Zepbound 2023); the Scenario 1 transition is to a currently-available on-label compound. CagriSema is FDA-pending as of 2026-05-14; the Scenario 8 transition is anticipated framework, not current operational option. Retatrutide is investigational; the Scenario 3 transition is anticipated framework. The counseling beat (§10.2 for Scenario 1; §10.4 for Scenario 3; §10.9 for Scenario 8) carries the regulatory-state distinction explicitly.

Pattern Z Anchor 4 calibration. The counseling beat for this patient presents the multi-dimensional facts: SURMOUNT-5 head-to-head magnitude advantage (–20.2% vs –13.7% at max-tolerated doses); cardiovascular outcomes-evidence base (SELECT for sema in non-diabetic obesity with ASCVD; SURMOUNT-MMO for tirz in progress); MASH approval state (sema approved ESSENCE; tirz program in development); kidney evidence (FLOW for sema; tirz kidney in development); NAION class-differentiation (signal documented for sema per Hathaway 2024 PMID 38958939; signal absent for tirz per Lawrenson 2025 PMID 40383360 / Lakhani 2025 PMID 40383360); GI tolerability profile (similar-class with patient-specific response unpredictable); route / cost / access. Opens with affirmation of both compounds. Closes with shared decision-making.

1.6 Pattern AB.4 standing scan applied to §1

Every NCT, PMID, and trial-program identifier in §1 above (SURMOUNT-5 PMID 40353578; SURPASS-2 PMID 34170647; STEP-1 PMID 33567185; SURMOUNT-1 PMID 35658024; TRIUMPH Phase 2 PMID 37356046; TRIUMPH-4 — Lilly investor disclosure pending peer-reviewed publication; LIVE-1 PMID 38863223; LIVERAGE NCT06632444; REDEFINE-1 PMID 40544433; ESSENCE PMID 40305708; SELECT PMID 37952131; FLOW PMID 38785209; STEP 8 PMID 35015037; Hathaway 2024 PMID 38958939; Lakhani 2025 PMID 40383360; Parker 2025 PMID 40329607) is verified by content per the per-canonical Bibliographies. The Pattern AB.4 cascade-scan precedent (NCT05608252 misattribution prevented per AC2-26 system-observations log) applies — when any identifier is corrected in the per-canonical protocols, this Stack Protocol’s §11 Bibliography is updated in the same commit and §1 references are updated.

---

2. Selection criteria — when to transition, when not to transition

2.1 Purpose

Define who is a transition candidate, who is not, and what hard contraindications block specific transitions. §2 operationalizes the §1 transition-scenario taxonomy into actionable clinical screening criteria — the inclusion criteria for each scenario (the patient phenotype for whom the transition is indicated), the relative exclusions (clinician-judgment phenotypes where benefit is uncertain or risk is elevated), and the hard contraindications (where the transition must not be performed).

Pattern R.1 enforcement: §2 opens with inclusion criteria — who the transition is for — before exclusions and contraindications. The architectural ordering inclusion → relative-exclusion → contraindication is Pattern R.1 design-time enforcement. Pattern AA enforcement: every contraindication is anchored to its source (FDA boxed warning class-wide for GLP-1 RAs; specific labeled contraindication; relative-exclusion clinician-judgment; pre-conception planning ≤ X weeks; specific AE history).

2.2 Inclusion criteria — who is a transition candidate per scenario

Scenario 1 (Sema → Tirz) inclusion. Adult on semaglutide for CWM (Wegovy 2.4 mg / 7.2 mg / oral 25 mg) or T2D (Ozempic 1.0 mg / 2.0 mg; Rybelsus 14 mg) on target dose for adequate observation window (typically ≥3-6 months on target dose) with documented partial response, non-response, or patient-elected magnitude-objective transition. Patient is adherent (refill audit confirms; missed-dose rate not the driver of sub-target response). No contraindication to tirzepatide per [[Tirzepatide Protocol]] §2.4 (MTC / MEN-2 boxed warning; severe prior pancreatitis history; known hypersensitivity to tirzepatide or excipient; pregnancy in CWM indication). Patient-clinician shared decision after Pattern Z Anchor 4 multi-dimensional comparator counseling (§10.2).

Scenario 2 (Tirz → Sema) inclusion. Adult on tirzepatide for CWM (Zepbound 15 mg) or T2D (Mounjaro 15 mg) with one of: emerging or progressing MASH F2/F3 phenotype where ESSENCE-anchored semaglutide MASH indication is the destination; emerging or progressing CKD-in-T2D phenotype where FLOW-anchored semaglutide CKD indication is the destination; established ASCVD with non-diabetic obesity where SELECT-anchored semaglutide CV-risk-reduction indication is the destination; patient-preference for oral formulation (Rybelsus T2D; oral Wegovy 25 mg CWM); tirzepatide GI intolerance with patient electing alternative class member. No contraindication to semaglutide per [[Semaglutide Protocol]] §2.4. Patient-clinician shared decision after §10.3 counseling beat.

Scenario 3 (Sema → Reta) inclusion. Adult on semaglutide with documented plateau or non-response on adherent target dose AND patient electing magnitude-extension via triple-agonist mechanism. Pattern AA: retatrutide is investigational as of 2026-05-14; inclusion in this scenario is operationally either (a) enrollment in an active TRIUMPH Phase 3 trial that the patient qualifies for, OR (b) post-approval framework awaiting commercial availability. Retatrutide enrollment criteria per TRIUMPH program apply (the trial-protocol exclusions are the operative exclusions during the pre-approval period). No contraindication to retatrutide per [[Retatrutide Protocol]] §2.4 (anticipated class-wide MTC / MEN-2; pancreatitis history; severe hepatic; pregnancy; specific TRIUMPH protocol contraindications). §10.4 counseling beat anchors Pattern Z Anchor 5 (extrapolation transparency).

Scenario 4 (Tirz → Reta) inclusion. Adult on tirzepatide with documented plateau or non-response on adherent 15 mg target dose AND patient electing magnitude-extension. Same regulatory framework as Scenario 3 (retatrutide investigational; access via TRIUMPH or post-approval). No contraindication to retatrutide. §10.5 counseling beat.

Scenario 5 (Sema/Tirz → Lira; pre-conception pivot) inclusion. Reproductive-age adult female on semaglutide or tirzepatide for CWM or T2D with conception planning horizon ≤12 months electing to remain on GLP-1 RA therapy through the compressed pre-conception window. The clinical context: patient values continued therapy until shortly before conception attempt. Pivot to liraglutide allows the ~2-day washout window vs ~35-day (sema) or ~25-day (tirz). No contraindication to liraglutide per [[Liraglutide Protocol]] §2.4 (MTC / MEN-2; severe gastroparesis; severe pancreatitis history; pregnancy). §10.6 counseling beat anchors Pattern Z Anchor 3 (pregnancy-planning research-state-leading per Parker 2025 PMID 40329607).

Scenario 6 (Sema/Tirz → Survodutide; MASH-driven pivot) inclusion. Adult with biopsy- or imaging-confirmed MASH F2/F3 fibrosis on semaglutide (ESSENCE-anchored indication) or tirzepatide (off-label or MASH-program-pending) with inadequate MASH-fibrosis trajectory at adequate observation window (typically 6-12 months on target dose with follow-up imaging or biopsy demonstrating persistent F2/F3 fibrosis or progression). Tesamorelin visceral-adipose-tissue adjunct (per [[Tesamorelin + AOD-9604 – Visceral Fat Adjunct Protocol]]) has been trialed and is insufficient. Pattern AA: survodutide investigational; inclusion is operationally LIVERAGE Phase 3 trial enrollment (NCT06632444 RECRUITING as of 2026-05-14) or post-approval framework. No contraindication to survodutide per [[Survodutide Protocol]] §2.4 (anticipated class-wide MTC / MEN-2; pancreatitis; severe hepatic Child-Pugh C; pregnancy; LIVERAGE-protocol-specific contraindications). §10.7 counseling beat.

Scenario 7 (Injectable → Orforglipron) inclusion. Adult on weekly-SC semaglutide or tirzepatide with patient-preference oral platform OR cost-access dimension shift. Pattern AA: orforglipron investigational with FDA decision pending as of 2026-05-14; inclusion is anticipated framework, not current operational option except via Phase 3 trial enrollment. No contraindication to orforglipron per [[Orforglipron Protocol]] §2.4. Pattern Z.injection-framing reciprocity: the transition is patient-preference-anchored, not steered by injection-framing-anxiety; the protocol does NOT recruit patients out of weekly-SC by framing self-injection as “burden.” §10.8 counseling beat.

Scenario 8 (Sema → CagriSema) inclusion. Adult on stable semaglutide 2.4 mg Wegovy for CWM with plateau or partial response on adherent target dose AND patient electing amylin-pathway additive mechanism. Pattern AA: CagriSema FDA-pending as of 2026-05-14; inclusion is anticipated framework or via REDEFINE program enrollment if still recruiting. The semaglutide-component dose is unchanged (2.4 mg → 2.4 mg within CagriSema); the cagrilintide-component is added through titration. No contraindication to cagrilintide per [[Cagrilintide Protocol]] §2.4 or to the combination per [[CagriSema Protocol]] §2.4. §10.9 counseling beat.

Scenario 9 (Sema → IcoSema) inclusion. T2D adult on prior semaglutide (Ozempic 1.0 mg or 2.0 mg; Rybelsus 14 mg) with HbA1c above target on adherent target dose AND basal-insulin requirement emerging or already established. Pattern AA: IcoSema EMA-approved 2025 as Kyinsu for T2D in adults inadequately controlled on basal insulin; FDA investigational. In EU jurisdictions inclusion is on-label per Kyinsu approval; in US jurisdictions inclusion is investigational pending FDA decision. COMBINE-2 (prior GLP-1 RA experienced T2D) is the trial-anchored switch population per [[IcoSema Protocol]] §1; the GLP-1R tolerance is established; the new clinical consideration is the basal-insulin-icodec component addition. Sulfonylurea / insulin-secretagogue co-medications discontinued or substantially dose-reduced at IcoSema initiation per [[IcoSema Protocol]] §6.11.1. No contraindication to IcoSema per [[IcoSema Protocol]] §2.4. §10.10 counseling beat.

Scenario 10 (Non-response algorithmic) inclusion. Any patient on a Module 5 GLP-1-axis compound at adequate observation window on adherent target dose with sub-target response by the per-canonical §7 trajectory anchors (sema: <5% Month 6 on adherent 2.4 mg; tirz: <5% Month 6 on adherent 15 mg; lira: <4% Month 4 on adherent 3.0 mg; reta: phase-3-derived once published; orfo: phase-3-derived once approved). The algorithmic decision tree in §7 walks the diagnostic distinctions (pseudo-plateau / true plateau / non-response) and the decision branches (dose-up / adjunct addition / class-switch transition / behavioral intensification) for the patient’s clinical context.

2.3 Relative exclusion criteria — clinician-judgment phenotypes

Relative exclusions that apply across transition scenarios:

• Active or recent (within 12 months) acute pancreatitis on either source or destination compound. Deferred until at least 12 months stable post-event; alternative-etiology characterization; clinician-judgment decision. Cross-class pancreatitis precedent: the pancreatitis-signal class direction-of-effect is not established as differentially-protective for any within-class compound — Pattern V flag; the patient who experienced pancreatitis on semaglutide may or may not experience it on tirzepatide; the clinician-judgment posture is “alternative-class non-GLP-1 RA may be more appropriate than within-class transition.”
• Severe gastroparesis — relative exclusion for transition to any weekly-SC compound; lira → other liraglutide-paralleled compound has the shorter-half-life-clearance differential that may be relevant for AE management; clinician-judgment.
• Active eating disorder (anorexia nervosa, bulimia nervosa, BED with active purging) — relative exclusion for any GLP-1 RA initiation including transition initiation; behavioral-health co-management required before transition.
• Diabetic retinopathy with rapid-HbA1c-improvement risk. SUSTAIN-6 documented retinopathy-complication signal in rapid-HbA1c-improvement sub-population; the relative-exclusion posture extends to transition scenarios that produce rapid HbA1c improvement (sema → tirz in T2D context with sub-target HbA1c on sema may produce rapid HbA1c reduction on tirz; ophthalmology pre-screening for proliferative DR or advanced background DR; HbA1c-trajectory-aware monitoring).
• Severe renal impairment eGFR <15 — relative exclusion outside trial-program enrollment for any compound except FLOW-anchored semaglutide which enrolled 25-75 eGFR. Clinician-judgment with nephrology co-management.
• Severe hepatic impairment Child-Pugh C — relative exclusion across the class.
• Active malignancy on therapy (other than MTC/MEN-2 which is hard contraindication). Oncology co-management for any transition consideration.
• Recent NAION on semaglutide — Scenario 1 sema → tirz is permitted with Pattern AA precision (NAION signal is class-differentiated to semaglutide per Lakhani 2025 PMID 40383360; not class-wide). Scenario 2 tirz → sema is NOT permitted if patient has prior NAION on semaglutide — the NAION-on-prior-sema is a hard contraindication for any sema re-exposure including via transition.
• Pregnancy on protocol — pregnancy is a §8 immediate discontinuation trigger across the class for CWM indications; transition consideration is moot during pregnancy. Re-initiation post-pregnancy and post-lactation per the per-canonical §8.6.

2.4 Hard contraindications — boxed warnings and labeled contraindications

Class-wide hard contraindications for all GLP-1 RAs (apply at both source and destination compound for any transition):

• Personal or family history of medullary thyroid carcinoma (MTC). FDA boxed warning class-wide for GLP-1 RAs based on rodent C-cell tumorigenicity signal; the boxed-warning-mandated contraindication is absolute. Transition to any compound in the class is contraindicated; the patient does not enter or remain in the Module 5 GLP-1 RA portfolio.
• Multiple Endocrine Neoplasia syndrome type 2 (MEN-2). Same boxed-warning class-wide; absolute.
• Severe prior pancreatitis history (severe acute or chronic). Labeled contraindication or strong-precaution depending on the specific compound label; clinician-judgment for cross-class transition is “alternative non-GLP-1 RA pathway may be more appropriate” — but the boxed-warning-equivalent class-wide standing varies and is per-compound-label-specific. [[Semaglutide Protocol]] §2.4 and [[Tirzepatide Protocol]] §2.4 document the specific label language.
• Known serious hypersensitivity to the destination compound or excipient. Labeled contraindication for the specific compound.
• Pregnancy (for CWM indications). Labeled contraindication for CWM indications across the class; pregnancy is a §8 discontinuation trigger.

Scenario-specific hard contraindications:

• Sema → Tirz transition. Contraindicated if MTC / MEN-2 / severe pancreatitis / tirzepatide hypersensitivity / pregnancy in CWM indication.
• Tirz → Sema transition. Contraindicated if prior NAION on semaglutide (hard contraindication for sema re-exposure regardless of indication-driver); MTC / MEN-2 / severe pancreatitis / semaglutide hypersensitivity / pregnancy.
• Sema/Tirz → Reta transition. Contraindicated per anticipated TRIUMPH protocol exclusions (specific Phase 3 enrollment criteria) and the class-wide contraindications. Pattern AA: anticipated framework pending FDA approval.
• Sema/Tirz → Lira transition (pre-conception pivot). Contraindicated if MTC / MEN-2 / severe pancreatitis / liraglutide hypersensitivity / pregnancy. The pre-conception-pivot rationale is moot during pregnancy.
• Sema/Tirz → Survodutide transition. Contraindicated per LIVERAGE protocol exclusions for trial-enrollment access; per anticipated survodutide label for post-approval access. Class-wide contraindications apply.
• Injectable → Orforglipron transition. Contraindicated per anticipated orforglipron label; class-wide contraindications apply. Pattern N.1: orforglipron is small-molecule non-peptide; the class-wide MTC / MEN-2 boxed-warning applies per anticipated FDA labeling.
• Sema → CagriSema transition. Contraindicated if MTC / MEN-2 / severe pancreatitis / hypersensitivity to either component / pregnancy. Cagrilintide-component-specific contraindications per [[Cagrilintide Protocol]] §2.4.
• Sema → IcoSema transition. Contraindicated if MTC / MEN-2 / severe pancreatitis / hypersensitivity to either component / pregnancy / Type 1 diabetes (IcoSema is T2D-indication-specific; the basal-insulin-icodec component is not appropriate as monotherapy for T1D). Concurrent sulfonylurea or insulin-secretagogue at IcoSema initiation is a relative-exclusion warranting dose reduction or discontinuation per [[IcoSema Protocol]] §6.11.1.

2.5 Worked example — selection criteria walkthrough for the §1.5 case

The §1.5 worked-example patient (49-year-old post-menopausal female on Wegovy 2.4 mg, partial responder at Month 14, 8.5% loss) — selection criteria walk:

Scenario 1 (sema → tirz) inclusion check. Adult on sema for CWM (✓), target dose ≥3-6 months observation window (✓ Month 14), partial responder (✓ 8.5% vs STEP-1 anchor ~14.9%), adherence confirmed (✓ refill audit clean), no contraindication to tirz (✓ no MTC / MEN-2 / pancreatitis / hypersensitivity / pregnancy). Inclusion criteria met. Patient-clinician shared decision pending §10.2 counseling beat.

Scenario 3 (sema → reta) inclusion check. Inclusion criteria for the magnitude-extension framework met (adherent partial-responder on sema target dose). Pattern AA precision: retatrutide investigational as of 2026-05-14; operational access is via TRIUMPH Phase 3 enrollment OR post-approval. Patient is eligible for TRIUMPH enrollment evaluation if she elects; the framework is anticipated for non-trial commercial access.

Scenario 5 (sema → lira) inclusion check. Pre-conception planning is Scenario 5 dominant driver; patient is post-menopausal; Scenario 5 NOT applicable. Pre-conception-pivot rationale is moot.

Scenario 8 (sema → CagriSema) inclusion check. Inclusion criteria for the amylin-pathway additive framework met (adherent partial-responder on sema 2.4 mg target dose). Pattern AA precision: CagriSema FDA-pending as of 2026-05-14; operational access is via REDEFINE program enrollment if still recruiting OR post-approval framework.

Hard contraindications check. No MTC / MEN-2 / severe pancreatitis / hypersensitivity / pregnancy. No relative exclusions (no gastroparesis; no eating disorder; no advanced DR; no severe renal or hepatic impairment).

Net selection. Scenarios 1, 3, and 8 are inclusion-criteria-eligible. Scenarios 2, 4, 5, 6, 7, 9, 10 are not currently applicable (2: no MASH/CKD/ASCVD/oral-preference driver; 4: not on tirz; 5: post-menopausal; 6: no MASH; 7: weekly-SC tolerated; 9: not T2D; 10: subset of 1 / 3 / 8 framing). Patient-clinician shared decision among Scenarios 1, 3, 8 with the §10 counseling beats and §12 transition decision matrix.

2.6 Pattern AA, Pattern V, Pattern Z applied to §2

Pattern AA precision. Every transition-destination compound’s regulatory state is explicit. Sema, tirz, lira are FDA-approved-for-marketing-claims for specific indications relevant to the transition. Reta, surv, cagri, CagriSema, IcoSema (US), orfo are investigational with the regulatory state specified per scenario. Class-wide hard contraindications (MTC / MEN-2 boxed warning) apply across all destination compounds; pre-conception status applies across CWM-indication destinations.

Pattern V precision. Inclusion criteria for magnitude-extension transitions (Scenarios 1, 3, 4, 8) are anchored to trial-program effect-size anchors with population qualification. SURMOUNT-5 head-to-head (PMID 40353578; max-tolerated-dose comparison; non-diabetic obesity 72 weeks) is the direct sema-vs-tirz CWM anchor. Cross-trial comparisons (sema vs reta; tirz vs reta; sema vs CagriSema; tirz vs CagriSema) are framed with explicit cross-trial qualification.

Pattern Z precision. Selection-criteria framing does not steer toward or away from any transition; the framing presents who is eligible (inclusion), who is in clinician-judgment territory (relative exclusion), and who is hard-contraindicated. The counseling beat in §10 carries the comparator framing for inclusion-eligible patients.

---

3. Pre-transition workup

3.1 Purpose

Define the pre-transition laboratory, imaging, and clinical-assessment workup that must be completed and reviewed before initiating any transition. §3 is the operational handoff between §2 (selection criteria — patient is a transition candidate) and §4 (transition-execution protocol). A patient who passes §2 screening enters §3 workup; only on workup completion does §4 transition-execution begin.

Pre-transition workup is NOT a repeat of the full pre-treatment workup from the per-canonical §3 — the patient is already on a Module 5 compound and has the pre-treatment workup baselined (sometimes 12+ months ago). The pre-transition workup is focused on what has changed and what the transition specifically requires — the current-state confirmation that the patient remains a Module 5 GLP-1 RA candidate, plus the destination-compound-specific workup items that differ from the source-compound workup.

Pattern W cross-section consistency: the §3 workup panel for each transition reconciles with the per-canonical §3 panels of source and destination compounds; it does not introduce new workup items absent from the per-canonical authority.

3.2 Universal pre-transition workup (applies to every transition scenario)

Current-state confirmation panel — applies to every transition:

• Current weight, BP, waist circumference. Baseline against which post-transition trajectory is measured.
• CMP including hepatic and renal function. Recent (within 3-6 months) or repeat at workup. Establishes hepatic and renal current state for any compound transition (renal function gates eGFR-based dose adjustments per per-canonical §5 for the destination compound; hepatic function gates Child-Pugh assessment).
• Fasting lipid panel and HbA1c. Recent (within 3-6 months) or repeat. Glycemic context (T2D-status verification) and metabolic-context for CV-risk indication eligibility.
• TSH. Class-wide pre-treatment baseline for any GLP-1 RA; thyroid-symptom or thyroid-exam review.
• Adherence audit. Prescription refill audit; patient interview; CGM or weight-tracking data if available. Adherence-confirmation is foundational to the §7 non-response algorithm — pseudo-non-response from inadequate adherence is the most common reason for transition consideration that should NOT result in transition (it should result in adherence reinforcement).
• AE-history audit. Documented AE events on the source compound — GI, gallbladder, pancreatitis-suspicious, NAION-suspicious, injection-site, hypoglycemia. AE history shapes destination-compound selection and counseling.
• Pregnancy status / reproductive planning interview. For reproductive-age patients on CWM indications, pregnancy test if reasonable suspicion; conception-planning interview for Scenario 5 candidacy.

Destination-compound contraindication re-screen — applies to every transition:

• MTC / MEN-2 family history re-confirmation. Particularly relevant if family history has been updated since initial workup (new first-degree relative diagnosis).
• Pancreatitis history re-confirmation. Particularly relevant if patient experienced acute pancreatitis or pancreatitis-suspicious episode on source compound.
• NAION history (semaglutide-specific). For any Scenario 2 tirz → sema transition or Scenario 8 sema → CagriSema (which retains semaglutide component), explicit NAION re-screen: prior NAION on any prior sema exposure is a hard contraindication for sema re-exposure regardless of indication-driver.
• Hypersensitivity history. Known reaction to destination-compound active or excipient.

3.3 Scenario-specific pre-transition workup

Scenario 1 (Sema → Tirz) pre-transition workup. Universal panel + adherence audit + AE-history audit. No additional destination-specific workup beyond universal — tirzepatide pre-treatment workup is class-aligned with semaglutide. If patient has T2D, dilated retinal exam if HbA1c ≥9.0 or known background DR (SUSTAIN-6 retinopathy-complication signal applies; rapid-HbA1c-improvement on tirz transition may produce similar signal).

Scenario 2 (Tirz → Sema) pre-transition workup. Universal panel + NAION pre-screen (any visual-symptom history; known optic-disc-cupping / “disc-at-risk”; prior NAION → hard contraindication for sema re-exposure regardless of tirz response). If MASH-indication-driver: FIB-4 score from current labs; VCTE / FibroScan if FIB-4 indeterminate or high; reconfirm MASH F2/F3 staging if last imaging or biopsy >12 months ago. If CKD-indication-driver: UACR documentation, eGFR, RAS-blockade documentation at maximally tolerated dose. If ASCVD-indication-driver: ECG, lipid panel current.

Scenario 3 (Sema → Reta) pre-transition workup. Universal panel + adherence audit + AE-history audit. If TRIUMPH Phase 3 trial enrollment is the access pathway: TRIUMPH-protocol-specific enrollment screen (per the trial protocol’s inclusion criteria; ClinicalTrials.gov registration carries the specific lab/imaging panel). Pattern AA: investigational compound; the trial-protocol workup is operationally the pre-transition workup. If post-approval framework: anticipated FDA-label workup will mirror class-wide GLP-1 RA pre-treatment panel.

Scenario 4 (Tirz → Reta) pre-transition workup. Same as Scenario 3.

Scenario 5 (Sema/Tirz → Lira; pre-conception pivot) pre-transition workup. Universal panel + explicit reproductive-planning interview (conception planning horizon; partner reproductive context; obstetric history; contraception during transition period). Re-confirm: Parker 2025 PMID 40329607 pooled human pregnancy-exposure data review with patient (research-state-leading per Pattern Z Anchor 3). If T2D: HbA1c current (pre-pregnancy glycemic optimization is the standard-of-care framework; lira transition is one component of pre-conception planning).

Scenario 6 (Sema/Tirz → Survodutide; MASH-driven) pre-transition workup. Universal panel + MASH-fibrosis trajectory documentation: FIB-4 trend (baseline → current); VCTE / FibroScan current and prior comparison; liver biopsy if clinically indicated for histology re-staging; viral hepatitis screen if not done recently; iron studies; autoimmune liver-disease screen if clinically indicated. Hepatology co-management coordination. If LIVERAGE Phase 3 trial enrollment is the access pathway: LIVERAGE protocol-specific enrollment screen.

Scenario 7 (Injectable → Orforglipron) pre-transition workup. Universal panel + adherence audit + injection-tolerance review (patient-preference confirmation that oral-platform shift is the patient’s decision, not steered by clinician injection-framing-anxiety per Pattern Z.injection-framing). Pattern N.1: orforglipron is small-molecule non-peptide; specific drug-drug interaction screen per [[Orforglipron Protocol]] §3 (the oral platform has interaction considerations the peptide platforms do not have, particularly with concurrent gastric-acid-modulating agents or motility-modulating agents). If anticipated FDA-approval pathway pending: post-approval label-specific workup will mirror anticipated framework.

Scenario 8 (Sema → CagriSema) pre-transition workup. Universal panel + sema-component adherence audit + adherence audit on whether prior sema 2.4 mg was tolerated (CagriSema retains 2.4 mg sema component). NAION re-screen (sema-component retained). If T2D: HbA1c current. Body-composition baseline (DEXA or BIA) — the amylin-pathway additive mechanism’s body-composition signature differs from sema-monotherapy and the post-transition trajectory is body-composition-aware (REDEFINE-1 data anchors).

Scenario 9 (Sema → IcoSema) pre-transition workup. Universal panel + T2D status verification (IcoSema is T2D-indication-specific; if patient is non-diabetic the transition is moot — IcoSema is not the right destination). HbA1c current; fasting C-peptide if not previously documented; basal-insulin status documentation (current basal-insulin regimen if any; the COMBINE-1 / COMBINE-2 / COMBINE-3 transition framework per [[IcoSema Protocol]] §1 is determined by basal-insulin history). CGM if available — hypoglycemia surveillance baseline is foundational to safe IcoSema initiation. Sulfonylurea / insulin-secretagogue audit — these are discontinued or substantially dose-reduced at IcoSema initiation per [[IcoSema Protocol]] §6.11.1; the audit identifies the operational dose-adjustment step.

Scenario 10 (Non-response algorithmic) pre-transition workup. Specific to the destination compound the §7 algorithm directs the patient toward. Universal panel + adherence audit + AE-history audit is foundational; the destination-specific items are scenario-specific per Scenarios 1-9 above.

3.4 Worked example — pre-transition workup for the §1.5 case

The §1.5 / §2.5 patient (49-year-old post-menopausal female, Wegovy 2.4 mg partial responder at Month 14, considering Scenario 1 sema → tirz or Scenario 8 sema → CagriSema or Scenario 3 sema → reta).

Universal panel. Current weight 78 kg (down from 86 kg baseline; 9.3% loss as of current visit, slightly above the §1.5 stated 8.5% from data 2 months prior). BP 128/82 (improved from 142/88 baseline). Waist circumference 92 cm (down from 102 cm baseline). CMP within normal limits. Lipid panel improved (LDL down ~15 mg/dL; HDL stable). HbA1c 5.6 (pre-diabetic range; not T2D). TSH normal. Adherence audit: clean — refills consistent, no gaps. AE history: mild Grade 1 nausea Months 4-6 of titration; resolved; no GI AE since Month 9. No gallbladder events. No NAION. Pregnancy status: post-menopausal, no contraception needed.

Destination-compound contraindication re-screen. No MTC / MEN-2 family history. No pancreatitis history. No NAION (relevant for Scenario 8 sema-component-retained; not relevant for Scenario 1 tirz-only). No hypersensitivity to tirz or to cagri or to reta.

Scenario 1 (sema → tirz) specific. No additional workup beyond universal — patient is ready for §4.2 transition-execution.

Scenario 8 (sema → CagriSema) specific. Body-composition DEXA: 23% body fat (down from 31% baseline); lean mass preserved; no Axis 10 lean-mass adjunct trigger. Ready for §4.9 transition-execution pending CagriSema availability post-FDA-approval.

Scenario 3 (sema → reta) specific. TRIUMPH Phase 3 trial-enrollment evaluation per ClinicalTrials.gov current registration; patient meets common TRIUMPH inclusion criteria (BMI ≥30 — patient BMI ~28 currently which may not qualify; specific trial-protocol BMI requirement check needed). If trial enrollment not available: post-approval framework awaits FDA decision. Patient counseled per §10.4 Pattern Z Anchor 5.

3.5 Pattern W cross-section consistency applied to §3

Every workup item in §3 above is reconciled with the per-canonical §3 pre-treatment panel for source and destination compounds. The pre-transition workup is a subset of the universe of per-canonical pre-treatment workups, focused on (a) current-state confirmation, (b) destination-compound contraindication re-screen, and (c) scenario-specific indication-driver workup. The §3 panel for each scenario is the operational pre-transition screen; the per-canonical full §3 pre-treatment panel was completed at the patient’s original Module 5 initiation and is the baseline.

---

4. Transition-execution protocol (the actual switching mechanics)

4.1 Purpose and framework

§4 is the load-bearing operational section of this Stack Protocol. Where the per-canonical §4 specifies the starting dose, titration schedule, and tolerability-management cadence for compound initiation from naive, the Stack Protocol §4 specifies the transition mechanics — hold prior compound, washout window, AE-tolerability re-priming, new-compound starting dose — for each of the ten transition scenarios.

The transition-execution decision tree has three sub-decisions that every scenario answers:

1. Hold pattern. Stop prior compound abruptly OR taper it before switching OR continue it through a brief overlap. The default for within-class GLP-1 RA transitions where AE-attributable etiology drove the transition is abrupt hold; the default for patient-preference or magnitude-extension transitions is to hold at the last weekly-injection date and proceed with washout-then-initiate.
2. Washout window. The interval between the last dose of the prior compound and the first dose of the new compound. Driven by the prior compound’s half-life (substantial pharmacokinetic clearance ≈ 5 half-lives) plus a clinical margin. For transitions WITHIN the GLP-1 RA class where receptor-pharmacology is overlapping but not identical, the washout window may be shortened from full PK clearance (the new compound can be initiated while residual prior-compound is still pharmacologically active because both engage GLP-1R) — but the AE-tolerability re-priming consideration becomes load-bearing in the shortened-window framework.
3. New-compound starting dose. The destination compound’s standard initiation dose per the per-canonical §4, OR a modified starting dose that accounts for the patient’s prior GLP-1 RA exposure (some clinical practices initiate the new compound at the next step above the standard starting dose given established GLP-1R tolerance; M5.8 v3 §4.5 and the per-canonical §4 across the portfolio adopt the conservative discipline of full re-titration from the standard starting dose, recognizing that prior GLP-1 RA exposure may accelerate tolerance in clinical practice but the registration-trial titration discipline is the conservative anchor).

Cross-titration vs straight switch — the framework. A patient at max-tolerated dose of the prior compound facing a transition has two operational paths:

• Straight switch (default for within-class transitions). Stop prior compound; brief washout; initiate new compound at its standard starting dose per per-canonical §4; complete the new compound’s full titration. This is the conservative path with the lowest AE-emergence risk during the early titration steps of the new compound (prior GLP-1R tolerance supports tolerability through early new-compound titration steps but does not waive the discipline).
• Cross-titration (clinician-judgment, not registration-trial-validated for any GLP-1 RA pair). Continue prior compound at reduced dose while initiating new compound at starting dose; gradually shift the dose-weight from prior to new over a defined period (typically 2-4 weeks). Cross-titration is NOT registration-trial-validated for any GLP-1 RA pair as of 2026-05-14; Pattern Z.research-precision and Pattern V framework: cross-titration is a research-state-incomplete clinical-practice approach with theoretical AE-management advantages (smoother appetite-suppression transition; potentially reduced weight-rebound pulse during the transition window) and theoretical risks (additive GI AE during overlap; pharmacokinetic complexity). The per-canonical protocols do not register cross-titration as a standard approach; clinician-judgment within informed-consent applies for the specific patient context where the clinician judges cross-titration appropriate.

Pattern R.1 enforcement at §4: each scenario sub-section opens with the standard transition-execution protocol (the straight-switch default), then presents the cross-titration option as clinician-judgment within informed-consent if applicable, then presents the AE-management considerations during the transition window.

Pattern W cross-section consistency: every scenario’s transition-execution protocol reconciles with the per-canonical §4 initiation protocol for the destination compound and the per-canonical §8 discontinuation protocol for the source compound.

4.2 Scenario 1 — Sema → Tirz transition-execution

Hold pattern. Stop semaglutide at the last weekly-injection date. No taper required for transition-driven discontinuation (the patient is not entering a washout-and-stay-off state; the patient is transitioning to an in-class alternative). Pattern Z framing: this is symmetric to the per-canonical [[Semaglutide Protocol]] §8.7 Scenario C (AE-attributable discontinuation is abrupt; transition-driven discontinuation is also abrupt because the patient is replaced on the alternative-class agent within the same physiologic axis).

Washout window. No required washout for the AE-management dimension — both compounds engage GLP-1R and the patient’s GLP-1R tolerance is continuously maintained. The pharmacokinetic dimension: semaglutide elimination half-life ~1 week (160-168 hours); substantial PK clearance ~35 days; but operational washout for transition is typically 1 week (one missed semaglutide dose, then initiate tirzepatide at the next weekly-dose date). The 1-week operational window is the practical convention; clinician-judgment may extend it to 2 weeks if the patient experienced moderate-severity GI AE on semaglutide and a longer washout is desired before tirzepatide initiation. Pattern V research-precision: there is no head-to-head trial validating a specific sema-to-tirz washout window; SURMOUNT-5 (PMID 40353578) was a head-to-head comparison of de novo initiations, not a transition trial.

New-compound starting dose. Tirzepatide 2.5 mg subcutaneous once weekly per [[Tirzepatide Protocol]] §4.2 — the standard starting dose. Full titration per [[Tirzepatide Protocol]] §4.3 (2.5 mg × 4 weeks → 5 mg × 4 weeks → 7.5 mg × 4 weeks → 10 mg × 4 weeks → 12.5 mg × 4 weeks → 15 mg target dose for CWM; or 5 mg / 10 mg / 15 mg per T2D target per SURPASS data).

Clinical-practice variation — accelerated titration option. Some clinical practices accelerate the tirzepatide titration for patients with prior sustained GLP-1 RA exposure on the rationale that GLP-1R tolerance is established and the GI AE profile during early titration may be attenuated. M5.8 v3 §4.5 and [[Tirzepatide Protocol]] §4 caution that prior GLP-1 RA exposure may support tolerance through early titration steps but does not waive the standard titration discipline; full re-titration is the conservative approach. Accelerated titration is clinician-judgment within informed-consent; the AE-emergence risk during accelerated titration is not zero, and the published trial-program titration schedule is the anchor.

Cross-titration option. Not registration-trial-validated for sema → tirz. Clinician-judgment within informed-consent if the patient and clinician elect a 2-4 week overlap with reduced semaglutide dose + tirzepatide starting dose; additive GI AE is the principal risk. Most clinical practice uses straight switch with 1-week operational washout.

AE-tolerability re-priming. Despite the GLP-1R-tolerance carryover, patient counsel for tirzepatide-specific titration AE pattern — the dual GLP-1/GIP mechanism produces an AE pattern that is similar in class but not identical to semaglutide (the GIP-component contributes additional GI-effects in some patients; the per-canonical [[Tirzepatide Protocol]] §6 documents the AE-class profile). Tirzepatide trial-program GI AE incidence is similar-to-modestly-different than semaglutide per cross-trial comparison; the individual-patient response is not predictable from class-level data.

Operational pearls.

• Counsel patient that the SURMOUNT-5 head-to-head trial (PMID 40353578) demonstrated a magnitude advantage for tirzepatide at max-tolerated doses; this does not mean the patient will achieve the SURMOUNT-5 average effect-size minus the semaglutide-arm effect-size as the incremental gain — the patient’s response on tirzepatide is the patient’s response, not an arithmetic subtraction. Pattern V trial-anchored precision: the head-to-head effect-size differential is at the population level; the individual-patient response distribution is wide.
• Hold any sulfonylurea / insulin / insulin-secretagogue dose-adjustment per [[Tirzepatide Protocol]] §6.7 if patient is on these (hypoglycemia risk during titration; typical 20% insulin dose reduction at GLP-1 RA initiation or transition; sulfonylurea typically reduced ~50% or discontinued).
• Schedule Week 2 telehealth tolerability check; Week 5-6 in-person or telehealth at first titration step; Week 9-12 mid-titration; Week 17-20 target-dose attainment confirmation.

4.3 Scenario 2 — Tirz → Sema transition-execution

Hold pattern. Stop tirzepatide at the last weekly-injection date. Abrupt discontinuation; no taper required for transition-driven discontinuation.

Washout window. Tirzepatide elimination half-life ~5 days (per [[Tirzepatide Protocol]] §1.3); substantial PK clearance ~25 days; operational washout for transition typically 1 week (same convention as Sema → Tirz). Clinician-judgment may extend to 2 weeks if tirzepatide GI AE was the transition driver.

New-compound starting dose. Semaglutide depends on destination indication:

• For CWM (Wegovy): 0.25 mg subcutaneous once weekly per [[Semaglutide Protocol]] §4.2; full 16-week titration to 2.4 mg target.
• For T2D (Ozempic): 0.25 mg subcutaneous once weekly; titrate per [[Semaglutide Protocol]] §4.3 (0.25 mg × 4 wk → 0.5 mg × 4 wk → 1.0 mg target; or onward to 2.0 mg per SUSTAIN-FORTE).
• For oral semaglutide (Rybelsus 14 mg T2D; oral Wegovy 25 mg CWM): per the respective per-canonical §4; oral Wegovy 25 mg titration per OASIS 4 / FDA-approved label.
• For MASH (Wegovy 2.4 mg per ESSENCE-anchored indication): standard CWM titration to 2.4 mg.
• For CKD-in-T2D (Ozempic 1.0 mg per FLOW dose): standard T2D titration to 1.0 mg; 2.0 mg available if HbA1c remains above target.

Indication-driver considerations. The Scenario 2 transition is typically indication-driven (MASH / CKD / ASCVD / oral-preference) rather than magnitude-driven; the patient is moving to access the FDA-approved-for-marketing-claims semaglutide indication that tirzepatide does not yet cover. Counsel patient that weight-magnitude is anticipated to be modestly lower on semaglutide than tirzepatide per SURMOUNT-5 head-to-head data — the indication-driven transition involves an explicit weight-magnitude trade-off for the indication-coverage gain. Pattern Z Anchor 4 multi-dimensional framing in §10.3 carries this trade-off.

AE-tolerability re-priming. Despite the GLP-1R-tolerance carryover, patient counsel for semaglutide-specific AE pattern — NAION signal documented for semaglutide (Hathaway 2024 PMID 38958939); signal absent for tirzepatide per Lakhani 2025 PMID 40383360 — this is a class-differentiation finding the patient should be aware of at the transition counseling. Pattern AA precision: NAION is a post-marketing pharmacovigilance signal under active evaluation, not a labeled warning.

Hard contraindication check. Prior NAION on any prior semaglutide exposure is a hard contraindication for semaglutide re-exposure regardless of indication-driver. The pre-transition workup §3.3 includes NAION pre-screen.

Operational pearls.

• For T2D context with concurrent SGLT2 inhibitor / metformin / RAS-blockade: continue at current dose; no transition-specific adjustment.
• For MASH-indication-driver: hepatology co-management; FIB-4 / VCTE follow-up at Month 6, 12, 24 on semaglutide.
• For CKD-indication-driver: nephrology co-management; eGFR + UACR quarterly Year 1; verify RAS-blockade at maximally tolerated dose remains in place.
• For ASCVD-indication-driver: cardiology co-management; statin + antiplatelet continue per standard-of-care.
• Schedule Week 2 telehealth tolerability check; Week 5-6 in-person or telehealth; Week 9-12 mid-titration; Week 17-20 target-dose attainment.

4.4 Scenario 3 — Sema → Reta transition-execution (anticipated framework)

Pattern AA precision. Retatrutide is investigational as of 2026-05-14; the transition-execution framework is anticipated pending FDA approval OR operational via TRIUMPH Phase 3 trial enrollment. The framework below is anticipated; the eventual FDA label and the trial-protocol-specific framework will be operational authority.

Hold pattern. Stop semaglutide at the last weekly-injection date. Abrupt discontinuation for transition.

Washout window. Semaglutide ~1-week half-life; ~35-day PK clearance. For TRIUMPH Phase 3 enrollment: trial-protocol-specific washout requirements typically require ≥5 half-lives PK clearance (i.e., ~35 days for semaglutide) before retatrutide initiation. For anticipated post-approval framework: within-class transition operational washout is anticipated to be ~1 week (same as Sema → Tirz convention) but the eventual FDA label may specify otherwise.

New-compound starting dose. Retatrutide 2 mg subcutaneous once weekly per [[Retatrutide Protocol]] §4.2 (anticipated; the TRIUMPH-1 Phase 3 program starting dose). Anticipated full titration: 2 mg × 4 wk → 4 mg × 4 wk → 8 mg × 4 wk → 12 mg target dose for CWM (target may be specified differently per eventual FDA label). The triple-agonist mechanism (GLP-1 + GIP + glucagon) produces a magnitude advantage and an AE profile that includes GI-class effects plus glucagon-axis effects (anticipated; per TRIUMPH Phase 2 PMID 37356046 documented AE profile).

Cross-titration option. Not registration-trial-validated; not part of the TRIUMPH protocol framework. Straight switch is the only operational pathway.

AE-tolerability re-priming. Despite GLP-1R tolerance carryover, the GIP and glucagon receptor engagements are new for the patient transitioning from semaglutide (GLP-1 monoagonist) — the additional receptor engagements may produce AE pattern shifts the patient has not previously experienced. Patient counsel for retatrutide-specific AE pattern per anticipated [[Retatrutide Protocol]] §6 (GI-class, anticipated glucagon-axis HR / BP effects, dose-dependent GI AE incidence per TRIUMPH Phase 2).

Operational pearls.

• TRIUMPH Phase 3 trial-enrollment pathway: per ClinicalTrials.gov current registration; trial-protocol contraception requirements; trial-protocol monitoring cadence.
• Counsel patient that TRIUMPH Phase 2 effect-size (–24.2% at 12 mg) and TRIUMPH-4 Phase 3 disclosed effect-size (–28.7%) are trial-population averages; the individual-patient response distribution is wide; cross-trial vs SURMOUNT-1 tirzepatide (–22.5%) is not head-to-head — Pattern V cross-trial qualification applies.
• Pattern Z Anchor 5 (extrapolation transparency) governs §10.4 counseling beat.

4.5 Scenario 4 — Tirz → Reta transition-execution (anticipated framework)

Pattern AA precision. Retatrutide investigational; same regulatory framework as Scenario 3. Anticipated framework below; eventual label or TRIUMPH protocol is operational authority.

Hold pattern. Stop tirzepatide at the last weekly-injection date. Abrupt discontinuation for transition.

Washout window. Tirzepatide ~5-day half-life; ~25-day PK clearance. For TRIUMPH Phase 3 enrollment: trial-protocol-specific washout (typically ≥5 half-lives PK clearance ≈ 25 days for tirzepatide). For anticipated post-approval framework: operational washout anticipated ~1 week per within-class convention.

New-compound starting dose. Retatrutide 2 mg per [[Retatrutide Protocol]] §4.2; full titration per anticipated label.

AE-tolerability re-priming. Tirzepatide already engages GLP-1R + GIPR; the addition of glucagon-receptor engagement in retatrutide is the new component for the patient. The glucagon-axis AE considerations (anticipated HR increase 5-10 bpm at TRIUMPH-2 / TRIUMPH-4 dose-arms per Phase 2 / Phase 3 disclosure; anticipated mild BP changes; possible hepatic-axis considerations per glucagon receptor signaling) are the patient’s new AE-class to anticipate.

Cross-trial magnitude qualification. SURMOUNT-1 tirz 15 mg –22.5% (PMID 35658024) vs TRIUMPH Phase 2 reta 12 mg –24.2% (PMID 37356046) vs TRIUMPH-4 reta –28.7% — cross-trial differences; not head-to-head; Pattern V cross-trial qualification. Counsel patient that the tirz-to-reta magnitude differential is not as robustly evidence-anchored as the sema-to-tirz differential (which has SURMOUNT-5 head-to-head data).

Operational pearls. Same TRIUMPH-pathway considerations as Scenario 3. Pattern Z Anchor 5 (extrapolation transparency) governs §10.5 counseling beat.

4.6 Scenario 5 — Sema/Tirz → Lira transition-execution (pre-conception pivot)

Clinical scenario anchor. Reproductive-age patient on semaglutide or tirzepatide with conception planning horizon ≤6-12 months electing to remain on GLP-1 RA therapy through a compressed pre-conception window. The pivot to liraglutide’s short half-life (~13 hours) allows the substantial PK clearance window of ~2 days vs ~35 days (sema) or ~25 days (tirz). This compresses the pre-conception discontinuation window by approximately 33 days (sema → lira) or approximately 23 days (tirz → lira).

Hold pattern. Stop semaglutide or tirzepatide at the last weekly-injection date. Abrupt discontinuation.

Washout window. ~1 week operational washout from last sema/tirz weekly injection. Pattern Z calibration: the patient’s conception planning timeline drives the operational discipline; the washout window for the source-compound clearance is the constraint, then liraglutide initiation follows on its own daily-dose schedule.

New-compound starting dose. Liraglutide 0.6 mg subcutaneous once daily per [[Liraglutide Protocol]] §4.2 — the standard starting dose. Full titration per [[Liraglutide Protocol]] §4.3 (0.6 mg × 1 week → 1.2 mg × 1 week → 1.8 mg × 1 week → 2.4 mg × 1 week → 3.0 mg target for Saxenda CWM; 0.6 mg × 1 week → 1.2 mg × 1 week → 1.8 mg target for Victoza T2D). Total titration period for Saxenda CWM: ~4 weeks vs ~16 weeks for sema → Wegovy 2.4 mg or 16+ weeks for tirz 15 mg.

Cross-titration option for pre-conception pivot. Clinician-judgment within informed-consent: some practices initiate liraglutide while completing the sema/tirz weekly cycle (i.e., last sema/tirz dose on day 0, lira 0.6 mg daily starting day 1 or day 2-3). The rationale: continuous GLP-1R engagement minimizes appetite-rebound during the transition; the additive AE risk is theoretical and most patients tolerate the brief overlap. This is NOT registration-trial-validated; clinician-judgment.

Pre-conception window arithmetic post-transition. Once on liraglutide at target dose, the pre-conception discontinuation window is ~2 days (PK clearance) plus the labeled-precaution-margin (Saxenda label specifies discontinuation upon pregnancy awareness; the operational pre-conception window with clinical margin is approximately 1-2 weeks vs ~8 weeks for sema or ~4 weeks for tirz). The patient can therefore remain on liraglutide until ~1-2 weeks before attempting conception vs ~8 weeks pre-conception discontinuation on sema or ~4 weeks on tirz.

Pattern Z Anchor 3 LEADS counseling beat. §10.6 counseling beat for this scenario LEADS with Parker 2025 PMID 40329607 pooled human pregnancy-exposure data (“Incidence of congenital abnormalities appears relatively low”) — NOT with the PK arithmetic above. The PK arithmetic appears after the research-state-leading data, framed as factual scope. Animal data + Category-X-equivalent class contraindication framing is relegated to scoped factual context post-research-state lead.

AE-tolerability re-priming. Daily dosing platform shift — the patient transitions from weekly-injection routine to daily-injection routine. Pattern Z.injection-framing: daily injection is a routine clinical skill, equivalent to daily insulin or daily fertility-hormone self-injection; not framed as “burden” or “barrier.” Liraglutide GI AE profile per [[Liraglutide Protocol]] §6.2: similar class-pattern but with daily-dosing AE distribution (vs weekly bolus pattern of sema/tirz). Pre-titration counsel: AE pattern at 0.6 mg starting dose is typically mild; titration management per [[Liraglutide Protocol]] §4.4.

Pre-conception transition timeline — operational example.

Patient on Wegovy 2.4 mg, conception planning at 6-month horizon:

• Month 0: pre-transition counseling; §10.6 counseling beat; STEP 8 PMID 35015037 head-to-head magnitude differential acknowledged (semaglutide −15.8% vs liraglutide −6.4% at week 68 in non-diabetic obesity — explicit acknowledgment that liraglutide weight-magnitude is anticipated to be lower than semaglutide).
• Month 0 (Week 0): last Wegovy 2.4 mg injection.
• Week 1: 1-week operational washout (~1 half-life sema clearance).
• Week 2: initiate Saxenda 0.6 mg daily.
• Week 3-6: titrate per [[Liraglutide Protocol]] §4.3 to 3.0 mg target.
• Week 6 onward: maintenance Saxenda 3.0 mg; weight stabilization at lower-magnitude liraglutide effect.
• Approximately Month 5-6 of original timeline: patient elects to discontinue Saxenda ~1-2 weeks before conception attempt; PK clearance ~2 days plus margin.
• Conception attempt: 1-2 weeks post-Saxenda last dose.
• Post-conception: per [[Liraglutide Protocol]] §8.4 / Parker 2025 framework; obstetric co-management; re-initiation pathway post-pregnancy and post-lactation per §8.6 of the per-canonical.

Operational pearls.

• Counsel patient that the weight-magnitude differential between sema/tirz and lira is real and substantial — Pattern Z Anchor 4 multi-dimensional framing presents this honestly; the patient is making a trade-off (lower weight-magnitude during the pre-conception window) for a compressed pre-conception timeline.
• Counsel patient on the post-pregnancy and post-lactation re-initiation pathway; many patients return to sema or tirz post-lactation for the magnitude advantage.
• For T2D context: ensure pre-pregnancy glycemic optimization is part of the framework; HbA1c target ≤6.5 pre-conception per ADA Standards of Care; lira at target 1.8 mg may be insufficient — clinician-judgment for cross-class addition (metformin if not already; basal insulin if needed) or for a different transition framework.

4.7 Scenario 6 — Sema/Tirz → Survodutide transition-execution (MASH-driven)

Pattern AA precision. Survodutide investigational as of 2026-05-14; LIVE-1 Phase 2 (Sanyal 2024 NEJM, PMID 38863223) demonstrated 76% histologic resolution at F2/F3 vs ~14% placebo; LIVERAGE Phase 3 (NCT06632444) RECRUITING. Transition-execution framework is operationally LIVERAGE Phase 3 trial enrollment for current access; post-approval framework awaits FDA decision.

Hold pattern. Stop semaglutide or tirzepatide at the last weekly-injection date. Abrupt discontinuation; note that for the patient with MASH F2/F3 indication-driver, the semaglutide MASH-indication-FDA-approval (ESSENCE August 2025) was the source compound’s load-bearing indication and discontinuation is non-trivial — the patient is exiting an FDA-approved MASH therapy for an investigational alternative because the FDA-approved therapy did not produce adequate MASH-fibrosis trajectory.

Washout window. For LIVERAGE Phase 3 enrollment: trial-protocol-specific washout requirements typically require ≥5 half-lives PK clearance (sema ~35 days; tirz ~25 days). The LIVERAGE protocol specifies the operational washout; clinician verifies per current ClinicalTrials.gov registration. For anticipated post-approval framework: operational washout anticipated ~1 week per within-class convention.

New-compound starting dose. Survodutide initiation per [[Survodutide Protocol]] §4 anticipated framework: starting dose 0.3 mg subcutaneous once weekly with anticipated titration to target 6.0 mg per the SYNCHRONIZE / LIVERAGE protocol. The dual-agonist mechanism (GLP-1 + glucagon) produces an AE profile that includes GI-class effects plus glucagon-axis effects (per LIVE-1 Phase 2 documented AE profile).

AE-tolerability re-priming. GLP-1R tolerance carries over; the glucagon-receptor engagement is the new component. Patient counsel for glucagon-axis effects: anticipated HR increase 5-10 bpm during titration; possible hepatic glucose-output effects relevant for T2D context; AE management per [[Survodutide Protocol]] §6.

MASH-fibrosis trajectory monitoring. Post-transition MASH monitoring follows survodutide-specific framework per LIVERAGE protocol or [[Survodutide Protocol]] §5: FIB-4 trend; VCTE / FibroScan at Month 6 and 12 post-transition; liver biopsy if clinically indicated for histology re-staging or for trial-protocol-required interim biopsy.

Operational pearls.

• Hepatology co-management is foundational; the patient should not be on a MASH-driven transition without hepatology partnership.
• The MASH-fibrosis trajectory on prior sema or tirz is the diagnostic that drives the transition — patient with adequate response on sema (e.g., F2 → F1 fibrosis improvement) is typically not a Scenario 6 candidate; patient with persistent F2/F3 or progression to F3 on sema is the transition candidate.
• Pattern Z Anchor 5 (extrapolation transparency) governs §10.7 counseling beat — explicit framing that survodutide is investigational; LIVERAGE Phase 3 readout is pending; the transition is to a research-state therapy with promising Phase 2 magnitude (76% histologic resolution at F2/F3).

4.8 Scenario 7 — Injectable → Orforglipron transition-execution (oral platform)

Pattern AA precision. Orforglipron investigational as of 2026-05-14; ATTAIN-1 (DOI 10.1056/NEJMoa2511774) and ACHIEVE Phase 3 reads anchor the trial-program data; Eli Lilly filed FDA approval Q4 2025 for obesity and Q1 2026 for T2D; FDA decision near-term. Transition-execution framework is anticipated; eventual FDA label is operational authority. Pattern N.1: orforglipron is a small-molecule non-peptide oral GLP-1 RA — half-life ~29 hours; platform consequences differ from peptide weekly-SC.

Pattern Z.injection-framing discipline. The Scenario 7 transition is patient-preference-anchored, not steered by injection-framing-anxiety. The protocol does NOT default-frame self-injection as “burden” to be relieved by oral transition. The transition is appropriate for patients whose specific clinical context (frequent international travel disrupting weekly-SC cold-chain; peri-procedural medication-pause complexity for weekly-SC long-half-life compound; specific patient-preference oral over injectable) drives the platform shift. The counseling beat (§10.8) presents the platform options factually.

Hold pattern. Stop semaglutide or tirzepatide at the last weekly-injection date. Abrupt discontinuation.

Washout window. Sema ~1-week operational washout; tirz ~1-week operational washout per within-class convention. For post-approval framework: anticipated within-class transition framework (no clinical trial currently exists for the injectable → orforglipron transition).

New-compound starting dose. Orforglipron 3 mg orally once daily per [[Orforglipron Protocol]] §4.2 anticipated framework — the ATTAIN-1 Phase 3 starting dose. Anticipated full titration: 3 mg × 4 wk → 6 mg × 4 wk → 12 mg × 4 wk → 24 mg × 4 wk → 36 mg target dose for CWM (anticipated; eventual FDA label specifies). For T2D anticipated target: 12 mg per ACHIEVE.

Oral-platform-specific operational considerations.

• Pattern N.1 small-molecule non-peptide oral. Orforglipron is dosed orally without the Rybelsus SNAC discipline (empty stomach, ≤120 mL water, 30-minute pre-food window) — the small-molecule non-peptide platform does not require the peptide-protection-from-gastric-degradation framework that Rybelsus and oral Wegovy require. This is a substantive platform difference; clinician verifies current product-label specifics at the time of FDA approval.
• Drug-drug interaction screen. Per [[Orforglipron Protocol]] §3 anticipated framework; the oral platform has interaction considerations specifically with gastric-acid-modulating agents (PPIs, H2 blockers) and motility-modulating agents — clinician verifies absence of relevant DDI before initiation.
• Half-life consequence. ~29-hour half-life; substantial PK clearance ~6 days; this is shorter than sema (~35 days) or tirz (~25 days) — the pre-conception window arithmetic is correspondingly shorter (anticipated 2-4 weeks vs ~8 weeks for sema). For the Scenario 7 patient who is also reproductive-age with conception planning, this may be an additional consideration (overlap with Scenario 5).

AE-tolerability re-priming. GLP-1R tolerance carries over from sema or tirz. Orforglipron GI AE profile per [[Orforglipron Protocol]] §6 anticipated framework: similar class-pattern; ATTAIN-1 Phase 3 program documents AE incidence.

Operational pearls.

• Confirm patient-preference is the driver; do not steer toward oral platform by framing injection as burden.
• For T2D context: ensure HbA1c trajectory on the new compound is monitored at standard cadence; oral GLP-1 RA effect-size may be modestly different from weekly-SC; clinician-judgment for concurrent T2D regimen.
• For CWM context: counsel patient on the anticipated effect-size per ATTAIN-1 (–11.2% at 36 mg per Phase 3 disclosure; intermediate between sema and tirz weight-magnitudes; Pattern V cross-trial qualification).
• Pattern Z Anchor 5 (extrapolation transparency) governs §10.8 counseling beat for the investigational regulatory status.

4.9 Scenario 8 — Sema → CagriSema transition-execution (amylin-axis magnitude extension)

Pattern AA precision. CagriSema investigational as of 2026-05-14; REDEFINE-1 Phase 3 (PMID 40544433) demonstrated –20.4% (treatment-policy) / –22.7% (adherent) vs –3.0% placebo at 68 weeks in non-diabetic obesity; Novo Nordisk has filed for FDA approval. Transition-execution framework is anticipated; eventual FDA label specifies the operational framework.

Hold pattern — distinctive. CagriSema retains the semaglutide 2.4 mg component; the transition is NOT a stop-sema-then-start-CagriSema mechanic. The semaglutide-component dose is unchanged (2.4 mg → 2.4 mg within CagriSema); the cagrilintide-component is added through titration. Per [[CagriSema Protocol]] §8 and M5.8 v3 §4, there are two operational approaches:

Approach A — Direct fixed-combination transition (anticipated post-approval). At the next weekly-dose date, the patient transitions from Wegovy 2.4 mg standalone to CagriSema 2.4/0.25 mg combination (the lowest cagrilintide-component dose in the fixed-combination titration ladder). The semaglutide-component is delivered at 2.4 mg from day 0 of the transition; the cagrilintide-component titrates per the fixed-combination titration schedule (anticipated 0.25 mg → 0.50 mg → 1.0 mg → 2.0 mg → 2.4 mg cagrilintide-component over ~16-20 weeks). This approach is operationally simpler and is the anticipated commercial framework once CagriSema is FDA-approved.

Approach B — Add cagrilintide monotherapy then transition to fixed combination (operational if cagrilintide monotherapy approved before CagriSema fixed combination). Add cagrilintide subcutaneously alongside continued Wegovy 2.4 mg; titrate cagrilintide per [[Cagrilintide Protocol]] §4.2 from starting dose; once both components are at target dose, transition to the fixed-combination product. This approach involves two injections during the titration phase; operationally more complex; not the anticipated commercial framework. Note: as of 2026-05-14 cagrilintide monotherapy is investigational; this approach is theoretical pending separate regulatory pathway.

Washout window. No washout for the sema-component (continuous engagement maintained). The cagrilintide-component is initiated from naive; standard cagrilintide titration applies.

Cross-titration consideration. The Approach A framework is operationally a form of cross-titration — sema-component continuous, cagrilintide-component titrating from naive. This is REDEFINE-program-validated (REDEFINE-1 protocol used a parallel titration schedule).

AE-tolerability re-priming. Sema-component AE-tolerability is preserved (patient on stable 2.4 mg with established tolerance). Cagrilintide-component AE profile per [[Cagrilintide Protocol]] §6 / [[CagriSema Protocol]] §6: amylin-axis effects include additional GI-class effects (additive to sema-component GI profile), potentially nausea-additive during cagrilintide titration; injection-site-reaction profile similar; anticipated AE distribution per REDEFINE-1 trial data.

Operational pearls.

• Counsel patient that the REDEFINE-1 effect-size (–20.4% treatment-policy / –22.7% adherent) is the trial-population average; the individual incremental gain over sema 2.4 mg monotherapy (STEP-1 ~14.9% baseline) is approximately 5-8 percentage points at the population level, with individual variability.
• Schedule cadence: weekly during cagrilintide-component titration (~16-20 weeks); transition to maintenance cadence at target dose.
• Pattern Z Anchor 4 multi-dimensional framing in §10.9 — affirm sema 2.4 mg as evidence-based; affirm CagriSema as REDEFINE-anchored magnitude-extension; close with shared decision-making.

4.10 Scenario 9 — Sema → IcoSema transition-execution (T2D + basal insulin combo)

Pattern AA precision. IcoSema EMA-approved 2025 as Kyinsu for T2D in adults inadequately controlled on basal insulin; FDA submission status check current. In EU jurisdictions the transition is on-label per Kyinsu approval; in US jurisdictions the transition is investigational pending FDA decision. The transition-execution framework below mirrors the COMBINE-2 trial protocol (prior GLP-1 RA experienced T2D).

Hold pattern — distinctive. IcoSema retains the semaglutide component; the transition is mechanism-additive: stop sema as standalone, initiate IcoSema combination at the weekly cadence. The basal-insulin-icodec component is the new component for the patient; the GLP-1R tolerance carries over.

Washout window. No washout for the sema-component (continuous engagement maintained). The basal-insulin-icodec component is initiated at standard IcoSema initiation dose; hypoglycemia surveillance from day 0.

New-compound starting dose. IcoSema per [[IcoSema Protocol]] §4 anticipated framework. The COMBINE-2 transition protocol from prior GLP-1 RA experienced T2D: structured switch with consideration of the basal-insulin-icodec component addition. The GLP-1R tolerance is established; the new clinical consideration is the basal-insulin component addition with hypoglycemia surveillance from initiation.

Critical safety discipline — sulfonylurea / insulin-secretagogue management. Sulfonylurea or insulin-secretagogue co-medications discontinued or substantially dose-reduced at IcoSema initiation per [[IcoSema Protocol]] §6.11.1. This is the load-bearing safety discipline for the transition — combining IcoSema (which contains insulin icodec) with sulfonylureas substantially elevates hypoglycemia risk. Metformin can continue (the typical comprehensive T2D regimen). Pre-existing basal insulin if present is replaced by the icodec component of IcoSema; if patient was on basal-bolus regimen pre-transition (COMBINE-3 population), the basal is replaced and the bolus insulin is discontinued or dose-reduced per COMBINE-3 protocol.

CGM if available. Hypoglycemia surveillance during the transition window is foundational; CGM supports it. Patient counsel for hypoglycemia recognition and treatment; glucagon emergency kit consideration per ADA Standards.

AE-tolerability re-priming. GLP-1R tolerance preserved. The basal-insulin-icodec component is the new component; hypoglycemia is the principal AE-class concern. Per [[IcoSema Protocol]] §6, the COMBINE program documents hypoglycemia incidence and AE management framework.

Operational pearls.

• Confirm T2D diagnosis is operative; IcoSema is not appropriate for non-diabetic obesity (the basal-insulin-icodec component is T2D-specific).
• Confirm basal-insulin requirement; the COMBINE-1 / COMBINE-2 / COMBINE-3 framework per [[IcoSema Protocol]] §1 determines the transition protocol.
• Sulfonylurea / insulin-secretagogue audit at the pre-transition workup (§3.3); discontinue or substantially dose-reduce at IcoSema initiation.
• CGM if available; hypoglycemia surveillance during transition window.
• Pattern Z Anchor 4 multi-dimensional framing in §10.10 — affirm sema as evidence-based for the patient’s prior T2D context; affirm IcoSema as COMBINE-anchored for the T2D + basal-insulin context; close with shared decision-making.

4.11 Scenario 10 — Non-response algorithmic transitions (cross-canonical §7 logic)

§4.11 IS §7. The Scenario 10 transition-execution mechanics are the integration of Scenarios 1-9 above with the per-canonical §7 non-response algorithm. The full algorithm is developed in §7 of this Stack Protocol; the transition-execution mechanics for each algorithm-selected destination compound are §4.2-§4.10 above.

4.12 Worked example — transition-execution for the §1.5 / §2.5 case (sema → tirz)

The §1.5 / §2.5 / §3.4 patient (49-year-old post-menopausal female on Wegovy 2.4 mg, partial responder Month 14 with 9.3% loss) elects Scenario 1 sema → tirz after §10.2 counseling beat presenting multi-dimensional comparator framing.

Transition-execution walk:

• Day 0 (last Wegovy injection). Patient completes her usual Wegovy 2.4 mg weekly injection. Counseling reinforcement on the operational steps over the next 2-4 weeks.
• Day 7 (1-week operational washout). Patient does not take a Wegovy injection on Day 7; first scheduled tirzepatide injection on Day 7 or Day 8 per practice cadence.
• Day 7-8 (tirzepatide 2.5 mg start). Tirzepatide 2.5 mg subcutaneous; injection site rotation continues from sema technique (patient’s injection-technique skill carries over).
• Week 2 telehealth tolerability check. Patient reports mild fatigue Day 1-2 post-tirz injection; no nausea; appetite suppression similar to sema. Adherence-confirmation; no AE escalation.
• Week 5 (tirzepatide 5 mg titration). Standard titration step; patient tolerates.
• Week 9 (tirzepatide 7.5 mg). Continued titration; patient reports mild Grade 1 nausea on Day 1 post-injection at this step.
• Week 13 (tirzepatide 10 mg). Continued titration; nausea stable Grade 1 and self-limiting.
• Week 17 (tirzepatide 12.5 mg). Continued titration.
• Week 21 (tirzepatide 15 mg target dose). Target dose attained; Month 5 from transition start. Weight at Month 5: 73 kg (down from 78 kg at transition start; 6.4% additional loss in 5 months on tirz titration; cumulative 15% from pre-Wegovy baseline). Patient is on-trajectory for SURMOUNT-1 anchor (–22.5% at 15 mg / 72 weeks).
• Maintenance cadence per [[Tirzepatide Protocol]] §5.5. Quarterly Year 1 on target dose; body-composition, BP, weight; HbA1c not applicable (non-diabetic patient).

Pattern V trial-anchored validation. The patient’s transition trajectory is consistent with the SURMOUNT-5 head-to-head population-level differential (–6.5 percentage-point tirz advantage) — the individual-patient response (6.4% additional loss in 5 months on tirz titration) is within the expected range. Pattern V precision: the individual response is not a direct read-out of the head-to-head differential; trajectories vary.

Pattern Z Anchor 4 validation. The counseling beat at Day 0 presented the multi-dimensional comparator framing (magnitude per SURMOUNT-5; CV evidence — sema SELECT vs tirz SURMOUNT-MMO pending; MASH — sema ESSENCE vs tirz program pending; NAION class-differentiation; GI tolerability; route same; cost / access). The patient elected sema → tirz with informed-consent on the magnitude differential and the indication-coverage trade-off (loss of sema MASH / CKD / ASCVD indication coverage; patient has none of these comorbidities so trade-off is minimal).

4.13 Pattern AA, Pattern V, Pattern W, Pattern Z applied to §4

Pattern AA precision. Every transition-execution protocol carries the destination-compound regulatory state explicit: FDA-approved-for-marketing-claims (sema, tirz, lira for relevant indications) vs investigational pending FDA decision (reta, surv, orfo, CagriSema, IcoSema US) vs EMA-approved (IcoSema Kyinsu EU). Anticipated frameworks for investigational compounds are framed as anticipated, with eventual FDA label specified as operational authority.

Pattern V precision. Head-to-head trial data anchors transitions where it exists (SURMOUNT-5 sema vs tirz CWM; SURPASS-2 tirz vs sema T2D; STEP 8 sema vs lira CWM). Cross-trial framing is explicit where head-to-head does not exist (sema vs reta; tirz vs reta; sema vs CagriSema; sema vs survodutide; injectable vs orforglipron). The individual-patient response distribution is wide and not a direct read-out of trial-population differentials.

Pattern W cross-section consistency. Every transition-execution protocol reconciles with the per-canonical §4 initiation protocols (destination compound) and §8 discontinuation protocols (source compound). The Stack Protocol §4 does not introduce starting doses, titration schedules, or washout windows absent from the per-canonical authority; where this Stack Protocol cites a specific window or step, the per-canonical authority is the source.

Pattern Z precision. Transition-execution does not steer toward or away from any destination compound; the counseling beats in §10 carry the multi-dimensional comparator framing; the operational mechanics in §4 follow once the patient-clinician shared decision is made.

---

5. Post-transition monitoring and maintenance

5.1 Purpose

Define the first 4-6 weeks observation window after transition execution plus the longer-term maintenance cadence on the destination compound. §5 is the symmetric counterpart of §3 (pre-transition workup) — where §3 confirms the patient is ready for transition, §5 monitors the post-transition response, AE-emergence, and trajectory on the new compound.

The post-transition monitoring window is load-bearing for the transition success / non-success determination. A transition is not “complete” at the moment the new compound is started; the patient is in a transition-period for approximately the time-to-target-dose-attainment on the new compound plus a stability window of 8-12 weeks at target dose. Only at the post-transition 6-month mark on target dose is the transition response trajectory definitively characterizable (for CWM context); for T2D context, HbA1c trajectory at Month 6 from transition is the principal endpoint.

Pattern R.1 enforcement: §5 opens with what to monitor and what to expect — the response trajectory framework — before describing the dose-adjustment triggers and the second-line transition consideration (if the first transition does not produce the anticipated response). Pattern W cross-section consistency: §5 monitoring reconciles with per-canonical §5 maintenance protocols for the destination compound.

5.2 Universal post-transition monitoring panel (applies to every transition scenario)

Cadence framework — first 4-6 weeks post-transition:

• Week 1 post-transition. Telehealth or message check on tolerability and adherence; reassurance on AE emergence during the new compound’s early titration steps.
• Week 2-4 post-transition. In-person or telehealth at first new-compound titration step; weight + BP; AE-and-adherence interview.
• Week 6-8 post-transition. In-person or telehealth at mid-titration; weight + BP; trajectory check against per-canonical §5 trajectory anchors.

Cadence framework — Months 3-6 post-transition (titration complete; target-dose stabilization):

• Month 3. In-person; weight + BP; body-composition reassessment (BIA / DEXA) at typical 3-month interval; HbA1c if T2D; lipid panel annually.
• Month 6. In-person; weight + BP; trajectory check — the principal “transition success / non-success” data point. Per-canonical §7 non-response algorithm activated if sub-target response on adherent target dose at Month 6.
• Month 9, 12. In-person; weight + BP; body-composition reassessment; indication-specific labs.

Beyond Month 12 — maintenance cadence per destination compound’s per-canonical §5. [[Tirzepatide Protocol]] §5.5; [[Semaglutide Protocol]] §5.5; [[Liraglutide Protocol]] §5.5; etc. Quarterly Year 1 → biannual Year 2+ for stable patients.

5.3 Universal monitoring panel content

• Weight, BP, waist circumference. Trajectory against per-canonical anchors.
• AE-and-adherence interview. New-compound-specific AEs (vs source-compound AE history); adherence audit.
• Body composition (BIA or DEXA). Especially for CWM context; lean-mass trajectory baseline for Axis 10 adjunct decisions.
• HbA1c (if T2D context). Month 3 and Month 6 post-transition; quarterly Year 1 thereafter.
• Lipid panel. Annually.
• Indication-specific labs. UACR + eGFR if CKD-indication-driver; FIB-4 + VCTE if MASH-indication-driver; per per-canonical §5.

5.4 Scenario-specific post-transition monitoring considerations

Scenario 1 (Sema → Tirz) post-transition monitoring. Standard universal panel per [[Tirzepatide Protocol]] §5.5. Tirzepatide-specific Month 6 trajectory anchor: ≥10% weight loss at Month 6 on target dose (the SURMOUNT-1 25th percentile trajectory). If not met: §7 algorithm activated.

Scenario 2 (Tirz → Sema) post-transition monitoring. Standard universal panel per [[Semaglutide Protocol]] §5.5. Semaglutide-specific Month 6 trajectory anchor: ≥5% weight loss at Month 6 on 2.4 mg target dose. For MASH-indication-driver: FIB-4 + VCTE at Month 6 and 12 post-transition; histology re-staging if clinically indicated. For CKD-indication-driver: eGFR + UACR quarterly Year 1. For ASCVD-indication-driver: cardiology co-management; CV-event surveillance continues.

Scenario 3 (Sema → Reta) post-transition monitoring. Anticipated framework per [[Retatrutide Protocol]] §5; trial-protocol-specific monitoring during TRIUMPH enrollment. Anticipated Month 6 trajectory anchor: ≥10% weight loss at intermediate dose target (anticipated; per TRIUMPH Phase 2 / Phase 3 effect-size trajectory).

Scenario 4 (Tirz → Reta) post-transition monitoring. Same as Scenario 3 framework.

Scenario 5 (Sema/Tirz → Lira pre-conception pivot) post-transition monitoring. Standard universal panel per [[Liraglutide Protocol]] §5.5. Cadence accelerated for pre-conception planning — the patient’s conception timeline drives the monitoring cadence: monthly check-ins; pregnancy-test discipline; conception-attempt-date counseling at the appropriate point. Weight-magnitude on liraglutide is anticipated to be lower than on sema/tirz; the patient’s weight trajectory at Month 3-4 on Saxenda 3.0 mg target informs continuation vs alternative decision; the patient may elect partial weight-regain acceptance for the compressed pre-conception window.

Scenario 6 (Sema/Tirz → Survodutide MASH-driven) post-transition monitoring. Anticipated framework per [[Survodutide Protocol]] §5 or LIVERAGE trial protocol. MASH-fibrosis trajectory is the principal endpoint. FIB-4 trend at Month 3, 6, 12; VCTE / FibroScan at Month 6 and 12; liver biopsy if clinically indicated or trial-protocol-required at interim. Weight trajectory secondary endpoint. Hepatology co-management continues.

Scenario 7 (Injectable → Orforglipron) post-transition monitoring. Anticipated framework per [[Orforglipron Protocol]] §5. Standard universal panel. Pattern N.1 platform-specific considerations: drug-drug interaction surveillance during the early months post-transition.

Scenario 8 (Sema → CagriSema) post-transition monitoring. Anticipated framework per [[CagriSema Protocol]] §5. Standard universal panel. Body-composition baseline at transition start and reassessment at Month 3 and Month 6 (the amylin-axis additive mechanism produces a body-composition signature differing from sema-monotherapy; REDEFINE-1 data anchors). Anticipated Month 6 trajectory anchor: ≥10-12% incremental gain over the patient’s pre-transition stable weight at sema 2.4 mg.

Scenario 9 (Sema → IcoSema) post-transition monitoring. Anticipated framework per [[IcoSema Protocol]] §5 (EMA Kyinsu-approved framework in EU; anticipated framework in US). Hypoglycemia surveillance is foundational. CGM if available; HbA1c at Month 3 and Month 6; basal-insulin-icodec dose-adjustment per [[IcoSema Protocol]] §5 cadence. Sulfonylurea / insulin-secretagogue audit at every post-transition visit Month 1-6.

Scenario 10 (Non-response algorithmic) post-transition monitoring. Per the destination compound’s specific scenario per §5.4 above.

5.5 Dose-adjustment triggers post-transition

Target-not-met at Month 6 on adherent target dose — activate §7 non-response algorithm. Consider second transition (the first transition was sub-optimal; the second transition crosses to a third compound) only after the §7 algorithm has been walked.

AE-emergent on the new compound — manage per [[destination protocol]] §6 AE management. Dose-down within the destination compound’s label-permitted dose range as first-line; if AE persists on dose-down, the AE is the trigger for second-transition consideration.

Indication-shift on the new compound — if the destination compound is FDA-approved for the patient’s emerging or progressing indication (e.g., patient transitioned to tirz for magnitude but is now developing MASH F2/F3 phenotype on follow-up), the indication-coverage trade-off the transition created becomes relevant; second-transition consideration may apply (e.g., tirz → sema for ESSENCE-anchored MASH indication if MASH-fibrosis progression emerges on tirz).

5.6 Pattern Z calibration applied to §5

Post-transition monitoring counseling does not steer; the trajectory data is presented factually and the patient-clinician shared decision determines continuation, dose-adjustment, or second-transition. Pattern Z Anchor 4 multi-dimensional framing applies if a second transition is on the table — present the new comparator landscape, affirm the destination compound at its trial-anchored magnitude, close with shared decision-making.

---

6. Transition-period-specific adverse event management

6.1 Purpose

Define the AE-management algorithms specific to the transition period — the AEs that emerge during or shortly after a transition that differ from de novo initiation AEs or from maintenance AEs. §6 is structured by transition-period AE category: GI-tolerability re-priming, weight-rebound pulse during washout, hypoglycemia in concurrent-agent transitions, glucagon-axis AEs in transitions to dual / triple agonists, and patient-experience-of-transition AEs (anxiety, expectation-management).

Pattern R enforcement: §6 opens with anticipatory framing — what to expect during the transition window — before management algorithms. Pattern V framework: AE-class signals during transition are not necessarily generalizable across all GLP-1 RA pairs; the specific compound-pair determines the AE-class considerations.

6.2 GI-tolerability re-priming AE category

Anticipatory framing. Despite the GLP-1R-tolerance carryover from source to destination compound within the GLP-1 RA class, the new compound’s titration may produce GI AE in the patient who was tolerating the source compound at target dose without GI AE. This is the principal transition-period AE class — the patient is surprised because they had moved past GI AE on their prior compound; the destination compound’s titration restarts the GI-AE-emergence-at-each-step pattern (Pattern V trial-anchored — every per-canonical §4 documents the GI AE pattern at each titration step).

Trial-program prevalence. Within-class transition GI AE incidence is not specifically trial-program-documented (no head-to-head transition trial has measured the GI AE pattern in the transitioning sub-population vs the naive-initiating sub-population). The clinical-practice observation is that prior GLP-1 RA exposure typically attenuates but does not eliminate GI AE during destination-compound titration; the M5.8 v3 §4.5 framework is “prior GLP-1 RA exposure may support tolerance through early titration steps but does not waive the standard titration discipline.”

Identification. Patient-reported at the Week 1 / Week 2-4 post-transition tolerability checks.

First-line management. Per per-canonical destination-compound §6 — non-pharmacologic (meal-size, slow eating, low-fat, hydration), ondansetron PRN, dose-hold-or-extension of titration step if Grade 2 persists.

Escalation triggers. Grade 3 GI AE — hospitalization-warranting severe. Persistent Grade 2 beyond 4 weeks at stable destination titration step.

Discontinuation triggers. Severe AE that does not respond to dose-down within the destination compound. Discontinuation of a transition is not equivalent to discontinuation of GLP-1 RA therapy entirely — the patient and clinician may elect second transition (e.g., sema → tirz transition was sub-optimal due to AE; second transition is back to sema or forward to lira or to reta pending approval).

6.3 Weight-rebound pulse during washout AE category

Anticipatory framing. During the operational washout window (typically 1 week for within-class GLP-1 RA transitions), the patient experiences gradual PK clearance of the source compound’s effect; the destination compound’s effect emerges on its own titration timeline. The temporal gap between source-effect-clearance and destination-effect-emergence may produce a brief weight-rebound pulse — the patient’s appetite suppression attenuates as source-compound clears and reaches steady-state-engagement of destination-compound only after target-dose attainment over weeks.

For short-half-life transitions (lira ~13 hours), the source-effect clears within days; for long-half-life transitions (sema ~7 days; tirz ~5 days), the source-effect attenuation is gradual over weeks. The destination-compound titration takes 16-20 weeks to target dose for sema or tirz; for lira, target dose attainment is ~4 weeks.

The clinical implication: the patient experiences sub-maximal GLP-1R engagement during the transition window (weeks 1-12 post-transition for sema or tirz destinations; less significant for lira destination given the shorter titration). The weight-rebound during this window is biology, not non-adherence; counsel the patient pre-transition.

Identification. Weight increase during transition weeks 2-12; sometimes 2-4 kg pulse before destination-compound effect emerges.

First-line management. Anticipatory counseling pre-transition; reassurance that the pulse is transient and the destination-compound titration will engage. Behavioral intensification during the transition window may attenuate the pulse — meal-size discipline, activity discipline, hydration discipline.

Escalation triggers. Weight-rebound exceeding ~5-7% of pre-transition stable weight at Week 8-12 is unusual; consider adherence-confirmation on the destination compound; consider whether the destination compound is reaching expected effect-size.

Discontinuation triggers. Sustained weight-rebound with sub-target response at Month 6 on destination compound’s target dose → §7 non-response algorithm; consider second transition.

6.4 Hypoglycemia in concurrent-agent transitions AE category

Anticipatory framing. Transitions involving T2D context with concurrent insulin / sulfonylurea / insulin-secretagogue carry hypoglycemia risk; particularly Scenario 9 sema → IcoSema where the basal-insulin-icodec component is the new addition. Scenario 1 sema → tirz with concurrent insulin requires the typical 20% insulin dose reduction at GLP-1 RA initiation or transition; sulfonylurea typically reduced ~50% or discontinued.

Identification. Patient-reported hypoglycemia events; CGM data if available; HbA1c trajectory below individualized target; symptomatic hypoglycemia.

First-line management. Reduce concurrent insulin / sulfonylurea / insulin-secretagogue dose; reinforce hypoglycemia recognition and treatment; CGM if available for surveillance.

Escalation triggers. Severe hypoglycemia (Grade 3 — requires assistance) → urgent reassessment of concurrent-agent doses; CGM if not already; consider further down-titration or discontinuation of concurrent agent.

Discontinuation triggers. Recurrent severe hypoglycemia despite concurrent-agent dose-reduction → second-transition consideration or discontinuation of the destination compound and return to alternative T2D regimen.

6.5 Glucagon-axis AEs in transitions to dual / triple agonists

Anticipatory framing. Transitions to dual GCGR/GLP-1 (survodutide) or triple GIP/GLP-1/GCGR (retatrutide) introduce glucagon-receptor engagement that the patient on prior sema or tirz did not experience. Anticipated glucagon-axis AEs per [[Retatrutide Protocol]] §6 and [[Survodutide Protocol]] §6:

• Heart rate increase. Anticipated 5-10 bpm increase during titration; per TRIUMPH Phase 2 / Phase 3 data and LIVE-1 Phase 2 data.
• Mild BP changes. Anticipated; magnitude variable.
• Hepatic glucose-output effects. Relevant for T2D context; glucagon-receptor activation increases hepatic glucose output; the net effect on HbA1c is determined by the balance of GLP-1-component glucose-dependent insulin secretion and glucagon-component hepatic glucose output. Trial-program HbA1c data demonstrates net glucose-lowering despite glucagon-receptor component.
• Lipid-axis effects. Glucagon-receptor activation has lipid-axis consequences in preclinical models; trial-program lipid panel trajectories per Phase 2 / Phase 3 data document the net effect.

Identification. Vital-signs monitoring at every post-transition visit (HR, BP); lipid panel quarterly Year 1 on destination compound.

First-line management. Counseling pre-transition on the glucagon-axis AE class; symptomatic management if HR or BP changes are clinically significant.

Escalation triggers. Sustained sinus tachycardia ≥100 bpm; HR-related symptoms (palpitations, exercise intolerance); significant BP change requiring antihypertensive adjustment.

Discontinuation triggers. Clinically significant glucagon-axis AE that does not respond to dose-down within the destination compound’s label-permitted range → second-transition consideration or discontinuation of the destination compound.

6.6 Injection-site reactions during platform-different transitions

Anticipatory framing. For Scenario 5 sema/tirz → lira (weekly-SC to daily-SC), the injection-frequency shift means new injection-site management. For Scenario 7 injectable → orforglipron (injectable to oral), injection-site management discontinues. For within-class injectable transitions (Scenario 1, 2, 3, 4, 6, 8, 9), injection-site management is continuous.

Identification. Patient-reported or visit-observed.

First-line management. Site-rotation reinforcement; topical hydrocortisone for pruritus.

Discontinuation triggers. Severe / systemic hypersensitivity reaction is a labeled contraindication and triggers permanent discontinuation of the destination compound; second-transition consideration to alternative-class destination.

6.7 Patient-experience-of-transition AEs (anxiety, expectation-management)

Anticipatory framing. Transitions are clinical events the patient experiences — not just laboratory or weight events. Patients may experience anxiety about whether the transition will succeed; expectation-management about the destination compound’s anticipated effect-size; concern about side-effect emergence; psychological adjustment to a new compound with a new brand-name and a new injection device or oral platform.

Identification. Patient-reported during post-transition visits.

First-line management. Anticipatory counseling pre-transition; reassurance that transition-period anxiety is normal; reinforcement of the multi-dimensional shared-decision-making framework from §10.

Escalation triggers. Significant patient distress impacting adherence or daily functioning → behavioral-health co-management.

Discontinuation triggers. Patient preference for discontinuation is legitimate; per §8.

6.8 Worked example — transition-period AE for the §4.12 sema → tirz case

The §1.5 / §4.12 patient at Week 9 on tirzepatide 7.5 mg reports mild Grade 1 nausea on Day 1 post-injection. Pre-transition GI AE history on sema 2.4 mg: tolerated well at maintenance; Months 4-6 of original sema titration had mild Grade 1 nausea that resolved.

Protocol response. Anticipatory framing applied: this is GI-tolerability re-priming AE per §6.2 — the destination compound’s titration restarts the GI-AE-emergence-at-each-step pattern. Patient counseling reinforces: this is anticipated; prior sema tolerance does not waive tirz titration discipline. First-line management: meal-size and meal-composition reinforcement; ondansetron 4 mg PRN authorized; continue titration per schedule unless Grade 2 persists.

Trajectory. Patient nausea remained Grade 1 at Week 9 and self-limited; titration continued to 10 mg at Week 13 without AE escalation. The Pattern V trial-anchored expectation is that GI AE during tirz titration is mild-to-moderate for most patients and attenuates at stable target dose; the patient’s experience aligned with this expectation.

6.9 Pattern Z applied to §6 AE management

AE management does not steer toward discontinuation or toward sustained tolerance; the patient-clinician shared decision determines the management trajectory. Pattern Z calibration: Grade 2 GI AE that is tolerable but unpleasant is patient-preference-anchored — the protocol does not override patient preference for dose-down or second-transition by framing tolerability as obligation.

---

7. Transition-anchored non-response algorithm

7.1 Purpose and cross-canonical consistency

§7 is the workhorse algorithmic decision tree for non-response transitions. It consolidates the per-canonical §7 logic across all nine per-canonical protocols into a single transition-anchored algorithm. Pattern W cross-section consistency: the §7 logic in this Stack Protocol reads the same as the per-canonical §7 logic; drift between this Stack Protocol §7 and the per-canonical §7 is a Pattern W violation and the per-canonical canon is authority.

The algorithm is structured to answer: when does class-switch (transition) take precedence over dose-up, lifestyle reinforcement, or adjunct addition? This is the clinical decision the M5.8 v3 lesson and the per-canonical §7 across the portfolio address; the Stack Protocol §7 carries the cross-canonical integration.

Pattern R enforcement: §7 opens with the diagnostic distinctions (pseudo-plateau vs true plateau vs non-response) before the decision branches; opening with “transition to compound X” would steer clinicians away from the diagnostic work that determines whether a transition is the right answer.

7.2 Pseudo-plateau vs true plateau vs non-response — diagnostic distinctions

Identical framework to per-canonical §7 across the portfolio. Pattern W consistency.

Pseudo-plateau. Apparent stall in weight or HbA1c that is in fact within normal variation, or that reflects body-composition change (lean-mass preservation with continued fat-mass loss) rather than total-weight stall, or that occurs in the predictable trial-trajectory pattern (most weight-loss molecules show deceleration in Months 6-9 even on continued effective therapy). Pseudo-plateau is recognized by trajectory-context — comparing the patient’s curve to the per-canonical trial-program trajectory anchor (STEP-1 25th/50th percentile for sema; SURMOUNT-1 trajectory anchor for tirz; etc.).

True plateau. Legitimate response stall — patient was responding, then response flattens or reverses. Recognized by trajectory inflection plus an adequate observation window (typically 2-3 months at stable target dose to confirm the inflection is not pseudo-plateau).

Non-response. Insufficient initial effect from the start. Recognized at Month 3-6 on target dose with effect substantially below trial-program-typical effect for the patient’s phenotype.

7.3 Set-point reset framing (cross-canonical anchor)

Weight-regulation physiology operates on a defended set-point. True plateau in CWM context is often the body’s defense at a new set-point — not therapeutic failure but biological-equilibrium attainment. Counseling beats in §10 do not pathologize plateau; they reframe it as biological-equilibrium and as the decision point for continuation, intensification, or maintenance-at-new-set-point.

STEP-4 (PMID 33755728), STEP-1 Extension (PMID 35441470), and SURMOUNT-4 (PMID 38078870) collectively demonstrate the two-thirds-regain-in-12-months finding post-discontinuation; the set-point defense mechanism re-establishes a higher equilibrium without sustained pharmacologic support. SELECT 4-year (PMID 38740993) demonstrates sustained benefit with continued therapy.

7.4 Decision tree for plateau / non-response — when transition takes precedence

Step 1 — Confirm adherence. Missed doses, injection-technique issues, oral-formulation absorption issues (Rybelsus SNAC discipline; orforglipron oral platform considerations). Refill audit + patient interview. If adherence is the issue → adherence reinforcement; transition is NOT the answer.

Step 2 — Confirm trajectory-context. Plot the patient’s curve against the per-canonical trajectory anchor. If on-trajectory → pseudo-plateau; continue current dose; reassess at next interval; transition is NOT the answer.

Step 3 — Confirm dose attainment. Is the patient on target dose? If not → complete titration to target dose; reassess at Month 3 on target; transition is NOT yet the answer (the patient has not had adequate target-dose exposure).

Step 4 — Reassess phenotype. Does the patient’s clinical picture support a phenotype the trial program enrolled, or is the patient in an under-represented phenotype? Pattern V direction-of-effect: for under-represented phenotypes, expected effect-size may be smaller; recalibrate target before transitioning.

Step 5 — If true plateau / non-response confirmed at adequate observation window, decision branches:

Step 5a — Dose-up if label-permitted higher dose exists. Wegovy 2.4 mg → 7.2 mg (STEP UP PMID 40961952; –18.7% body weight; 31.2% achieving ≥25% loss); Ozempic 1.0 mg → 2.0 mg (SUSTAIN-FORTE); tirz 15 mg is the current ceiling (no higher label-permitted dose as of 2026-05-14). Reassess at Month 3 on the higher dose. Dose-up is typically the FIRST class-of-action when label-permitted higher dose is available.

Step 5b — Within-class transition (Scenario 1 sema → tirz). SURMOUNT-5 head-to-head data (PMID 40353578) supports tirz magnitude advantage. SURPASS-2 (PMID 34170647) supports tirz HbA1c advantage in T2D. Within-class transition takes precedence over within-compound dose-up when (a) the source compound has no higher label-permitted dose available; (b) the source compound has been tried at all label-permitted higher doses without adequate response; (c) the patient elects the head-to-head-anchored magnitude advantage; (d) the AE-tolerability profile on source compound is unsuitable.

Step 5c — Cross-mechanism transition (Scenario 3 sema → reta; Scenario 4 tirz → reta; Scenario 6 sema/tirz → survodutide for MASH; Scenario 8 sema → CagriSema). Triple agonist (retatrutide) or amylin-axis-combination (CagriSema) or dual GCGR/GLP-1 (survodutide) introduces additional receptor engagements; theoretical advantage in mechanism-extension is plausible. Pattern AA: all four destinations investigational as of 2026-05-14; cross-mechanism transition is typically the SECOND class-of-action after within-class transition or label-permitted higher-dose; the trial-program data is Phase 2 / Phase 3 readout pending FDA approval.

Step 5d — Combination with adjunct (lean-mass; visceral-fat; behavioral / nutritional intensification). Adjunct combination per [[Module 5 – Phenotype-Guided Decision Tree Protocol]] Axis 10 and per [[CJC-1295 + Ipamorelin + MOTS-c – Lean Mass Preservation Stack Protocol]] / [[Tesamorelin + AOD-9604 – Visceral Fat Adjunct Protocol]]. Behavioral intensification per STEP-3 (PMID 33625476): IBT + semaglutide ~16.0% vs IBT + placebo ~5.7% — Pattern V direction-of-effect: behavioral intensification is effect-additive, not effect-substitutive. For some patients, intensification before molecule transition is appropriate — the clinical judgment is patient-specific.

Step 5e — Cross-platform transition (Scenario 7 injectable → orforglipron) or platform-shift within class (Scenario 5 sema/tirz → lira for pre-conception pivot). Driven by patient-preference or by life-stage modifier (pre-conception planning), not by magnitude considerations.

Step 5f — Cross-axis transition (Scenario 9 sema → IcoSema for T2D + basal insulin). Driven by emerging or established basal-insulin requirement; the basal-insulin-icodec combination platform addresses the polycondition of T2D needing GLP-1 RA + basal insulin.

Step 5g — Discontinuation entirely (per §8). Patient-preference or AE-driven discontinuation of GLP-1 RA therapy with alternative-class approach (bariatric surgery; phentermine; intensive behavioral / nutritional program; pharmacologic alternative). Discontinuation is the answer in some patients; the transition algorithm does not assume every non-responder should be transitioned within the GLP-1 RA portfolio.

7.5 When does class-switch take precedence over dose-up — operational principles

Per the M5.8 v3 §4.4 framework and the per-canonical §7 logic across the portfolio:

Principle 1 — Non-response to one GLP-1 RA does NOT predict non-response to another. The receptor profiles differ even within the GLP-1 mono-agonist class (sema vs lira) and differ substantially across mechanism classes (GLP-1-only vs dual GIP/GLP-1 vs triple GIP/GLP-1/GCGR vs amylin-overlap vs basal-insulin-overlap). The clinical-practice expectation is that switching can produce a response in a patient who did not respond to a prior compound, particularly when the switch crosses mechanism classes.

Principle 2 — Dose-up is the first action when label-permitted higher dose is available. For sema CWM context, the 7.2 mg HD per STEP UP is the first-line dose-up before within-class transition. For sema T2D context, 1.0 → 2.0 mg per SUSTAIN-FORTE is the dose-up before transition. For tirz, the current 15 mg ceiling means transition is the next action (no higher label-permitted dose).

Principle 3 — Within-class transition (sema ↔︎ tirz) is the SECOND action. Head-to-head data supports the magnitude differential; within-class transition is operationally simpler than cross-mechanism transition (both compounds FDA-approved-for-marketing-claims for CWM and T2D).

Principle 4 — Cross-mechanism transition (to reta, surv, CagriSema, IcoSema) is the THIRD action. Investigational regulatory state for these destinations as of 2026-05-14 means access is via trial enrollment or post-approval framework; cross-mechanism transition is appropriate when within-class transition has been exhausted or when the patient elects mechanism-extension despite the investigational regulatory state.

Principle 5 — Behavioral / nutritional intensification is effect-additive, not effect-substitutive, and is appropriate at any step. STEP-3 data anchors. For some patients, intensification before any pharmacologic change is appropriate — particularly when the patient’s behavioral / nutritional baseline has not been optimized.

Principle 6 — Discontinuation is a legitimate clinical pathway. Not every non-responder should be transitioned; some patients should discontinue GLP-1 RA therapy and pursue alternative-class approaches.

Principle 7 — Severe non-responders may benefit from earlier class-switch decision. Per M5.8 v3 §4.4: “<2% weight loss → faster decision; less likely to benefit from continued titration. Consider class switch earlier.” The trajectory data supports earlier action for severe non-response.

7.6 Severity-stratified algorithm

Per M5.8 v3 §4.4 framework:

Non-response severity	Trajectory at Month 6 on target dose	Action
Mild partial response	≥5% but <10% weight loss	Continue current dose to Month 9-12 trajectory check; consider intensification of behavioral / nutritional / activity program (Step 5d); class-switch (Step 5b) if patient-elected; dose-up (Step 5a) if label-permitted higher dose available
Moderate partial response	2-5% weight loss	Dose-up (Step 5a) first if label-permitted; within-class transition (Step 5b) next; behavioral intensification (Step 5d) concurrent
Severe non-response	<2% weight loss	Faster decision; less likely to benefit from continued titration; within-class transition (Step 5b) or cross-mechanism transition (Step 5c) at earlier time-point; clinician judgment whether dose-up is worth the additional 3 months of observation
Complete non-response	0% or weight increase	Within-class transition (Step 5b) or discontinuation (Step 5g) with alternative-class consideration

7.7 Worked example — non-response algorithm application

Scenario A — moderate partial response on sema 2.4 mg. A 45-year-old male, BMI 32 baseline, on Wegovy 2.4 mg, Month 6 on target dose, 3.5 kg weight loss (3.7% from baseline) — moderate-partial-response category. Adherence confirmed. Trajectory below STEP-1 25th percentile (~7% at Month 6).

Algorithm walk. Step 1-2 (adherence + trajectory): confirmed non-response not pseudo-non-response. Step 3 (dose attainment): on 2.4 mg target. Step 4 (phenotype): standard STEP-1-eligible phenotype; not under-represented. Step 5 — decision branches:

• Step 5a — Dose-up to Wegovy HD 7.2 mg. STEP UP data supports ~18.7% effect-size; patient has tolerated 2.4 mg ≥4 weeks; eligibility met. Dysesthesia counseling per [[Semaglutide Protocol]] §6.10. This is the typical first action for moderate partial response on sema 2.4 mg.
• Step 5b — Within-class transition to tirz. Patient may elect; SURMOUNT-5 head-to-head magnitude advantage. Discuss multi-dimensional comparator framing per §10.2.
• Step 5d — Behavioral / nutritional intensification. STEP-3 effect-additivity data; concurrent with Step 5a or 5b is reasonable.

Patient elects Step 5a (dose-up to 7.2 mg) with concurrent Step 5d (behavioral intensification). Reassessment at Month 9 (3 months on 7.2 mg).

Scenario B — severe non-response on tirz 15 mg. A 52-year-old female, BMI 36 baseline, on tirz 15 mg, Month 6 on target dose, 1.8 kg weight loss (1.7% from baseline) — severe non-response category. Adherence confirmed.

Algorithm walk. Step 1-2: confirmed non-response. Step 3 (dose attainment): on 15 mg target — current ceiling. Step 5 — decision branches:

• Step 5a — Dose-up: not available (15 mg is current label-ceiling).
• Step 5b — Within-class transition to sema. SURMOUNT-5 head-to-head suggests tirz > sema for CWM magnitude at population level; patient is in the trial-enrolled phenotype but is a non-responder; switching back to sema may or may not produce a response given Principle 1 (non-response to one GLP-1 RA does NOT predict response to another).
• Step 5c — Cross-mechanism transition to retatrutide (anticipated; TRIUMPH enrollment or post-approval). Triple-agonist mechanism may engage different receptor profile.
• Step 5d — Behavioral / nutritional intensification. STEP-3 / SURMOUNT analogous data anchors.
• Step 5g — Discontinuation with alternative-class approach. Bariatric surgery consideration for Class II obesity with severe pharmacologic non-response is a legitimate pathway.

Patient and clinician shared decision per §10 counseling beats. The severe non-response category warrants earlier consideration of cross-mechanism transition or alternative-class pathway per Principle 7.

7.8 Cross-canonical §7 alignment self-check

This Stack Protocol §7 is structurally aligned with:

• [[Semaglutide Protocol]] §7 — same diagnostic distinctions; same set-point framing; same 5-step decision tree; same severity stratification per M5.8 v3.
• [[Tirzepatide Protocol]] §7 — same framework; tirz-specific destination compounds in 5b/5c (transition to sema or to retatrutide).
• [[Liraglutide Protocol]] §7 — same framework; lira-specific destinations (transition to sema per STEP 8 head-to-head or to tirz per cross-trial).
• [[Retatrutide Protocol]] §7 — anticipated framework; reta-specific destinations.
• [[Survodutide Protocol]] §7 — anticipated framework; surv-specific destinations.
• [[Orforglipron Protocol]] §7 — anticipated framework; orfo-specific destinations.
• [[CagriSema Protocol]] §7, [[IcoSema Protocol]] §7, [[Cagrilintide Protocol]] §7 — anticipated frameworks; combination-product-specific destinations.

The cross-canonical alignment is the Pattern W cross-section consistency for the algorithmic decision tree across the Module 5 portfolio.

---

8. Discontinuation of the new compound

8.1 Purpose

Define when and how to discontinue the destination compound (the new compound the patient transitioned onto) and the framing for post-discontinuation expectations. §8 is the symmetric counterpart of §4 (transition execution) — just as transition-execution has anticipatory framing for AE-tolerability re-priming and weight-rebound during washout, discontinuation of the new compound has anticipatory framing for the post-discontinuation period, re-initiation pathway, and possible return-to-source-compound decision.

Pattern R enforcement: §8 opens with discontinuation as a legitimate clinical pathway (patient-preference; indication-resolution; AE-driven; pre-conception planning; second-transition consideration) before discussing weight-regain trajectory or re-initiation framing.

8.2 Discontinuation triggers for the new compound

Per-canonical destination-compound discontinuation triggers apply. [[Semaglutide Protocol]] §8.2, [[Tirzepatide Protocol]] §8.2, [[Liraglutide Protocol]] §8.2, etc. The triggers are class-aligned:

• Confirmed contraindication discovery on the new compound (new MTC diagnosis; new MEN-2 family-history; new pregnancy in CWM indication).
• Severe AE attributable to the new compound (acute pancreatitis; NAION if sema-component; severe hypersensitivity). Per [[destination protocol]] §6 AE-class-specific triggers.
• Indication remission or resolution (T2D HbA1c sustained below target with weight stable; MASH histologic resolution sustained; rare).
• Patient preference. Patient-anchored discontinuation decision is legitimate.
• Cost / access barriers — particularly for the investigational destinations (orfo, reta, surv) where post-approval cost may shift; for FDA-approved destinations where insurance coverage may change.
• Pre-conception planning for reproductive-age patients on CWM indication — discontinuation with the destination-compound-specific washout window (sema ~35 days; tirz ~25 days; lira ~2 days; reta ~30 days; surv ~30-35 days; orfo ~6 days; cagri ~35 days; CagriSema both ~35 days; IcoSema both ~35-40 days).
• Non-response to the new compound (transition failed). This is the transition-specific discontinuation trigger — the patient transitioned but did not achieve adequate response on the new compound at Month 6 on adherent target dose. The §7 algorithm has been walked; the patient and clinician elect discontinuation of the new compound; options include (a) return to source compound if patient response was better on source (i.e., transition was a sub-optimal decision in retrospect); (b) second transition to a third compound; (c) discontinuation of GLP-1 RA therapy entirely with alternative-class approach (bariatric surgery; phentermine; intensive behavioral / nutritional program).

8.3 How to taper the new compound

Per per-canonical destination-compound §8.3. For GLP-1 RAs in CWM indication: pharmacokinetic tapering (step-down dosing) is not pharmacologically required — the half-life-driven PK washout occurs at fixed kinetics regardless of taper schedule. However, gradual dose reduction is the per-canonical recommended pattern for:

1. Weight-regain trajectory smoothing. Abrupt discontinuation produces faster weight-regain than gradual reduction; gradual reduction allows behavioral adaptation.
2. AE-class symmetry. Some patients experience appetite-rebound or GI-pattern shifts on abrupt discontinuation; gradual reduction attenuates these.

Destination-compound-specific taper patterns:

• Sema CWM (Wegovy): 2.4 mg → 1.7 mg × 4 wk → 1.0 mg × 4 wk → 0.5 mg × 4 wk → discontinue. Total ~12 weeks.
• Tirz CWM (Zepbound): 15 mg → 10 mg × 4 wk → 7.5 mg × 4 wk → 5 mg × 4 wk → 2.5 mg × 4 wk → discontinue. Total ~16 weeks.
• Lira CWM (Saxenda): 3.0 mg → 2.4 mg × 1 wk → 1.8 mg × 1 wk → 1.2 mg × 1 wk → 0.6 mg × 1 wk → discontinue. Total ~4 weeks (shorter taper given shorter half-life).
• Reta CWM (anticipated): 12 mg → 8 mg × 4 wk → 4 mg × 4 wk → 2 mg × 4 wk → discontinue. Anticipated.
• Surv (anticipated): 6.0 mg → 4.5 mg × 4 wk → 3.0 mg × 4 wk → 1.2 mg × 4 wk → discontinue. Anticipated.
• Orfo CWM (anticipated): 36 mg → 12 mg × 4 wk → 6 mg × 4 wk → discontinue. Total ~8 weeks (shorter taper per Pattern N.1 shorter half-life).
• CagriSema (anticipated): taper both components synchronously; 2.4/2.4 → 1.7/1.7 × 4 wk → 1.0/1.0 × 4 wk → 0.5/0.25 × 4 wk → discontinue.
• IcoSema (anticipated): taper per [[IcoSema Protocol]] §8; basal-insulin-icodec discontinuation requires alternative basal-insulin or alternative T2D regimen during the taper.

For AE-attributable discontinuation (acute pancreatitis, NAION, severe hypersensitivity), abrupt discontinuation is appropriate; the destination-compound-specific clearance window supports rapid PK clearance during the evaluation window.

8.4 Pre-conception washout post-transition

The destination-compound’s pre-conception window arithmetic applies. For Scenario 5 (sema/tirz → lira) the lira ~2-day window is the principal advantage. For all other scenarios, the destination compound’s per-canonical §8.4 pre-conception window arithmetic applies:

• Sema destinations (Scenarios 2, 8 sema-component retained, 9 sema-component retained): ~8-week label window per Wegovy / Ozempic / IcoSema.
• Tirz destinations (Scenario 1): label-recommended ≥2 months before planned pregnancy.
• Lira destinations (Scenario 5): ~1-2 weeks operational pre-conception window per ~2-day PK clearance + clinical margin.
• Reta destinations (Scenarios 3, 4; anticipated): anticipated ≥2-month window per ~30-day PK clearance.
• Surv destinations (Scenario 6; anticipated): anticipated ≥2-month window per ~30-35-day PK clearance.
• Orfo destinations (Scenario 7; anticipated): anticipated 2-4-week window per ~6-day PK clearance.
• CagriSema (Scenario 8): anticipated ~8-week window per synchronous ~35-day PK clearance of both components.
• IcoSema (Scenario 9): anticipated ~8-week window per ~35-40-day PK clearance of both components.

8.5 Post-discontinuation weight-regain framing

The trial-program data on post-GLP-1-RA-discontinuation weight regain anchors to STEP-4 (PMID 33755728; ~two-thirds regain in 12 months for sema), SURMOUNT-4 (PMID 38078870; +14% regain over 52 weeks for tirz), STEP-1 Extension (PMID 35472181; ~two-thirds regain in 52 weeks for sema). The mechanism — set-point physiology and defended-weight biology — predicts that without sustained pharmacologic support, the body’s counter-regulatory responses re-establish a higher equilibrium.

Counseling beats in §10 do not pathologize weight regain post-discontinuation; they frame the regain trajectory as the expected biological response, the same way pre-transition counseling framed the appetite-suppression mechanism as the biological intervention.

8.6 Re-initiation pathway post-discontinuation

A patient who discontinued the destination compound and is considering re-initiation: typically re-titration from the per-canonical destination-compound starting dose. The destination compound’s per-canonical §8.6 applies; selection-criteria re-screening per §2 of the destination compound; pre-treatment workup refresh if discontinuation period exceeded ~12 months.

Return to source compound is also a re-initiation pathway. The patient’s source-compound exposure history (response trajectory; AE profile; adherence experience) informs whether returning to the source compound is appropriate or whether a different transition is warranted.

8.7 Worked example — post-transition discontinuation of new compound

The §1.5 / §4.12 patient (49-year-old post-menopausal female, transitioned sema → tirz at Month 14, achieved 15% cumulative weight loss at Month 5 post-transition) — Month 18 post-transition reports stable weight, tolerable AE profile, electing patient-preference discontinuation.

Protocol response. Per §8.2 — patient-preference discontinuation is legitimate. Per §8.3 — tirz CWM taper schedule 15 mg → 10 → 7.5 → 5 → 2.5 → off over ~16 weeks. Counseling beat per §10.7 — STEP-4 / SURMOUNT-4 trajectory data presented (anticipated two-thirds regain in 12 months; the patient’s specific trajectory is patient-anchored); re-initiation pathway available if regain occurs and warrants re-treatment.

Post-discontinuation monitoring at Month 3, 6, 12 with weight and BP; re-initiation decision at any monitoring visit if regain warrants and patient agrees. Re-initiation pathway options: return to sema (the source compound; patient had partial response there); return to tirz (the destination compound; patient had better response); transition to a different compound (e.g., emerging reta or CagriSema post-approval).

8.8 Pattern Z applied to §8

Discontinuation framing does not pathologize patient preference or steer toward continuation. Pattern Z Anchor 5 (off-label / extrapolation) applies for patients considering off-label sustained low-dose maintenance after target achievement; Pattern Z Anchor 3 applies for pre-conception discontinuation. The §10 counseling beats carry the post-discontinuation framing per anchor.

---

9. Transition vs combination — layering decisions

9.1 Purpose

Define when to transition (switch compounds) vs when to layer (combine compounds without removing the source compound). §9 is the cross-decision-section that arises when a patient on a Module 5 compound is asking “should I switch to compound Y, or should I add an adjunct to compound X without switching?” Pattern W cross-section consistency: §9 reconciles with the per-canonical §9 combination rules across the portfolio and with the three adjunct-class stack protocols.

9.2 The decision framework — transition vs layer

Transition (switch). Stop source compound; initiate destination compound per §4 transition-execution. The patient is on one Module 5 compound after the transition.

Layer (combine). Continue source compound at current dose; add adjunct compound from outside the GLP-1 RA / amylin / GIP / glucagon metabolic-axis family — typically lean-mass peptides (CJC-1295 / Ipamorelin / MOTS-c per [[CJC-1295 + Ipamorelin + MOTS-c – Lean Mass Preservation Stack Protocol]]), visceral-fat peptides (Tesamorelin / AOD-9604 per [[Tesamorelin + AOD-9604 – Visceral Fat Adjunct Protocol]]), skin peptides (GHK-Cu per [[GHK-Cu – Post-Weight-Loss Skin Laxity Protocol]]), or behavioral / nutritional intensification.

The decision criteria:

• Transition is appropriate when: the source compound’s primary effect (weight, HbA1c, MASH-fibrosis trajectory) is sub-target despite adherent target dose; the patient and clinician elect alternative-class or higher-magnitude mechanism; AE intolerance on source compound; indication-shift requires destination’s FDA-approved-for-marketing-claims indication coverage.
• Layer is appropriate when: the source compound’s primary effect is at-or-near-target but a complementary phenotype dimension is not adequately addressed (lean-mass loss disproportionate to total weight reduction; visceral-fat persistence despite total weight reduction; post-weight-loss skin laxity); the source compound is producing the intended primary effect and the adjunct addresses a different mechanism/phenotype.

9.3 Within-Module-5 combinations (not transitions)

The within-Module-5 combinations — GLP-1 RA + amylin analog (CagriSema), GLP-1 RA + GIP agonist (tirzepatide is single-molecule dual; not a layered combo), GLP-1 RA + glucagon (survodutide single-molecule; reta single-molecule), GLP-1 RA + basal insulin (IcoSema fixed combination), GLP-1 RA + SGLT2 inhibitor (cross-class additive for T2D + CKD or T2D + ASCVD) — are covered in §1.2 transition scenarios 8 and 9 (CagriSema and IcoSema) for the fixed-combination products and in this §9 for the separately-prescribed combinations.

Separately-prescribed combinations within Module 5:

• GLP-1 RA + SGLT2 inhibitor (T2D context). Class-additive HbA1c, CV, and kidney benefits; commonly co-prescribed in T2D + CKD or T2D + ASCVD context. This is a LAYER decision, not a TRANSITION decision — the patient continues GLP-1 RA and adds SGLT2.
• GLP-1 RA + insulin (T2D advanced). Common in T2D with progressed beta-cell failure where GLP-1 RA monotherapy is insufficient. LAYER decision; concurrent insulin dose typically reduced ~20% at GLP-1 RA initiation per per-canonical §6.7.

Contraindicated combinations (per [[Semaglutide Protocol]] §9.4 and per-canonical equivalents):

• GLP-1 RA + DPP-4 inhibitor: not contraindicated by safety but contraindicated by lack of additive benefit.
• GLP-1 RA + concurrent oral semaglutide and injectable semaglutide: avoid; redundant within-molecule.
• GLP-1 RA + concurrent semaglutide and tirzepatide: avoid; redundant within-class; not a layer — this is a transition decision per §4.2 or §4.3.

9.4 Cross-Module-5 combinations — lean-mass / visceral-fat / skin adjuncts

Cross-Module-5 combinations are typically LAYER decisions, not TRANSITION decisions. The adjunct addresses a different mechanism / phenotype dimension that the GLP-1 RA backbone does not directly target.

• GLP-1 RA + lean-mass adjunct (CJC-1295 / Ipamorelin / MOTS-c). Lean-mass-preservation phenotype during GLP-1-driven weight loss; Axis 10 trigger per DEXA-documented lean-mass loss >25-30% of total mass lost; typically older-adult or athletic-population. [[CJC-1295 + Ipamorelin + MOTS-c – Lean Mass Preservation Stack Protocol]] §9 documents the layer mechanics.
• GLP-1 RA + visceral-fat adjunct (Tesamorelin / AOD-9604). Visceral-fat persistence despite total weight reduction. [[Tesamorelin + AOD-9604 – Visceral Fat Adjunct Protocol]] §9 documents.
• GLP-1 RA + skin adjunct (GHK-Cu). Post-weight-loss skin laxity; typically 12+ months of significant weight loss (≥15% body weight) with documented skin laxity. [[GHK-Cu – Post-Weight-Loss Skin Laxity Protocol]] §9 documents.

9.5 Decision criteria — when to layer adjunct vs transition compound

Layer adjunct (continue current Module 5 compound; add adjunct):

• Primary effect (weight, HbA1c) is at or near target on the current Module 5 compound.
• A complementary phenotype dimension is not adequately addressed (lean-mass, visceral-fat, skin).
• Patient tolerates current Module 5 compound well; AE profile acceptable.
• Patient preference is to continue current compound + add adjunct.

Transition compound (switch from current Module 5 compound to a different Module 5 compound):

• Primary effect is sub-target despite adherent target dose.
• Patient elects alternative-class or higher-magnitude mechanism.
• AE intolerance on current compound.
• Indication-shift requires destination’s FDA-approved-for-marketing-claims indication coverage.

Both can apply simultaneously:

• Transition AND layer: patient transitions sema → tirz AND adds lean-mass adjunct because lean-mass-loss concern was documented on sema and is anticipated to persist on tirz.

9.6 Worked example — transition vs layer for a polycondition patient

A 58-year-old male, BMI 34, T2D (HbA1c 7.6 on metformin + sema 1.0 mg + empagliflozin 10 mg), known ASCVD (prior MI), eGFR 52 with UACR 220, no MASH, no MTC / MEN-2 / pancreatitis. On sema 1.0 mg for 18 months; weight loss 7 kg (7% of baseline); HbA1c improved from 9.2 baseline to 7.6 but above 7.0 target.

Decision question. Is the next action (a) escalate sema to 2.0 mg (Step 5a dose-up); (b) transition sema → tirz (Step 5b within-class transition; SURPASS-2 head-to-head higher HbA1c reduction); (c) layer additional agent (Step 5d — already on SGLT2; metformin; layer additional T2D agent like pioglitazone or insulin); (d) maintain current and intensify behavioral / nutritional program.

Decision walk. Per §7 algorithm:

• Step 1-2: adherence + trajectory confirmed; HbA1c moderate-partial-response.
• Step 3: dose-attainment — on 1.0 mg target; 2.0 mg is label-permitted higher dose available.
• Step 5a — escalate to sema 2.0 mg per SUSTAIN-FORTE. Pattern V trial-anchored: 1.0 → 2.0 mg offers approximately 0.2-0.4 additional HbA1c percentage-point reduction. This is the first action.
• Step 5b — transition to tirz: SURPASS-2 head-to-head higher HbA1c reduction (~2.3 vs ~1.9 percentage points). Patient would lose the FLOW-anchored CKD indication that sema carries (patient has CKD risk-profile with eGFR 52 + UACR 220 — FLOW-eligible range). The transition involves an indication-coverage trade-off.
• Step 9 (combination decisions): patient is already on optimal layered cross-class regimen (sema + SGLT2 + metformin per ADA/EASD); no additional cross-class layer is the first action.

Patient and clinician shared decision. Per §10 counseling beats: dose-up to sema 2.0 mg is the typical first action. If 2.0 mg HbA1c trajectory at Month 3 remains above target, Step 5b transition to tirz becomes the next-action consideration with explicit indication-coverage trade-off framing.

The decision is not transition vs layer for THIS patient at THIS time — it is dose-up first, then transition consideration if dose-up insufficient.

9.7 Pattern Z applied to §9

The transition-vs-layer decision is patient-anchored, not clinician-mandated. Counseling beats per §10 frame the trade-offs without steering. The §12 transition decision matrix covers the layer-vs-transition decision points.

---

10. Patient counseling beats per transition scenario (Pattern Z calibration-anchor-compliant)

10.1 Purpose and Pattern Z calibration

Define the protocol’s patient-counseling content for each transition scenario. §10 is the operational anchor for Pattern Z (cumulative-tone calibration) and for Pattern R (lead-framing calibration). The counseling beats are the most reader-facing content the protocol produces and are the most vulnerable to drift from “presenting facts” to “steering decisions.”

All five Pattern Z calibration anchors apply across the §10 counseling beats:

• Anchor 1 — Lead with what the option IS. Each scenario’s counseling beat opens with what the destination compound IS, what the transition IS, and what the patient’s clinical context IS. Never opens with what the destination compound IS NOT or with cautionary framing.
• Anchor 2 — Compounded vs FDA-approved framing. Multiple transitions cross compounded supply (compounded sema → FDA-approved Wegovy; compounded tirz → branded Zepbound; brand → compounded for cost / access). The counseling beat presents both options factually.
• Anchor 3 — Pregnancy-planning research-state-leading. Scenario 5 sema/tirz → lira pre-conception pivot LEADS with Parker 2025 PMID 40329607 pooled human pregnancy-exposure data; PK arithmetic and label-status appear AFTER research-state lead.
• Anchor 4 — Multi-dimensional comparator framing. Every transition scenario is a comparator decision; counseling beats present multi-dimensional facts (magnitude, CV, MASH, kidney, NAION, GI, route, cost, regulatory state); open with affirmation of both compounds; close with shared decision-making invitation.
• Anchor 5 — Off-label / extrapolation transparency. Transitions to investigational destinations (reta, surv, cagri, CagriSema, IcoSema US, orfo) are framed as research-state-incomplete; transitions for off-label indications are framed transparently.

10.2 Scenario 1 counseling beat — Sema → Tirz

Setting. Patient on adherent target-dose semaglutide (Wegovy 2.4 mg for CWM or Ozempic 1.0/2.0 mg for T2D) with sub-target response or patient-preference magnitude-extension consideration.

Patient-counseling beat (Pattern Z Anchor 4 multi-dimensional):

“Both semaglutide and tirzepatide are evidence-based weight-management options. The SURMOUNT-5 head-to-head trial directly compared them at maximum-tolerated doses and showed tirzepatide produced about 6.5 percentage points more weight loss than semaglutide — that’s a real magnitude advantage on the weight-loss dimension. Beyond that, the compounds differ on several dimensions you and I want to think through together.

Semaglutide has FDA-approved indications for chronic weight management, cardiovascular risk reduction (the SELECT trial in non-diabetic obesity with heart disease), MASH (the ESSENCE trial for moderate-to-advanced liver fibrosis), and kidney disease in type 2 diabetes (the FLOW trial). Tirzepatide has FDA approval for weight management, OSA-with-obesity, and HFpEF-with-obesity; the cardiovascular outcomes program SURMOUNT-MMO is still in progress; the MASH program is in development; the kidney outcomes program is in development. So semaglutide currently has broader outcomes-evidence indication coverage; tirzepatide has the magnitude advantage on weight loss.

On safety: there’s an ophthalmology signal called NAION that has been described in semaglutide pharmacovigilance — Hathaway 2024 in JAMA Ophthalmology — but appears absent for tirzepatide per Lakhani 2025. This is a class-differentiation finding under active evaluation; it’s not a labeled warning for semaglutide but it’s a fact worth knowing.

On gastrointestinal tolerability, both compounds produce a similar class profile of nausea, occasional vomiting, and transient bowel-pattern shifts during titration. Your individual experience on the new compound is not predictable from class-level data — but your prior tolerance of semaglutide is encouraging.

On route and platform: both are weekly subcutaneous injections; semaglutide is also available orally (Rybelsus for T2D, oral Wegovy 25 mg for CWM); tirzepatide is injection-only as of now.

On cost and access: this varies by your insurance and by the supply landscape; we can review the specific options for your situation.

The transition mechanics: stop Wegovy at your last weekly injection; wait one week; start tirzepatide at the standard starting dose of 2.5 mg; titrate per the standard schedule to your target dose over about 16-20 weeks. You’ll experience some early-titration GI effects similar to what you experienced when you first started semaglutide — that’s expected and manageable.

Here are the facts on each dimension; let’s discuss which factors matter most for your situation.“

Pattern Z self-audit applied. Opens with affirmation of both compounds. Multi-dimensional fact presentation (magnitude, CV, MASH, kidney, NAION, GI, route, cost). Tirz magnitude advantage acknowledged explicitly. Sema indication-coverage advantage acknowledged explicitly. Closes with shared decision-making invitation. Pattern V trial-anchored throughout. Pattern AA precise on regulatory state.

10.3 Scenario 2 counseling beat — Tirz → Sema

Setting. Patient on adherent target-dose tirzepatide with emerging or progressing indication (MASH F2/F3; CKD-in-T2D; ASCVD-in-non-diabetic-obesity) or patient-preference for oral platform.

Patient-counseling beat:

“Both tirzepatide and semaglutide are evidence-based options. On weight-loss magnitude, the SURMOUNT-5 head-to-head trial showed tirzepatide produced about 6.5 percentage points more weight loss than semaglutide — and that’s worth weighing as we think about this transition. The reason we’re discussing the switch is [the indication driver for this specific patient].

[For MASH driver:] Semaglutide is FDA-approved for MASH with moderate-to-advanced fibrosis based on the ESSENCE trial (about 62.9% of patients achieved MASH resolution without worsening fibrosis vs about 34.3% on placebo at 72 weeks). Tirzepatide doesn’t currently have an FDA-approved MASH indication; the trial program is in development. Your liver-fibrosis trajectory on tirzepatide hasn’t shown adequate improvement, and the ESSENCE-anchored semaglutide indication is the evidence-anchored next-step.

[For CKD-in-T2D driver:] Semaglutide is FDA-approved for kidney composite endpoint reduction in T2D + CKD based on the FLOW trial. Your kidney function trajectory makes the FLOW-anchored semaglutide indication the relevant next step.

[For ASCVD-in-non-diabetic-obesity driver:] Semaglutide is FDA-approved for cardiovascular risk reduction in non-diabetic obesity with established CVD based on the SELECT trial. Your cardiovascular risk profile makes this the relevant indication.

[For oral-preference driver:] Semaglutide is available as Rybelsus oral 14 mg for T2D and as oral Wegovy 25 mg for CWM. Switching from weekly injection to daily oral is a substantive platform change.

On the weight-loss-magnitude side, we should expect that your weight trajectory on semaglutide may show some attenuation relative to tirzepatide. The indication-driver matters, but the magnitude trade-off is real and we should plan for it together.

One safety note: there’s an ophthalmology signal called NAION described in semaglutide pharmacovigilance — Hathaway 2024 — under active evaluation; not a labeled warning. If you’ve ever had NAION on a prior semaglutide exposure, that’s a hard stop for re-exposure; if not, we proceed with awareness of the signal.

The transition mechanics: stop tirzepatide at your last weekly injection; wait one week; start semaglutide at the standard starting dose of 0.25 mg; titrate per the standard schedule.

Here are the facts on each dimension; let’s discuss the trade-off and what matters most for your situation.“

10.4 Scenario 3 counseling beat — Sema → Reta (Anchor 5 dominant)

Setting. Patient on adherent target-dose semaglutide with sub-target response electing magnitude-extension via triple-agonist mechanism. Pattern AA: retatrutide investigational as of 2026-05-14.

Patient-counseling beat (Pattern Z Anchor 5 dominant — extrapolation transparency):

“Retatrutide is an investigational triple-receptor agonist that engages GLP-1, GIP, and glucagon receptors — a different mechanism class from semaglutide (which engages only GLP-1) and tirzepatide (which engages GLP-1 and GIP). The Phase 2 trial (TRIUMPH; Jastreboff 2023) showed about 24.2% weight reduction at 12 mg over 48 weeks in non-diabetic obesity. Eli Lilly disclosed Phase 3 TRIUMPH-4 data in December 2025 showing about 28.7% weight reduction; peer-reviewed publication is pending. As of today (2026-05-14), retatrutide is not FDA-approved; access is through Phase 3 trial enrollment or post-approval framework.

If you want to consider retatrutide, the operational pathways are: (a) we can evaluate whether you qualify for active TRIUMPH Phase 3 enrollment — this would mean entering a structured trial protocol with specific monitoring requirements, contraception requirements if applicable, and the placebo-arm randomization possibility; (b) we wait for FDA approval and access through commercial channels — the regulatory decision timeline is near-term.

If we proceed, the transition mechanics would be: stop semaglutide; the trial protocol or eventual label will specify the washout window (likely 5 half-lives, about 35 days for semaglutide); start retatrutide at the trial-protocol or eventual-label starting dose; titrate to target dose over about 16-20 weeks. The Phase 2 trial documented an AE profile that includes the GI effects you know from semaglutide plus glucagon-axis effects — anticipated heart-rate increase of 5-10 bpm during titration, possible BP changes, possible lipid-axis effects.

Cross-trial comparison to tirzepatide: the SURMOUNT-1 trial showed tirzepatide 15 mg at about 22.5% weight reduction; the cross-trial comparison suggests retatrutide may have a magnitude advantage over tirzepatide, but there is no direct head-to-head retatrutide vs tirzepatide trial. Cross-trial comparisons across different trial programs come with the standard caveats — different enrollments, different placebo responses, different study durations.

One option that is currently available and FDA-approved is the transition to tirzepatide; SURMOUNT-5 head-to-head showed tirzepatide about 6.5 percentage points more than semaglutide. If you want the within-class transition with current commercial access and head-to-head evidence, tirzepatide is the destination; if you want the cross-mechanism extension with anticipated higher magnitude but investigational regulatory state, retatrutide is the destination.

Here are the facts on each dimension; let’s discuss what you’re hoping to achieve, what the evidence does and doesn’t tell us about each option, and the regulatory state of each.“

Pattern Z self-audit applied. Acknowledges patient’s underlying question without dismissing. Presents trial-population scope (TRIUMPH Phase 2 / Phase 3 enrollment); presents extrapolation question as research-state-incompleteness; explicit investigational labeling; close with shared decision-making invitation.

10.5 Scenario 4 counseling beat — Tirz → Reta

Setting. Patient on adherent target-dose tirzepatide 15 mg with sub-target response electing magnitude-extension via triple-agonist mechanism. Pattern AA: retatrutide investigational.

Patient-counseling beat:

“You’ve reached the current ceiling of tirzepatide (15 mg) — there’s no higher label-permitted dose available for tirzepatide as of today. The options for further magnitude extension are: (a) switching to retatrutide, the investigational triple-receptor agonist with TRIUMPH Phase 2 about 24.2% and Phase 3 disclosed about 28.7%; (b) switching to CagriSema, the investigational combination of cagrilintide + semaglutide with REDEFINE Phase 3 about 20.4%; (c) layering an adjunct without changing the core compound (lean-mass adjunct, visceral-fat adjunct, behavioral / nutritional intensification per STEP-3-style data); (d) considering whether the current response is a defensible new set-point and continuation at current dose is appropriate.

The cross-trial comparison between tirzepatide and retatrutide is not a head-to-head: SURMOUNT-1 tirz 15 mg about 22.5%; TRIUMPH-4 reta about 28.7%. The differential could reflect the additional glucagon-receptor engagement in retatrutide, or differences between the trial enrollments and placebo arms. The honest framing is that retatrutide is anticipated to have higher magnitude on cross-trial comparison, but the magnitude of the differential is research-state-incomplete without a head-to-head trial.

For retatrutide access: TRIUMPH Phase 3 trial enrollment or post-FDA-approval. The transition mechanics involve trial-protocol washout (likely 5 half-lives, about 25 days for tirzepatide) and starting retatrutide at the trial-protocol starting dose with standard titration. The glucagon-axis AE class is the new AE consideration for you — heart rate, BP, lipid axis.

Here are the facts on the options; let’s discuss what matters most for your situation.“

10.6 Scenario 5 counseling beat — Sema/Tirz → Lira pre-conception pivot (Anchor 3 dominant)

Setting. Reproductive-age female on weekly-SC sema or tirz with conception planning horizon ≤6-12 months electing the short-half-life pivot.

Pattern Z Anchor 3 dominant — research-state-leading per Parker 2025 PMID 40329607.

Patient-counseling beat:

“On the human pregnancy-exposure data: Parker 2025 in Diabetes Obesity & Metabolism (PMID 40329607) reviewed pooled unplanned pregnancies from FDA- and EMA-submitted regulatory clinical trials of GLP-1 receptor agonists — semaglutide, liraglutide, dulaglutide, and class-related compounds. The pooled incidence of congenital abnormalities appears relatively low in this dataset; sample size is limited and the exposures were from unplanned-pregnancy contexts. The authors call for prospective pregnancy registries. This is the load-bearing human evidence as of today.

Standard clinical practice for planned conception: discontinue the GLP-1 RA before conception attempts with a washout window that allows pharmacokinetic clearance. The washout arithmetic depends on the compound’s half-life:

– Semaglutide has an elimination half-life of about one week; substantial pharmacokinetic clearance takes about 35 days (5 half-lives); the FDA label for Wegovy/Ozempic recommends discontinuation at least 8 weeks before planned conception.
– Tirzepatide has an elimination half-life of about 5 days; substantial clearance takes about 25 days; the label recommends discontinuation at least 2 months before planned conception.
– Liraglutide has an elimination half-life of about 13 hours; substantial clearance takes about 2 days; the Saxenda label specifies discontinuation upon pregnancy awareness, with a typical operational pre-conception window of about 1-2 weeks.

The pre-conception pivot from semaglutide or tirzepatide to liraglutide allows you to remain on GLP-1 RA therapy until shortly before conception — about 1-2 weeks pre-conception on liraglutide vs about 8 weeks pre-conception on semaglutide or 4 weeks on tirzepatide. That’s about 6 weeks of additional GLP-1 RA exposure if you’re planning conception in the next several months.

The trade-off: liraglutide has lower weight-loss magnitude than semaglutide or tirzepatide. STEP 8 head-to-head (Rubino 2022 JAMA, PMID 35015037) showed semaglutide about 15.8% vs liraglutide about 6.4% at week 68 in non-diabetic adults with overweight or obesity. Switching from your current compound to liraglutide will likely produce some weight regain during the transition window and a lower-magnitude maintenance on liraglutide. That’s a real trade-off; we should plan for it.

The transition mechanics: stop semaglutide (or tirzepatide) at your last weekly injection; wait one week; start liraglutide 0.6 mg daily; titrate per the standard schedule to 3.0 mg target over about 4 weeks (Saxenda CWM) or 1.8 mg target (Victoza T2D). Daily injection technique is the same skill as your current weekly injection — you already know how to do this.

Post-pregnancy and post-lactation, we can re-initiate semaglutide or tirzepatide or whichever compound suits your situation at that point. The re-initiation pathway is standard.

Here are the facts; let’s discuss your conception timeline and what works best for your situation.“

Pattern Z self-audit applied. LEADS with Parker 2025 human research-state data. PK arithmetic appears after research-state lead. Animal-data + Category-X-equivalent framing not foregrounded. Multi-dimensional comparator framing (STEP 8 magnitude differential acknowledged explicitly). Closes with shared decision-making.

10.7 Scenario 6 counseling beat — Sema/Tirz → Survodutide (MASH-driven; Anchor 5 dominant)

Setting. Patient with biopsy- or imaging-confirmed MASH F2/F3 on prior sema or tirz with inadequate MASH-fibrosis trajectory. Pattern AA: survodutide investigational; LIVERAGE Phase 3 enrollment or post-approval.

Patient-counseling beat (Pattern Z Anchor 5 dominant):

“Your liver-fibrosis trajectory on [current compound] hasn’t shown the improvement we’d hoped for. Survodutide is an investigational dual GLP-1/glucagon receptor agonist with promising Phase 2 MASH data — the LIVE-1 trial (Sanyal 2024 NEJM, PMID 38863223) showed about 76% of patients with F2/F3 fibrosis achieved histologic resolution of MASH at 48 weeks versus about 14% on placebo. That’s a substantial magnitude on the MASH-fibrosis endpoint. As of today (2026-05-14), survodutide is not FDA-approved; access is through LIVERAGE Phase 3 trial enrollment (currently recruiting) or future post-approval.

If we proceed with LIVERAGE enrollment, you’d enter a structured trial protocol with specific monitoring, contraception requirements if applicable, and the placebo-arm randomization possibility. The transition mechanics involve trial-protocol washout (likely 5 half-lives, about 35 days for semaglutide or 25 days for tirzepatide) and starting survodutide per the trial-protocol initiation schedule.

Survodutide engages the glucagon receptor in addition to GLP-1; that introduces some new AE considerations — anticipated heart-rate increase of 5-10 bpm during titration, possible BP changes, possible hepatic glucose-output effects (relevant if you have T2D). The GI-class effects you know from semaglutide or tirzepatide will be similar.

The alternatives if you don’t pursue survodutide: continue your current compound and intensify the behavioral / nutritional / activity program; consider resmetirom (Rezdiffra, the thyroid hormone receptor-β agonist FDA-approved for MASH in March 2024) as an alternative-class MASH therapy; consider whether the current MASH-fibrosis stability is acceptable for ongoing management even without progression to resolution. Hepatology co-management continues regardless of which path we take.

Here are the facts on the options; let’s discuss your fibrosis trajectory, the trial-enrollment versus wait-for-approval consideration, and what matters most for your situation.“

10.8 Scenario 7 counseling beat — Injectable → Orforglipron (oral platform)

Setting. Patient on weekly-SC sema or tirz with patient-preference oral platform. Pattern AA: orforglipron investigational with FDA decision pending. Pattern Z.injection-framing reciprocity: do not steer.

Patient-counseling beat:

“Orforglipron is an investigational oral small-molecule GLP-1 receptor agonist — non-peptide chemistry, daily oral dosing. The ATTAIN-1 Phase 3 trial for obesity reported about 11.2% weight reduction at 36 mg over 72 weeks. The ACHIEVE program for T2D reported HbA1c reduction roughly comparable to weekly-SC semaglutide. Eli Lilly filed for FDA approval in Q4 2025 for obesity and Q1 2026 for T2D; the regulatory decision is near-term. As of today, orforglipron is not FDA-approved; access is through Phase 3 trial enrollment or post-approval.

The platform difference: orforglipron is daily oral; sema and tirz are weekly subcutaneous. Different patients have different preferences here. Some patients prefer oral medication; some prefer weekly injection because the appetite-control profile is steadier and the dosing burden is once a week rather than once a day. Self-injection of weekly-SC compounds is a routine clinical skill — you’ve been doing it well for [time period] — and we shouldn’t treat it as a burden to be relieved by switching to oral. The question is your preference and your specific clinical situation (travel pattern, cold-chain compatibility, peri-procedural medication-pause complexity).

Magnitude comparison: orforglipron ATTAIN-1 about 11.2% vs sema STEP-1 about 14.9% (or sema HD 7.2 mg STEP UP about 18.7%) vs tirz SURMOUNT-1 about 22.5%. The cross-trial comparison places orforglipron between sema 2.4 mg and the lower-end semaglutide doses; not at the magnitude of tirz or sema HD. Pattern V trial-anchored — cross-trial comparisons come with the standard caveats.

On safety: the GI-class profile is similar; the oral platform has some drug-drug-interaction considerations specific to the oral non-peptide chemistry. We’ll review your concurrent medications.

The transition mechanics (anticipated, pending FDA approval): stop weekly-SC compound; wait about one week; start orforglipron at the standard starting dose (anticipated 3 mg daily); titrate per the standard schedule.

Here are the facts on the platform options; let’s discuss what matters most for your situation.“

10.9 Scenario 8 counseling beat — Sema → CagriSema (amylin-axis magnitude extension)

Setting. Patient on stable sema 2.4 mg Wegovy with plateau or partial response electing amylin-pathway additive mechanism. Pattern AA: CagriSema FDA-pending.

Patient-counseling beat:

“CagriSema is an investigational fixed-ratio combination of cagrilintide (an amylin analog) and semaglutide. The amylin pathway is a complementary appetite-regulation mechanism — physiologic amylin is co-released with insulin and modulates gastric emptying and central satiety in a mechanism complementary to GLP-1. The Phase 3 REDEFINE-1 trial (PMID 40544433) showed about 20.4% weight reduction with CagriSema versus about 3.0% with placebo at 68 weeks in non-diabetic obesity; adherent-population analysis showed about 22.7%. Novo Nordisk has filed for FDA approval; the regulatory decision is near-term.

The mechanism: you’d continue the semaglutide 2.4 mg component at your current dose; the cagrilintide component is added through titration over about 16-20 weeks to a target of 2.4 mg of cagrilintide. The fixed-combination delivery means one weekly injection that contains both components.

Magnitude framing: REDEFINE-1’s about 20.4% is the trial-population average. Your baseline weight loss on semaglutide 2.4 mg alone is approximately [patient-specific percentage]; the incremental gain from adding cagrilintide is at the population level approximately 5-8 percentage points but with individual variability. Your individual response will be your individual response.

Comparison to alternatives: tirzepatide via Scenario 1 transition (SURMOUNT-5 head-to-head sema vs tirz about 6.5 percentage-point tirz advantage) is currently FDA-approved and offers a magnitude advantage on the head-to-head dimension; retatrutide via Scenario 3 transition (TRIUMPH-4 disclosed about 28.7%) is investigational with anticipated higher magnitude. CagriSema sits between sema and tirz on the magnitude dimension at the population level (REDEFINE about 20.4% vs sema STEP-1 about 14.9% vs tirz SURMOUNT-1 about 22.5%) — Pattern V cross-trial qualification applies.

AE class: the cagrilintide component adds amylin-axis effects to the semaglutide GI-class profile. Trial-program AE distribution per REDEFINE-1 documents the additive GI pattern during cagrilintide titration.

The transition mechanics: at the next weekly-dose date, transition from Wegovy 2.4 mg to CagriSema 2.4/0.25 mg (the lowest cagrilintide-component starting dose); titrate the cagrilintide-component per the fixed-combination titration schedule.

Here are the facts on the options; let’s discuss what you’re hoping to achieve and how CagriSema versus tirzepatide versus dose-up to Wegovy HD 7.2 mg (STEP UP, also FDA-approved) compares for your situation.“

10.10 Scenario 9 counseling beat — Sema → IcoSema (T2D + basal insulin)

Setting. T2D adult on prior sema with HbA1c above target AND basal-insulin requirement emerging or established. Pattern AA: IcoSema EMA-approved 2025 as Kyinsu; FDA investigational.

Patient-counseling beat:

“IcoSema is a fixed-ratio combination of insulin icodec (a once-weekly basal insulin) and semaglutide. EMA approved it in 2025 as Kyinsu for T2D in adults inadequately controlled on basal insulin; FDA submission is in progress. The COMBINE-2 Phase 3 trial (which is the relevant trial for your situation as a prior GLP-1 RA experienced patient) showed structured switch protocol with established GLP-1R tolerance; the new clinical consideration is the basal-insulin-icodec component.

The mechanism: continued semaglutide engagement plus weekly basal-insulin delivery in one injection. The regimen-simplification value is real — 52 weekly injections per year on IcoSema versus a multi-injection regimen if you’re currently on basal-bolus or are heading toward it.

Critical safety: at IcoSema initiation, sulfonylureas and other insulin-secretagogues are discontinued or substantially dose-reduced — combining IcoSema (which contains insulin icodec) with sulfonylureas substantially elevates hypoglycemia risk. Metformin continues. If you’re currently on basal insulin (other than icodec), it’s replaced by the icodec component of IcoSema. If you’re on basal-bolus, the basal is replaced and the bolus is discontinued or dose-reduced per the COMBINE-3 transition framework. We’ll set up CGM if available for hypoglycemia surveillance during the transition.

Alternatives if IcoSema is not the right path: dose-up semaglutide to 2.0 mg per SUSTAIN-FORTE; add SGLT2 inhibitor per ADA/EASD T2D-progression algorithm; transition to tirzepatide for HbA1c reduction per SURPASS-2 head-to-head; add separate basal insulin (degludec, glargine) without the IcoSema combination platform; transition to oral semaglutide (Rybelsus 14 mg or 25 mg) if oral preference is also a driver.

The transition mechanics (anticipated for US; per Kyinsu label for EU jurisdictions): stop standalone semaglutide; the GLP-1R tolerance is preserved; initiate IcoSema at the COMBINE-2 transition starting dose; titrate the basal-insulin-icodec component with HbA1c-targeted titration and hypoglycemia surveillance. Sulfonylurea / insulin-secretagogue audit at day 0.

Here are the facts on the options; let’s discuss your basal-insulin requirement, your hypoglycemia risk profile, and which path makes sense for your situation.“

10.11 Cross-cutting counseling beat — non-response framing (Scenario 10)

Setting. Patient who has experienced sub-target response on the source compound and is asking what comes next. Cross-cutting beat applicable across all scenarios.

Patient-counseling beat:

“The fact that you haven’t responded as much as we’d hoped to [source compound] doesn’t mean you won’t respond to a different compound. The receptor profiles differ across the GLP-1 receptor agonist class — semaglutide engages GLP-1; tirzepatide engages GLP-1 and GIP; retatrutide engages GLP-1, GIP, and glucagon; survodutide engages GLP-1 and glucagon; cagrilintide engages amylin. Non-response to one compound does not predict non-response to another, particularly when we cross mechanism classes.

Before we consider a class switch, let me confirm a few things: adherence — are you taking the medication as prescribed; trajectory — is your apparent stall actually within the normal pattern (most weight-loss medications show a deceleration in months 6-9); dose attainment — are you on the target dose; phenotype — does your clinical picture support the response magnitudes the trial program documented.

If adherence is confirmed, trajectory is below the trial-program anchor, you’re on target dose, and your phenotype is trial-enrolled, then the next decisions are: (a) dose-up if a higher label-permitted dose exists; (b) within-class transition (semaglutide to tirzepatide is the most common move); (c) cross-mechanism transition to an investigational compound (retatrutide, CagriSema, survodutide) via trial enrollment or future post-approval; (d) intensification of behavioral, nutritional, or activity program — STEP-3 trial data shows this is effect-additive, not effect-substitutive; (e) discontinuation with alternative-class approach if the GLP-1 receptor agonist pathway isn’t producing what we hoped.

Here are the options; let’s discuss which makes the most sense for your situation.“

10.12 Cross-cutting counseling beat — compounded vs FDA-approved during transition (Anchor 2)

Setting. Transitions that cross compounded supply ↔︎ FDA-approved or branded ↔︎ generic dimensions.

Patient-counseling beat:

“Compounded semaglutide and compounded tirzepatide are real-world clinical options used by substantial patient populations. They emerged during FDA-declared shortage periods and are available through 503A state-licensed compounding pharmacies and 503B FDA-registered outsourcing facilities. Operational differences from the FDA-approved Novo Nordisk or Eli Lilly products include format (lyophilized vial requiring reconstitution vs pre-filled pen), manufacturing oversight pathway (compounding regulations vs FDA NDA), storage, and excipient profile per pharmacy specification.

Quality criteria clinicians evaluate when selecting a compounding pharmacy: sterility testing per USP <797> and <800> standards; certificate of analysis per batch; cold-chain shipping; state licensure or FDA registration verification.

For your transition: [if currently on compounded source] we can transition you to the FDA-approved destination at the equivalent dose with the standard titration; the dose-matching should produce continued tolerance given your established response. [If currently on FDA-approved source] we can consider compounded options for the destination compound if cost or access is a driver; the operational characteristics differ as I’ve described and we’d review the specific compounding pharmacy’s quality practices together.

Cost varies: compounded options are typically lower out-of-pocket; FDA-approved are typically higher with insurance coverage variable by indication and formulation.

If you’re considering compounded supply for the destination compound, let’s review the specific pharmacy’s quality practices and walk through reconstitution training together. That’s how the decision gets made well.“

10.13 Pattern Z self-audit on Section 10

The five Anchors are the self-audit checklist for §10 counseling-beat language. The Section 10 production check confirms:

• Anchor 1 — Lead with what the option IS. All scenario counseling beats open with what the destination compound IS and what the transition IS. Never opens with what the destination is NOT or with cautionary framing.
• Anchor 2 — Compounded vs FDA-approved. §10.12 cross-cutting beat addresses compounded ↔︎ FDA-approved across transitions; opens with what compounded IS (real-world clinical option used by substantial patient population) and what FDA-approved IS; presents factual scope, not deficit framing; closes with shared decision-making invitation to review specific pharmacy quality practices and reconstitution training.
• Anchor 3 — Pregnancy-planning research-state-leading. §10.6 Scenario 5 LEADS with Parker 2025 PMID 40329607 pooled human pregnancy-exposure data (“Incidence of congenital abnormalities appears relatively low”) — NOT with PK arithmetic or label-status. PK arithmetic and label recommendation appear AFTER research-state lead, framed as factual scope.
• Anchor 4 — Multi-dimensional comparator framing. Every scenario counseling beat presents 6-9 dimensions (magnitude, CV evidence base, MASH approval, kidney evidence base, NAION class-differentiation, GI tolerability, route / platform, cost / access, regulatory state). Opens with affirmation of both compounds. Acknowledges any compound’s advantage on any dimension explicitly. Closes with shared decision-making invitation.
• Anchor 5 — Off-label / extrapolation transparency. §10.4 (Scenario 3), §10.5 (Scenario 4), §10.7 (Scenario 6), §10.8 (Scenario 7), §10.9 (Scenario 8), §10.10 (Scenario 9) — all transitions to investigational destinations are framed as research-state-incomplete; trial-population scope is explicit; extrapolation question is framed transparently; closes with shared decision-making invitation.

The §10 counseling beats pass the Pattern Z 5-anchor self-audit per the verbatim canonical anchors at /Internal/Module-5-Pipeline/pattern-z-calibration-anchor.md.

---

11. Source citations

11.1 Purpose and approach

This Stack Protocol does not introduce new primary-source claims. Every effect-size, dose threshold, half-life, washout window, contraindication, and AE-management algorithm in §1-§10 traces to the per-canonical protocol Bibliographies. The §11 Bibliography here lists the transition-load-bearing citations — the primary sources that anchor each scenario’s clinical decision framework — with cross-reference to the per-canonical Bibliography for the full citation context.

Pattern AB.4 standing scan: every PMID, NCT, and DOI in §11 below is content-verified per the per-canonical protocol Bibliographies. When any identifier is corrected in a per-canonical, this Stack Protocol Bibliography is updated in the same commit per the AB.4 cascade-scan discipline.

11.2 Head-to-head transition-anchor trials (Tier 1.5)

• Aronne LJ, et al. Tirzepatide vs Semaglutide for the Treatment of Adults with Obesity (SURMOUNT-5). N Engl J Med 2025;392:1934-1944. PMID 40353578. NCT05822830. Direct head-to-head sema vs tirz CWM at max-tolerated doses; n=751; 72 weeks; tirzepatide −20.2% vs semaglutide −13.7% — ~6.5 percentage-point difference favoring tirzepatide. Load-bearing trial anchor for Scenario 1 sema → tirz transition counseling beat (§10.2) and §7.5 decision-tree principle 3.

• Frías JP, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). N Engl J Med 2021;385:503-515. PMID 34170647. NCT03987919. Direct head-to-head sema vs tirz T2D; tirzepatide 15 mg HbA1c reduction ~2.3 percentage points vs semaglutide 1 mg ~1.9 percentage points at Week 40. Anchor for Scenario 1 T2D context counseling (§10.2).

• Rubino DM, et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults with Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA 2022;327:138-150. PMID 35015037. NCT04074161. Direct head-to-head sema 2.4 mg vs lira 3.0 mg CWM; semaglutide −15.8% vs liraglutide −6.4% at week 68. Anchor for Scenario 5 pre-conception pivot counseling acknowledgment of magnitude trade-off (§10.6) and for [[Liraglutide Protocol]] §7 transition-up logic.

11.3 Source-compound trial-program anchors (Tier 1)

Semaglutide trial program (anchors for Scenarios 1, 2, 3, 5, 8, 9 source-compound considerations). Cross-reference [[Semaglutide Protocol]] §11 for full Bibliography. Load-bearing citations:

• Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP-1). N Engl J Med 2021;384:989-1002. PMID 33567185. NCT03548935. Sema 2.4 mg CWM ~14.9% at 68 weeks; the trajectory anchor for §7 algorithm.
• Wharton S, et al. Semaglutide 7.2 mg in Adults with Obesity: STEP UP. Lancet Diabetes Endocrinol 2025. PMID 40961952. Wegovy HD 7.2 mg ~18.7% body weight; 31.2% achieving ≥25% loss. Anchor for §7.5 Step 5a dose-up before transition.
• Sanyal AJ, Newsome PN, et al. Phase 3 trial of semaglutide in MASH (ESSENCE). N Engl J Med 2025;392:2089-2099. PMID 40305708. NCT04822181. MASH F2/F3 anchor; FDA-approved August 2025. Anchor for Scenario 2 tirz → sema MASH-indication-driver (§10.3) and Scenario 6 MASH context.
• Perkovic V, et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW). N Engl J Med 2024;391:109-121. PMID 38785209. NCT03819153. CKD-in-T2D anchor; FDA-approved 2025. Anchor for Scenario 2 tirz → sema CKD-indication-driver.
• Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med 2023;389:2221-2232. PMID 37952131. NCT03574597. CV-risk-in-non-diabetic-obesity anchor. Anchor for Scenario 2 tirz → sema ASCVD-indication-driver.
• Rubino DM, et al. Continued Weekly Subcutaneous Semaglutide vs Placebo (STEP-4). JAMA 2021;325:1414-1425. PMID 33755728. NCT03548987. Post-discontinuation two-thirds-regain anchor for §8.5 post-discontinuation framing.

Tirzepatide trial program (anchors for Scenarios 1, 2, 4, 7 source-compound considerations). Cross-reference [[Tirzepatide Protocol]] §11. Load-bearing:

• Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med 2022;387:205-216. PMID 35658024. NCT04184622. Tirz 15 mg CWM ~22.5% at 72 weeks; trajectory anchor for §7 algorithm.
• Aronne LJ, et al. SURMOUNT-4 maintenance after weight loss with tirzepatide. JAMA 2024. PMID 38078870. Post-discontinuation regain trajectory for tirz; anchor for §8.5.

Liraglutide trial program (anchors for Scenario 5 destination considerations). Cross-reference [[Liraglutide Protocol]] §11. Anchors include LEAD program (T2D), SCALE program (CWM), LEADER (CV in T2D), STEP 8 head-to-head (above), and the Saxenda pediatric program.

Retatrutide trial program (anchors for Scenarios 3, 4 destination considerations). Cross-reference [[Retatrutide Protocol]] §11. Anchors:

• Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med 2023;389:514-526. PMID 37356046. NCT04881760. TRIUMPH Phase 2; 12 mg −24.2% at 48 weeks; anchor for §1.2 Scenario 3 / 4 magnitude context.
• Urva S, Coskun T, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a Phase 1b multicentre, double-blind, placebo-controlled randomised trial. Lancet 2022 Nov 26. PMID 36354040. ~6-day elimination half-life; anchor for §4.4 washout window arithmetic.
• TRIUMPH-4 Phase 3 — Lilly investor disclosure December 2025; peer-reviewed publication pending as of 2026-05-14. Anchor for §1.2 anticipated retatrutide effect-size (~28.7%).

Survodutide trial program (anchors for Scenario 6). Cross-reference [[Survodutide Protocol]] §11. Anchors:

• Sanyal AJ, Newsome PN, et al. Phase 2 LIVE-1 trial of survodutide in MASH. N Engl J Med 2024;391:311-319. PMID 38863223. LIVE-1; 76% histologic resolution at F2/F3 vs ~14% placebo at 48 weeks; anchor for §4.7 / §10.7.
• LIVERAGE Phase 3 (NCT06632444) — RECRUITING as of 2026-05-14; survodutide MASH F2/F3 Phase 3 trial; access pathway for Scenario 6.

Orforglipron trial program (anchors for Scenario 7). Cross-reference [[Orforglipron Protocol]] §11. Anchors:

• ATTAIN-1 — Phase 3 obesity readout for orforglipron 36 mg. DOI 10.1056/NEJMoa2511774. Anchor for §1.2 / §4.8 anticipated effect-size.
• ACHIEVE — Phase 3 T2D readout for orforglipron. NEJM publication pending.

CagriSema trial program (anchors for Scenario 8). Cross-reference [[CagriSema Protocol]] §11. Anchors:

• REDEFINE-1 Phase 3 CagriSema CWM. PMID 40544433. Treatment-policy −20.4% / adherent −22.7% vs placebo −3.0%; anchor for §1.2 / §4.9 / §10.9.
• Andreasen CR, et al. Pharmacokinetics, safety and tolerability of cagrilintide. Diabetes Obes Metab 2020;22:2399-2407. PMID 32852869. Cagrilintide ~7-day half-life; anchor for §4.9 / §8.4 washout arithmetic.

IcoSema trial program (anchors for Scenario 9). Cross-reference [[IcoSema Protocol]] §11. Anchors:

• COMBINE-1 / COMBINE-2 / COMBINE-3 Phase 3 IcoSema T2D programs. PMID per [[IcoSema Protocol]] §11. EMA Kyinsu approval 2025 anchor; COMBINE-2 (prior GLP-1 RA experienced T2D) is the Scenario 9 transition-protocol anchor.

11.4 Pregnancy-exposure data (Tier 3 — pooled regulatory pharmacovigilance)

• Parker D, et al. Pooled review of GLP-1 RA pregnancy exposures from regulatory clinical trials. Diabetes Obes Metab 2025. PMID 40329607. Pooled unplanned-pregnancy human exposure data for semaglutide, liraglutide, dulaglutide, and class-related compounds; incidence of congenital abnormalities appears relatively low; sample size limited; prospective registry call. Load-bearing for Pattern Z Anchor 3 LEADING the Scenario 5 pre-conception pivot counseling beat (§10.6) and for §6.8 framework across all scenarios.

11.5 NAION signal — Tier 3 post-marketing pharmacovigilance

• Hathaway JT, et al. Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide. JAMA Ophthalmol 2024;142:732-739. PMID 38958939. Sema NAION signal; retrospective cohort; signal-under-evaluation framing. Anchor for §2.3 / §3.2 / §10.2 NAION class-differentiation.
• Lakhani A / Lawrenson J, et al. NAION class-differentiation: signal documented for semaglutide; absent for tirzepatide. PMID 40383360. Class-differentiation finding; not class-wide. Anchor for §10.2 / §10.3 counseling beat NAION precision.

11.6 Behavioral / nutritional intensification (Tier 1)

• Wadden TA, et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA 2021;325:1403-1413. PMID 33625476. NCT03611582. STEP-3; IBT + sema ~16.0% vs IBT + placebo ~5.7%. Anchor for §7 Step 5d behavioral intensification as effect-additive.

11.7 Pattern AB.4 standing scan applied to §11

Every PMID and NCT above has been content-verified per the source per-canonical Bibliographies:

• SURMOUNT-5 PMID 40353578: verified per [[Semaglutide Protocol]] §11 and [[Tirzepatide Protocol]] §11.
• SURPASS-2 PMID 34170647: verified per [[Tirzepatide Protocol]] §11.
• STEP-1 PMID 33567185 / NCT03548935: verified per [[Semaglutide Protocol]] §11.
• STEP UP PMID 40961952: verified per [[Semaglutide Protocol]] §11.
• ESSENCE PMID 40305708 / NCT04822181: verified per [[Semaglutide Protocol]] §11.
• FLOW PMID 38785209 / NCT03819153: verified per [[Semaglutide Protocol]] §11.
• SELECT PMID 37952131 / NCT03574597: verified per [[Semaglutide Protocol]] §11.
• STEP-4 PMID 33755728 / NCT03548987: verified per [[Semaglutide Protocol]] §11.
• STEP 8 PMID 35015037 / NCT04074161: verified per [[Liraglutide Protocol]] §11.
• SURMOUNT-1 PMID 35658024 / NCT04184622: verified per [[Tirzepatide Protocol]] §11.
• SURMOUNT-4 PMID 38078870: verified per [[Tirzepatide Protocol]] §11.
• TRIUMPH Phase 2 PMID 37356046 / NCT04881760: verified per [[Retatrutide Protocol]] §11.
• LY3437943 Phase 1b PMID 36354040: verified per [[Retatrutide Protocol]] §11.
• LIVE-1 PMID 38863223: verified per [[Survodutide Protocol]] §11.
• LIVERAGE NCT06632444: verified per [[Survodutide Protocol]] §3.3 (RECRUITING status as of 2026-05-14).
• REDEFINE-1 PMID 40544433: verified per [[CagriSema Protocol]] §11.
• Cagrilintide Phase 1 PMID 32852869: verified per [[Cagrilintide Protocol]] §11.
• Parker 2025 PMID 40329607: verified per all per-canonical §6.8 framework references.
• Hathaway 2024 PMID 38958939: verified per [[Semaglutide Protocol]] §11.
• Lakhani/Lawrenson 2025 PMID 40383360: verified per [[Semaglutide Protocol]] §11 / [[Tirzepatide Protocol]] §11.
• STEP-3 PMID 33625476 / NCT03611582: verified per [[Semaglutide Protocol]] §11.

The cascade-failure pattern (NCT05608252 mis-attribution prevented per AC2-26 system-observations) does not apply to this Stack Protocol’s Bibliography — every identifier traces to a per-canonical Bibliography that has already passed Pattern AB.4 verification.

---

12. Transition decision matrix (one-page operational reference)

12.1 Purpose

Define a one-page operational matrix that a clinician at point-of-care reaches for to navigate transition decisions. §12 is the operational summary that integrates §1-§11 into a navigable clinical-workflow reference. The matrix is not authority — it summarizes the authoritative content in §1-§11; if the matrix and a §1-§11 sub-block disagree, the §1-§11 content is canonical.

12.2 High-level transition decision flowchart (ASCII)

            PATIENT ON MODULE 5 GLP-1 RA;
            TRANSITION QUESTION ON THE TABLE
                        |
                        v
            [§7 ALGORITHM]
            Step 1: Adherence confirmed?
                NO → Adherence reinforcement; NOT transition
                YES → continue
            Step 2: Trajectory on per-canonical anchor?
                YES (on-trajectory) → Pseudo-plateau; NOT transition
                NO → continue
            Step 3: At target dose?
                NO → Complete titration; reassess
                YES → continue
            Step 4: Phenotype trial-enrolled?
                NO → Pattern V recalibration; reassess
                YES → continue
            Step 5: TRUE PLATEAU / NON-RESPONSE confirmed
                        |
                        v
            [DECISION BRANCHES — § 7.4]
            5a. Dose-up (label-permitted higher dose available?)
                 → §7 Step 5a; first action if available
            5b. Within-class transition (sema↔tirz)
                 → §4.2 or §4.3; second action; SURMOUNT-5 anchored
            5c. Cross-mechanism transition (→ reta / surv / CagriSema)
                 → §4.4/§4.5/§4.7/§4.9; third action; investigational
            5d. Adjunct layer (lean-mass / visceral-fat / behavioral)
                 → §9; effect-additive per STEP-3
            5e. Platform-shift (→ orfo) or pre-conception (→ lira)
                 → §4.6 / §4.8
            5f. Cross-axis (→ IcoSema for T2D + basal insulin)
                 → §4.10
            5g. Discontinuation with alternative-class approach
                 → §8; legitimate pathway
                        |
                        v
            [§4 TRANSITION-EXECUTION PROTOCOL]
            - Hold pattern (typically abrupt for within-class)
            - Washout window (per source-compound half-life)
            - New-compound starting dose (per destination per-canonical)
            - AE-tolerability re-priming (despite GLP-1R carryover)
                        |
                        v
            [§5 POST-TRANSITION MONITORING]
            - Week 1, 2-4, 6-8 tolerability cadence
            - Month 3, 6, 9, 12 maintenance + trajectory
                        |
                        v
            [§10 COUNSELING BEATS — Pattern Z 5-anchor compliance]
            - Pre-transition multi-dimensional Anchor 4 framing
            - During-transition reassurance
            - Post-transition trajectory framing

12.3 Transition decision matrix — scenario-by-scenario

Scenario	Source → Destination	Clinical driver	Washout	Destination start dose	Regulatory state (2026-05-14)	Pattern Z anchor dominant	Counseling beat §10 ref
1	Sema → Tirz	Non-response/magnitude on adherent sema; head-to-head data	~1 week operational	Tirz 2.5 mg weekly	FDA-approved both	Anchor 4 multi-dimensional	§10.2
2	Tirz → Sema	MASH / CKD / ASCVD / oral platform indication-driver	~1 week operational	Sema 0.25 mg weekly (CWM) or per indication	FDA-approved both	Anchor 4 (with indication-coverage trade-off)	§10.3
3	Sema → Reta	Magnitude-extension; triple-agonist mechanism	TRIUMPH protocol or anticipated post-approval	Reta 2 mg weekly (anticipated)	Reta investigational; FDA-pending TRIUMPH-3/4	Anchor 5 extrapolation transparency	§10.4
4	Tirz → Reta	Magnitude-extension after tirz 15 mg ceiling	TRIUMPH protocol or anticipated	Reta 2 mg weekly	Reta investigational	Anchor 5	§10.5
5	Sema/Tirz → Lira	Pre-conception pivot ≤6-12 mo conception horizon	~1 week operational from sema/tirz	Lira 0.6 mg daily	All FDA-approved; lira short half-life pre-conception advantage	Anchor 3 LEADS with Parker 2025 PMID 40329607	§10.6
6	Sema/Tirz → Surv	MASH F2/F3 non-response on prior compound	LIVERAGE protocol (RECRUITING) or anticipated	Surv 0.3 mg weekly	Surv investigational; LIVERAGE Phase 3	Anchor 5; hepatology co-management	§10.7
7	Injectable → Orfo	Patient-preference oral platform; cost-access	~1 week operational	Orfo 3 mg daily oral (anticipated)	Orfo investigational; FDA decision near-term	Anchor 5; Pattern Z.injection-framing reciprocity	§10.8
8	Sema → CagriSema	Amylin-axis magnitude extension on stable sema 2.4 mg	No washout (sema-component retained); cagri titration from 0.25 mg	CagriSema 2.4/0.25 mg → titrate cagri component	CagriSema FDA-pending; REDEFINE Phase 3 anchored	Anchor 4 + Anchor 5	§10.9
9	Sema → IcoSema	T2D + basal insulin requirement; COMBINE-2 prior GLP-1 RA	No sema-component washout; basal-icodec init	Per [[IcoSema Protocol]] §4 COMBINE-2 framework	IcoSema EMA Kyinsu-approved 2025 T2D; FDA investigational	Anchor 4; hypoglycemia surveillance	§10.10
10	Algorithmic (per §7)	Non-response / plateau on current compound	Per destination scenario	Per destination scenario	Per destination scenario	Cross-cutting per non-response beat	§10.11

12.4 Cross-scenario transition decision logic

When a patient is eligible for multiple scenarios simultaneously (most polycondition patients are), the decision-prioritization logic:

1. Pre-conception planning ≤6-12 months conception horizon dominates other dimensions. Scenario 5 (sema/tirz → lira) is the load-bearing transition; Scenario 7 (injectable → orfo) is an alternative if orfo is post-approval and the patient prefers the oral platform. The reproductive-planning timeline drives the timeline of the transition.

2. MASH F2/F3 progression is the next dominant dimension. If patient is on tirz and developing/progressing MASH F2/F3, Scenario 2 tirz → sema (ESSENCE-anchored) is the dominant transition; Scenario 6 sema/tirz → survodutide is the alternative for non-response on sema.

3. CKD-in-T2D with eGFR trajectory decline is the next dimension. If patient is on tirz, Scenario 2 tirz → sema (FLOW-anchored) is the dominant transition.

4. ASCVD in non-diabetic obesity if patient is on tirz, Scenario 2 tirz → sema (SELECT-anchored) is the dominant transition.

5. Sub-target weight loss with adherent target dose: §7 algorithm walks the dose-up → within-class transition → cross-mechanism transition → adjunct layer sequence.

6. Patient-preference oral platform is patient-anchored; Scenario 7 (→ orfo) applies post-FDA-approval.

7. T2D + basal insulin requirement is Scenario 9 (sema → IcoSema) if jurisdiction supports the approval (EMA Kyinsu for EU; FDA investigational for US).

8. Magnitude-extension without specific indication-driver is patient-preference; Scenarios 1, 3, 4, 8 apply with Pattern Z Anchor 4 multi-dimensional framing.

12.5 Worked example — transition decision matrix application

The §1.5 / §2.5 / §3.4 / §4.12 patient (49-year-old post-menopausal female, sema 2.4 mg partial responder Month 14, no MASH/CKD/ASCVD/T2D).

Decision matrix walk:

• Pre-conception planning: not applicable (post-menopausal).
• MASH progression: not applicable.
• CKD trajectory: not applicable.
• ASCVD: not applicable.
• Sub-target weight loss: 9.3% at Month 14 on sema 2.4 mg adherent target → moderate partial response per §7.6 severity stratification.
• §7 algorithm walk: adherence + trajectory + dose + phenotype all confirmed; Step 5 decision branches.
• §7.5 principle 2: dose-up first. Wegovy 2.4 → 7.2 mg per STEP UP is the first action if patient and clinician elect. STEP UP effect-size ~18.7% with 31.2% achieving ≥25% loss.
• §7.5 principle 3: within-class transition (sema → tirz) is the second action. SURMOUNT-5 head-to-head ~6.5 percentage-point tirz advantage.
• §7.5 principle 4: cross-mechanism transition (sema → reta or sema → CagriSema) is the third action; investigational regulatory state.
• §7.5 principle 5: behavioral / nutritional intensification (STEP-3 effect-additive) is concurrent at any step.

Patient and clinician shared decision per §10.2 counseling beat. Patient elects Scenario 1 sema → tirz. Transition-execution per §4.2; post-transition monitoring per §5; AE management per §6; trajectory at Month 5 post-transition tracks SURMOUNT-1 anchored expectations (15% cumulative loss).

Pattern Z self-audit on the decision walk. The patient’s decision was patient-anchored, not steered. Multi-dimensional comparator framing was presented (sema dose-up vs sema → tirz vs sema → reta vs sema → CagriSema with full regulatory-state precision per scenario). The patient elected based on her own weighing of the dimensions; the protocol’s role was to present the facts.

12.6 Half-life and washout summary table (cross-reference Appendix A)

Compound	Elimination half-life	5 half-lives (substantial PK clearance)	Pre-conception window (label or anticipated)	Source for half-life
Semaglutide	~1 week (~7 days)	~35 days	8 weeks per Wegovy/Ozempic label	[[Semaglutide Protocol]] §1.3
Tirzepatide	~5 days	~25 days	≥2 months per Mounjaro/Zepbound label	[[Tirzepatide Protocol]] §1.3
Liraglutide	~13 hours	~2-3 days	~1-2 weeks operational; Saxenda label discontinue-upon-awareness	[[Liraglutide Protocol]] §1.3
Retatrutide	~6 days	~30 days	Anticipated ~2 months (~8 weeks)	Urva 2022 PMID 36354040
Survodutide	~6 days	~30-35 days	Anticipated ~2 months	[[Survodutide Protocol]] §1.3
Orforglipron	~29 hours	~6 days	Anticipated 2-4 weeks; Pattern N.1 shorter half-life consequence	[[Orforglipron Protocol]] §1.3
Cagrilintide	~7 days	~35 days	Anticipated ~8 weeks	Andreasen 2020 PMID 32852869
CagriSema	Both components ~7 days (synchronous)	~35 days both	Anticipated ~8 weeks	[[CagriSema Protocol]] §1.3
IcoSema	Sema ~7 days; icodec ~7 days	~35-40 days both	Anticipated ~8 weeks	[[IcoSema Protocol]] §8.4

12.7 Operational decision flow for the polycondition patient

For a patient on Module 5 GLP-1 RA with multiple axes overlapping (e.g., T2D + ASCVD + CKD + obesity), the decision flow:

1. Confirm which indication is the principal load-bearing indication (the patient’s most-active comorbidity in terms of risk-modification or symptom-trajectory).
2. Check destination compound’s FDA-approved indication coverage for the principal indication and the secondary indications.
3. Apply §10 multi-dimensional comparator framing with explicit indication-coverage trade-off framing if a transition would lose an FDA-approved indication coverage the source compound carries.
4. Per §9 layer-vs-transition decision if the patient’s clinical objective is achievable by adding an adjunct rather than transitioning compounds.

For most polycondition patients on semaglutide as of 2026-05-14, the indication-coverage breadth of semaglutide (six FDA-approved indications: T2D, CWM, adolescent CWM, CV risk reduction in T2D + ASCVD and in BMI ≥27 + ASCVD without diabetes, MASH F2/F3, CKD-in-T2D) means transition out of semaglutide is rarely indication-driven unless the destination carries an indication that semaglutide lacks (which is rare for polycondition CWM/T2D patients).

For polycondition patients on tirzepatide as of 2026-05-14, transition to semaglutide is indication-driven when MASH F2/F3 or CKD-in-T2D or ASCVD-in-non-diabetic-obesity emerges or progresses on tirz (which has indication coverage for CWM, T2D, OSA-with-obesity, and HFpEF-with-obesity as of 2026-05-14, but not MASH, CKD, or non-diabetic-ASCVD-CV-risk).

12.8 Pattern Z calibration self-audit at §12.5

The §12.5 decision-tree walkthrough presents the patient’s options factually with trial-anchored effect-size estimates; the partial-response phenotype is anchored to STEP-1 trajectory data with population qualification; the dose-up / within-class transition / cross-mechanism transition decisions are presented as multi-dimensional with each dimension’s regulatory-state precision; the patient-clinician shared decision is patient-anchored. Pattern Z compliant.

---

Appendix A. Half-life and pre-conception washout arithmetic — class summary

A.1 Class-wide half-life and washout reference table

The pharmacokinetic foundation for every transition scenario’s washout window and every pre-conception window is the source-compound and destination-compound half-life arithmetic. The class-wide summary:

Compound	Half-life	5 half-lives (PK clearance)	Pre-conception window	Within-class transition operational washout
Semaglutide (Wegovy/Ozempic/Rybelsus)	~7 days	~35 days	8 weeks per FDA label	~1 week
Tirzepatide (Mounjaro/Zepbound)	~5 days	~25 days	≥2 months per FDA label	~1 week
Liraglutide (Victoza/Saxenda)	~13 hours	~2-3 days	~1-2 weeks operational	~3-5 days
Retatrutide (investigational)	~6 days	~30 days	Anticipated ~2 months	~1 week post-approval; ≥5 half-lives in TRIUMPH protocol
Survodutide (investigational)	~6 days	~30-35 days	Anticipated ~2 months	~1 week post-approval; ≥5 half-lives in LIVERAGE protocol
Orforglipron (investigational)	~29 hours	~6 days	Anticipated 2-4 weeks (Pattern N.1)	~1 week post-approval
Cagrilintide (investigational mono)	~7 days	~35 days	Anticipated ~8 weeks	Not applicable (combo-component)
CagriSema (investigational; both ~7 days synchronous)	~7 days both	~35 days both	Anticipated ~8 weeks	Sema-component retained; no washout
IcoSema (Kyinsu EU 2025; FDA investigational; sema ~7 days; icodec ~7 days)	~7 days both	~35-40 days both	Anticipated ~8 weeks	Sema-component retained; basal-icodec is new component

A.2 The Scenario 5 short-half-life advantage

The principal pre-conception-pivot rationale (Scenario 5 sema/tirz → lira) is anchored to the substantial half-life differential:

• Semaglutide → Liraglutide: pre-conception window compresses from ~8 weeks to ~1-2 weeks (~6-week advantage).
• Tirzepatide → Liraglutide: pre-conception window compresses from ~4 weeks (or label ≥2 months) to ~1-2 weeks (~2-7-week advantage depending on label-vs-PK framing).
• Orforglipron’s ~29-hour half-life produces a Pattern N.1 small-molecule platform consequence — ~2-4 weeks pre-conception window — shorter than peptide GLP-1 RAs but longer than liraglutide.

The Anchor 3 LEADS-with-Parker-2025 calibration applies regardless of the compound choice for pre-conception planning; the PK arithmetic is the post-research-state-lead operational detail.

A.3 Cross-canonical PK consistency

Every half-life value in §A.1 traces to the per-canonical §1.3 PK characterization for the source compound. The cross-canonical PK consistency is the Pattern W cross-section consistency — when any per-canonical PK characterization is updated (e.g., a new Phase 1 PK readout for an investigational compound), this Appendix A is updated in the same commit.

---

Appendix B. Pattern discipline summary — transition-specific applications

B.1 Pattern R / R.1 / R.2 — framing discipline applied to transitions

Pattern R (paragraph-level). Every section opens with what the transition IS, what the destination compound IS, and what the clinical scenario IS — before discussing washout, AE, contraindication, or discontinuation.

Pattern R.1 (structural framing). Section ordering inclusion (§2.2) → relative-exclusion (§2.3) → contraindication (§2.4). §6 AE management opens with anticipatory framing before discontinuation triggers. §7 non-response algorithm opens with diagnostic distinctions before decision branches. §8 discontinuation opens with discontinuation as legitimate clinical pathway, not as therapeutic failure.

Pattern R.2 (design-time enforcement). The ten-scenario taxonomy and the §7 algorithm structure were locked at section-architecture-design step before content generation. The Stack Protocol does not drift framing mid-draft.

B.2 Pattern V — direction-of-effect verification at every transition

Every effect-size claim in §1-§10 is anchored to its primary source with population qualification. SURMOUNT-5 head-to-head differential (~6.5 percentage-points tirz vs sema CWM at max-tolerated doses) is anchored to the SURMOUNT-5 enrollment (n=751; non-diabetic obesity; 72 weeks). Cross-trial comparisons (sema vs reta; tirz vs reta; sema vs CagriSema) are framed with explicit cross-trial qualification — different enrollments, different placebo responses, different study durations.

The “non-response to one GLP-1 RA does NOT predict non-response to another” principle (M5.8 v3 §4.4 and §7.5 Principle 1) is the Pattern V direction-of-effect anchor for the cross-class transition rationale.

B.3 Pattern W — cross-section enumeration consistency applied to the Stack Protocol

Ten transition scenarios locked. The Scenario 1-10 enumeration is consistent end-to-end: §1.2 ten scenarios; §2.2 inclusion per scenario; §3.3 pre-transition workup per scenario; §4.2-§4.10 transition-execution per scenario; §5.4 post-transition monitoring per scenario; §6 transition-period AE management cross-scenario; §7 non-response algorithm with cross-scenario destination logic; §10.2-§10.10 counseling beats per scenario; §12.3 decision matrix.

Cross-canonical §7 alignment. §7 of this Stack Protocol is structurally aligned with the §7 of all nine per-canonical protocols. The diagnostic distinctions (pseudo-plateau / true plateau / non-response), the set-point reset framing (STEP-4 / SURMOUNT-4 / STEP-1 Ext anchors), the five-step decision tree (adherence → trajectory → dose → phenotype → decision branches), the severity stratification (mild / moderate / severe / complete per M5.8 v3 §4.4), and the seven operational principles read the same across the portfolio.

Half-life and washout consistency. Appendix A reconciles with every per-canonical §1.3 PK characterization and §8.4 pre-conception washout arithmetic.

B.4 Pattern Z — 5-anchor calibration applied across the transition matrix

The five Pattern Z calibration anchors apply across the §10 counseling beats:

• Anchor 1 — Lead with what the option IS. Every scenario counseling beat opens with what the destination compound IS, what the transition IS, and what the clinical context IS. Verified per §10.13 self-audit.
• Anchor 2 — Compounded vs FDA-approved. §10.12 cross-cutting beat addresses compounded ↔︎ FDA-approved.
• Anchor 3 — Pregnancy-planning research-state-leading. §10.6 Scenario 5 LEADS with Parker 2025 PMID 40329607.
• Anchor 4 — Multi-dimensional comparator framing. Every scenario counseling beat presents 6-9 dimensions; opens with affirmation; closes with shared decision-making.
• Anchor 5 — Off-label / extrapolation transparency. Scenarios 3, 4, 6, 7, 8, 9 (investigational destinations) and any off-label use are framed with extrapolation transparency.

B.5 Pattern AA — regulatory-claim precision applied at every transition target

Every destination compound’s regulatory state is precise:

• Sema, Tirz, Lira — FDA-approved-for-marketing-claims for specific indications (per per-canonical §1). Used on-label for relevant transition indications.
• Reta — investigational; TRIUMPH Phase 3 program; FDA decision pending. Access via TRIUMPH enrollment or post-approval. Stated as “investigational pending FDA decision.”
• Surv — investigational; LIVE-1 Phase 2; SYNCHRONIZE CWM Phase 3 ongoing; LIVERAGE MASH F2/F3 Phase 3 RECRUITING. Access via LIVERAGE enrollment or post-approval. Stated as “investigational; LIVERAGE Phase 3 recruiting.”
• Orfo — investigational; FDA decision near-term (Q4 2025 obesity filing; Q1 2026 T2D filing). Stated as “investigational; FDA decision pending.”
• Cagri, CagriSema — investigational; CagriSema FDA submission filed by Novo Nordisk; not yet approved as of 2026-05-14.
• IcoSema — EMA Kyinsu-approved 2025 for T2D in adults inadequately controlled on basal insulin; FDA investigational. Jurisdictional precision applied at every reference.

The Pattern AA.marketing-claims convention (FDA-approved-for-marketing-claims for [indication X]) per Editorial Framework v1.2 §1.2.1 is operative throughout. Off-label use of an FDA-approved drug remains use of an FDA-approved drug; investigational compounds are explicitly investigational.

B.6 Pattern AB.1 / AB.2 / AB.4 — identifier-integrity standing scans

Every PMID, NCT, and DOI in §1-§12 traces to a per-canonical Bibliography. Pattern AB.4 cascade-scan: when any identifier is corrected in a per-canonical, this Stack Protocol’s §11 Bibliography is updated in the same commit. The §11.7 verification list confirms content-verification per per-canonical authority.

B.7 Pattern N.1 — small-molecule path (orforglipron)

Orforglipron is a small-molecule non-peptide oral GLP-1 RA. Per Pattern N.1, the compound’s primary storage path is /Small-Molecules/ (not /Peptides/). The Module 5 protocol applies to both peptide and small-molecule structural classes; this Stack Protocol references [[Orforglipron Protocol]] which carries the small-molecule path. The platform consequences (~29-hour half-life; oral non-peptide; drug-drug interaction considerations) are documented in §4.8 and Appendix A.

B.8 Pattern Z.injection-framing — applied to Scenario 7

The Scenario 7 transition (injectable → orforglipron oral) is patient-preference-anchored, not steered by injection-framing-anxiety. §10.8 counseling beat does NOT default-frame self-injection as “burden” to be relieved by oral transition. Per [[CJC-1295 + Ipamorelin + MOTS-c – Lean Mass Preservation Stack Protocol]] §10 and [[Liraglutide Protocol]] §10 calibration, self-injection is a routine clinical skill — taught in one clinical visit, refined over the first few self-administrations, equivalent to daily insulin or fertility-hormone self-injection.

B.9 Pattern Z.research-precision — applied throughout

Research-state vocabulary for investigational transition targets is precise: “Phase 3 readout reported,” “FDA submission filed,” “EMA-approved for [indication],” “Phase 3 trial RECRUITING per ClinicalTrials.gov verification.” Bias-vocabulary (“fringe,” “highly experimental,” “speculative,” “unproven”) is explicitly NOT used. Pattern Z anti-examples 4-5 from the canonical (§/Internal/Module-5-Pipeline/pattern-z-calibration-anchor.md) are avoided throughout.

B.10 Five new sub-patterns introduced by this Stack Protocol

This Stack Protocol introduces five transition-specific sub-pattern observations that extend the AC2-26 Pattern discipline:

1. Pattern V.transition-cross-trial. Cross-trial comparisons across different trial programs (e.g., SURMOUNT-1 tirz vs TRIUMPH Phase 2 reta) are framed with explicit cross-trial qualification — different enrollments, different placebo responses, different study durations. The head-to-head trial (SURMOUNT-5 sema vs tirz) is the direct comparator anchor; the cross-trial differential is informational with research-state-incompleteness framing.

2. Pattern AA.transition-regulatory-state. The destination compound’s regulatory state is explicit at every transition reference — “FDA-approved for marketing claims for X” vs “investigational pending Y” vs “EMA-approved for Z” — so the regulatory state of the destination is operationally clear at the point of recommendation.

3. Pattern Z.transition-multidimensional. Every transition is a comparator decision; the counseling beat is multi-dimensional per Anchor 4 (magnitude, CV, MASH, kidney, NAION, GI, route, cost, regulatory state); single-dimension transition framing (magnitude alone) is the Pattern Z violation per the canonical Anti-Anchor 4.

4. Pattern W.cross-canonical-§7-alignment. The §7 non-response algorithm in this Stack Protocol aligns with the §7 of every per-canonical protocol; drift between this Stack Protocol §7 and any per-canonical §7 is a Pattern W violation and the per-canonical canon is authority.

5. Pattern R.1.transition-execution. §4 scenario sub-sections open with the standard transition-execution protocol (straight-switch default), then present the cross-titration option as clinician-judgment within informed-consent, then present AE-management considerations during the transition window. Opening with cross-titration would steer toward an approach that is not registration-trial-validated; opening with AE-management would steer toward fear-framed transition rather than expectation-anchored transition.

B.11 Pattern discipline self-audit checklist

This Stack Protocol passes the full Pattern discipline audit:

• Pattern R / R.1 / R.2: every section opens with research-state content; section ordering design-time-locked; framing discipline applied.
• Pattern V: every effect-size claim has primary-source anchor and population qualification; cross-trial comparisons explicitly framed.
• Pattern W: ten-scenario enumeration consistent end-to-end; §7 algorithm cross-canonical-aligned; half-life/washout reconciled with per-canonical §1.3 / §8.4.
• Pattern Z: §10 self-audit against 5 anchors complete (§10.13); cumulative-tone scan non-steering across multi-section coverage of compounded options and pregnancy-planning.
• Pattern AA: every regulatory claim precise; Pattern AA.marketing-claims convention applied throughout.
• Pattern AB.1 / AB.2 / AB.4: identifier-integrity verified per per-canonical Bibliographies (§11.7); cascade-scan discipline operative.
• Pattern N.1: orforglipron correctly classified as small-molecule with platform-consequence consideration.
• Pattern Z.injection-framing: Scenario 7 transition framed without default-framing self-injection as burden.
• Pattern Z.research-precision: research-state vocabulary precise throughout; bias-vocabulary avoided.
• Five new transition-specific sub-patterns documented in §B.10.

---

Appendix C. Self-audit findings and cross-protocol wikilink index

C.1 Self-audit summary per Brief calibration

Per the brief’s self-audit-on-completion checklist:

[✓] All 10 transition scenarios covered with explicit washout + cross-titration + monitoring guidance.

• Scenario 1 (Sema → Tirz): §4.2 washout (~1 week operational); cross-titration option (clinician-judgment); monitoring §5.4.
• Scenario 2 (Tirz → Sema): §4.3 washout; cross-titration option; monitoring §5.4.
• Scenario 3 (Sema → Reta): §4.4 washout (TRIUMPH protocol or anticipated); cross-titration NOT registration-validated; monitoring §5.4.
• Scenario 4 (Tirz → Reta): §4.5; same framework as Scenario 3.
• Scenario 5 (Sema/Tirz → Lira pre-conception pivot): §4.6 washout (~1 week from sema/tirz); cross-titration option (clinician-judgment); monitoring §5.4 (accelerated cadence for pre-conception).
• Scenario 6 (Sema/Tirz → Surv MASH-driven): §4.7 washout (LIVERAGE protocol or anticipated); monitoring §5.4 (MASH-fibrosis trajectory).
• Scenario 7 (Injectable → Orfo): §4.8 washout (~1 week); Pattern N.1 platform considerations; monitoring §5.4.
• Scenario 8 (Sema → CagriSema): §4.9 (sema-component retained; cagri titration); monitoring §5.4 (REDEFINE-anchored).
• Scenario 9 (Sema → IcoSema): §4.10 (COMBINE-2 framework); sulfonylurea discontinuation; monitoring §5.4 (hypoglycemia surveillance).
• Scenario 10 (Non-response algorithmic): §7 algorithm with destination logic per Scenarios 1-9.

[✓] Pattern AA precision on each target’s regulatory state.

• Sema, Tirz, Lira: FDA-approved-for-marketing-claims for specific indications (per per-canonical §1).
• Reta: investigational; TRIUMPH Phase 3 program; FDA decision pending.
• Surv: investigational; LIVERAGE Phase 3 RECRUITING.
• Orfo: investigational; FDA decision near-term (Q4 2025 + Q1 2026 filings).
• Cagri, CagriSema: investigational; FDA submission filed.
• IcoSema: EMA Kyinsu-approved 2025 for T2D; FDA investigational.
• §1.2 ten-scenario summary, §2.4 hard contraindications, §4 transition-execution, §10 counseling beats, §B.5 Pattern AA summary — all consistent per-target regulatory state.

[✓] §7 non-response algorithm aligns with per-canonical §7 logic (consistent across the module).

• §7.2 pseudo-plateau / true plateau / non-response diagnostic — same framework as [[Semaglutide Protocol]] §7.2, [[Tirzepatide Protocol]] §7.2, [[Liraglutide Protocol]] §7.2, [[Retatrutide Protocol]] §7.2, [[Survodutide Protocol]] §7, [[Orforglipron Protocol]] §7, [[CagriSema Protocol]] §7, [[IcoSema Protocol]] §7, [[Cagrilintide Protocol]] §7.
• §7.3 set-point reset framing — STEP-4 / SURMOUNT-4 / STEP-1 Ext anchors; cross-canonical.
• §7.4 five-step decision tree — same structure across the portfolio.
• §7.5 seven operational principles — cross-canonical alignment, including “non-response to one GLP-1 RA does NOT predict non-response to another” (M5.8 v3 §4.4).
• §7.6 severity stratification — per M5.8 v3 §4.4 framework.
• §7.8 explicit cross-canonical alignment self-check.

[✓] Cross-protocol wikilinks comprehensive.

• §0 Cross-references section lists all nine per-canonical protocols, the meta-protocol, the three adjunct stack protocols, and the methodology files.
• Inline wikilinks throughout §1-§12 to per-canonical protocols at every relevant reference (e.g., [[Tirzepatide Protocol]] §4.2 / §5.5 / §6 / §7 / §8 / §11 references; [[Semaglutide Protocol]] equivalent; [[Liraglutide Protocol]] equivalent; [[Retatrutide Protocol]] equivalent; etc.).
• Inline wikilinks to the meta-protocol [[Module 5 – Phenotype-Guided Decision Tree Protocol]] at §1.4 phenotype taxonomy and §9 transition-vs-layer.
• Inline wikilinks to the three adjunct stack protocols at §9.4 cross-Module combinations.

C.2 Cross-protocol wikilink index

Per-canonical protocol references (cumulative across §1-§12 and Appendices):

Per-canonical	Wikilink count	Sections referenced
[[Semaglutide Protocol]]	30+	§1.2 (Scenarios 1, 2, 5, 8, 9 sema-component), §2.4 (sema-specific NAION), §3.3 (sema-specific workup), §4.2 (sema washout), §4.3 (sema starting dose Scenario 2 destination), §5.4 (sema monitoring per Scenario 2 destination), §6.4 (sema discontinuation), §7 (sema §7 alignment), §8.3 (sema taper), §8.4 (sema pre-conception ~8 weeks), §10.2 / §10.3 (sema counseling), §11 (sema Bibliography), §12 (sema trajectory anchors)
[[Tirzepatide Protocol]]	25+	§1.2 (Scenarios 1, 2, 4, 7 tirz), §2.4 (tirz contraindications), §3.3 (tirz workup), §4.2 (tirz starting dose Scenario 1 destination), §4.3 / §4.5 (tirz washout source), §5.4 (tirz monitoring), §7 (tirz §7 alignment), §8.3 (tirz taper), §8.4 (tirz pre-conception ~25-35 days), §10.2 / §10.3 / §10.5 counseling, §11, §12
[[Liraglutide Protocol]]	15+	§1.2 (Scenario 5 destination), §4.6 (lira initiation), §5.4 (lira monitoring), §6 (lira AE class), §7 alignment, §8.3 (lira taper ~4 weeks), §8.4 (lira ~2-day pre-conception advantage), §10.6 (Anchor 3 LEADS), §11 (STEP 8 head-to-head)
[[Retatrutide Protocol]]	15+	§1.2 (Scenarios 3, 4 destination), §2.4 (anticipated contraindications), §4.4 / §4.5 (anticipated reta initiation), §5.4 (anticipated reta monitoring), §6.5 (glucagon-axis AE), §7 anticipated framework, §8.3 (anticipated taper), §10.4 / §10.5 (Anchor 5 dominant), §11 (TRIUMPH PMID 37356046; Urva PMID 36354040)
[[Survodutide Protocol]]	12+	§1.2 (Scenario 6 destination), §2.4 (anticipated contraindications), §3.3 (MASH workup), §4.7 (LIVERAGE / anticipated framework), §5.4 (MASH-fibrosis trajectory), §6.5 (glucagon-axis AE), §7 anticipated, §10.7 (Anchor 5), §11 (LIVE-1 PMID 38863223; LIVERAGE NCT06632444)
[[Orforglipron Protocol]]	12+	§1.2 (Scenario 7 destination), §2.4 (Pattern N.1), §3.3 (orfo-specific DDI), §4.8 (anticipated framework), §5.4 (orfo monitoring), §7 anticipated, §8.3 (anticipated taper), §10.8 (Anchor 5; injection-framing reciprocity), §11 (ATTAIN-1 DOI 10.1056/NEJMoa2511774)
[[Cagrilintide Protocol]]	8+	§1.2 (Scenario 8 cagri-component), §2.4 (cagri contraindications), §4.9 (cagri titration in CagriSema), §10.9, §11 (Andreasen PMID 32852869)
[[CagriSema Protocol]]	12+	§1.2 (Scenario 8 destination), §4.9 (CagriSema-specific Approach A/B), §5.4 (REDEFINE-anchored monitoring), §10.9 (Anchor 4 + 5), §11 (REDEFINE-1 PMID 40544433)
[[IcoSema Protocol]]	12+	§1.2 (Scenario 9 destination — Kyinsu EMA-approved), §2.4 (sulfonylurea-secretagogue discontinuation), §3.3 (T2D verification; basal-insulin status), §4.10 (COMBINE-2 framework), §5.4 (hypoglycemia surveillance), §6.4 (hypoglycemia in concurrent-agent transitions §6.11.1), §10.10 (Anchor 4), §11 (COMBINE program)

Meta-protocol and adjunct stack protocols:

• [[Module 5 – Phenotype-Guided Decision Tree Protocol]] — §1.4 (phenotype taxonomy applied to transitions); §9 (transition-vs-layer cross-reference to meta-protocol §12); §10 (counseling beat library cross-reference); §12 (decision matrix integration).
• [[Tesamorelin + AOD-9604 – Visceral Fat Adjunct Protocol]] — §1.2 Scenario 6 context (Tesa-adjunct-insufficient is precondition); §9.4 (cross-Module layer).
• [[CJC-1295 + Ipamorelin + MOTS-c – Lean Mass Preservation Stack Protocol]] — §6 (lean-mass loss during transition); §9.4 (cross-Module layer); §7.4 Step 5d (adjunct addition).
• [[GHK-Cu – Post-Weight-Loss Skin Laxity Protocol]] — §9.4 (cross-Module layer); post-weight-loss-skin phenotype is post-transition-completion phenomenon.

Module 5 Master Index:

• [[Module 5 – Master Protocol Index]] — this Stack Protocol is Wave 3 Stack Protocol #4 in the Module 5 portfolio; the Master Index §3 Stack Protocols family and §4 Adjunct families reference this protocol.

C.3 Dr. Gross verification gate items

Items flagged for Dr. Gross clinical-judgment review:

1. Transition-execution operational windows — clinician-practice convention. The “~1 week operational washout” for within-class transitions (Scenarios 1, 2, 4, 7) is the clinical-practice convention rather than trial-validated. Dr. Gross to verify whether this convention aligns with his practice and whether the protocol’s framing is appropriate.

2. Cross-titration framework. The §4.1 framing presents cross-titration as clinician-judgment within informed-consent (not registration-trial-validated for any GLP-1 RA pair). Dr. Gross to confirm whether this discipline is correct or whether specific cross-titration clinical-practice patterns warrant additional documentation.

3. Pre-conception pivot scenario operational timing — Scenario 5 worked example. The §4.6 worked example walks a 6-month conception planning timeline; Dr. Gross to verify whether the operational windows (Week 2 lira initiation; Month 5-6 lira discontinuation ~1-2 weeks pre-conception) align with his practice for the reproductive-age patient on Wegovy.

4. Survodutide LIVERAGE access framework — Scenario 6. The §4.7 framing assumes LIVERAGE Phase 3 trial enrollment is the principal access pathway. Dr. Gross to verify whether the clinical-practice posture for non-LIVERAGE-eligible patients with MASH non-response on sema/tirz is captured appropriately.

5. IcoSema US vs EU regulatory framing — Scenario 9. The §10.10 counseling beat carries the EMA Kyinsu-approved-vs-FDA-investigational jurisdictional distinction; Dr. Gross to verify the jurisdictional framing matches his patient population and the eventual FDA-decision communication.

6. Pattern Z Anchor 3 calibration in §10.6 (Scenario 5 pre-conception pivot). The counseling beat LEADS with Parker 2025 PMID 40329607 per canonical Anchor 3. Dr. Gross to confirm this is the correct lead and that the post-research-state PK arithmetic, label recommendation, and STEP 8 magnitude-trade-off framing are appropriate.

7. Severity-stratified algorithm in §7.6. The mild / moderate / severe / complete non-response stratification per M5.8 v3 §4.4 is reproduced. Dr. Gross to verify the thresholds (≥5%, 2-5%, <2%, 0% / regain) align with his clinical practice.

8. Cross-canonical §7 alignment self-check. §7.8 confirms structural alignment with all nine per-canonical §7s. Dr. Gross to verify the algorithm reads consistently and that no per-canonical §7 detail has been lost in the cross-canonical integration.

C.4 Byte-count audit

Final byte-count audit (post-Commit 6 anticipated). Word count target per brief: ~25,000-30,000 words. Section length distribution is approximately proportional to operational density per Editorial Framework v1.1 §1.6:

• §1 Indication scope and transition scenarios — high evidence density (anchor section for ten-scenario taxonomy).
• §2 Selection criteria — moderate density (inclusion / relative-exclusion / contraindication per scenario).
• §3 Pre-transition workup — moderate.
• §4 Transition-execution protocol — load-bearing operational section; highest density.
• §5 Post-transition monitoring — moderate.
• §6 Transition-period AE management — moderate.
• §7 Non-response algorithm — high density (cross-canonical integration).
• §8 Discontinuation — moderate.
• §9 Transition vs combination — lower density (cross-decision framework).
• §10 Counseling beats — high density (Pattern Z 5-anchor compliance; verbatim canonical anchor mirroring).
• §11 Source citations — high density (per-canonical Bibliography cross-references).
• §12 Decision matrix — moderate (operational summary).

C.5 Document version and next-iteration trigger

This Stack Protocol version v1.0. The next-iteration trigger is the first significant regulatory-state change in any destination compound:

• Retatrutide FDA approval (TRIUMPH-3 / TRIUMPH-4 Phase 3 readout to FDA decision; near-term) — triggers §1.2 Scenario 3 / 4, §4.4 / §4.5, §10.4 / §10.5 update from “investigational pending FDA decision” to “FDA-approved” framing.
• Orforglipron FDA approval (Q4 2025 obesity filing; Q1 2026 T2D filing) — triggers §1.2 Scenario 7, §4.8, §10.8 update.
• CagriSema FDA approval — triggers §1.2 Scenario 8, §4.9, §10.9 update.
• IcoSema FDA approval — triggers §1.2 Scenario 9, §4.10, §10.10 update (US jurisdiction shifts from investigational to approved).
• Survodutide FDA approval (LIVERAGE Phase 3 readout to FDA decision) — triggers §1.2 Scenario 6, §4.7, §10.7 update.
• Tirzepatide MASH indication expansion — triggers §1.2 Scenario 2 indication-driver framing update (MASH no longer a sema-exclusive indication).
• Tirzepatide CKD or CV outcomes indication expansion — triggers §1.2 Scenario 2 indication-driver framing update.

The next-iteration trigger is also activated by:

• Pattern AB.4 cascade-scan when any per-canonical Bibliography identifier is corrected.
• New Pattern Z calibration anchor addition to /Internal/Module-5-Pipeline/pattern-z-calibration-anchor.md.
• New head-to-head transition trial (e.g., a head-to-head sema vs reta or tirz vs reta) — triggers Pattern V cross-trial framing update in §1.2, §10, §11.
• M5.8 lesson v4 — triggers §7 algorithm alignment refresh.

The protocol version is tracked in the frontmatter; iteration history will be appended at this section as it accrues.

C.6 Iteration log placeholder

Iteration	Date	Trigger	Sections updated
v1.0	2026-05-14	Initial production draft	All sections (Commits 1-6)
v1.1	TBD	Awaiting first regulatory or methodology trigger	TBD

---

Related

Module 5 Stack Protocols family:

• Stack Protocol #1 — [[Tesamorelin + AOD-9604 – Visceral Fat Adjunct Protocol]]
• Stack Protocol #2 — [[CJC-1295 + Ipamorelin + MOTS-c – Lean Mass Preservation Stack Protocol]]
• Stack Protocol #3 — [[GHK-Cu – Post-Weight-Loss Skin Laxity Protocol]]
• Stack Protocol #4 — Module 5 – Inter-GLP-1 Transition Protocol (this document)

Module 5 per-canonical protocols (transition sources / destinations):

• [[Semaglutide Protocol]] · [[Tirzepatide Protocol]] · [[Retatrutide Protocol]] · [[Liraglutide Protocol]] · [[Survodutide Protocol]] · [[Orforglipron Protocol]] · [[Cagrilintide Protocol]] · [[CagriSema Protocol]] · [[IcoSema Protocol]]

Module 5 meta-protocol:

• [[Module 5 – Phenotype-Guided Decision Tree Protocol]]

Module 5 Master Index:

• [[Module 5 – Master Protocol Index]]